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Part I:  The total synthesis of fourteen C9 hydroxyhexahydrocannabinol analogs, with 
heteroadamantyl moieties incorporated into the aliphatic side chain at C3, is described.  
The key steps in the synthesis were the condensation of persilylated phloroglucinol with 
diacetates derived from nopinone, the TMSOTf mediated formation of the dihydropyran 
ring, selective triflation at C3, stereoselective reduction at C9, palladium catalyzed 
cyanation, and Suzuki cross coupling of a vinyl pinacol boronate.  Binding affinities of 
the analogs towards the cannabinoid receptors CB1 and CB2 were determined by in vitro 
assays.  All analogs showed at least micromolar affinity for the receptors, while the C9 β-
hydroxy 2-oxaadamantyl analog had the highest affinity for CB2 (Ki = 18.5 nM) and 
showed a slight preference for CB2 over CB1.  Molecular modeling of the analogs 
showed that the presence of a carbonyl or methylene linker at C1’ drastically increases 
the pharmacophoric space resulting in decreased binding affinity. 
 
PART II:  The total synthesis of nineteen β-hydroxyhexahydrocannabinol analogs, with 
heteroaroyl moieties introduced at C3, is described.  The key steps in the synthesis were 
the carbonylative Stille between the aryl triflate and heteroaroyl stannanes, addition of 
heteroaryl groups to the aromatic aldehyde, and protecting group removal with TMSBr.  
Binding affinities of the analogs towards the cannabinoid receptors CB1 and CB2 were 
determined by in vitro assays and all analogs showed at least micromolar affinity for the 
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receptors, with the 3-benzothiophene (Ki = 34.2 nM), 3-trifluoromethylphenyl (Ki = 45.8 
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1.1 Pharmacohistory of Cannabis sativa L.1,2 
Cannabis sativa L. is one of the most extensively used plants throughout time by man for 
fiber, food, medicine and social and religious rituals.  It is a fast growing herbaceous 
annual propagated by seed and exists as two varieties namely, indica and non indica.  
Hemp, C. sativa fiber, comes from the stem and is very durable and is used in the 
manufacturing of rope, clothing, paper and a variety of other items.  The flowers are 
typically small and green, yellow or white in color.  C. sativa also has very distinctive 
leaves which are arranged palmately in five, seven, nine or other odd saw-toothed 
leaflets.3  The female plants’ flowering tops are covered with glandular hairs that secrete 
a resin which becomes abundant late in the plant’s development and is believed to 
prevent desiccation of the seeds and to protect them during the ripening period.  The use 
of C. sativa as a drug varies widely around the world.  The most popular drug products 
derived from the plant are marijuana and hashish oil.  Marijuana consists of any part of 
the plant that has been dried and is typically smoked while hashish oil is the resin from 
the plant. 
C. sativa has been used as a folk medicine in various cultures since ancient times.4  One 
of the first recorded uses of C. sativa was from a Chinese treatise over 2000 years ago 
where C. sativa was mixed with wine as an anesthetic in surgery.5  C. sativa has also 
been used externally as a poultice or a constituent of various ointments for swelling and 
bruises.  The seeds have been crushed and used in food or drink to treat depression.  C. 
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sativa has also been used to alleviate arthritis pain, chronic headaches, some 
psychosomatic disorders, as a spasmolytic, hypnotic, analgesic and to increase body 
resistance to severe physical stress.6  Furthermore, C. sativa has been used as an appetite 
promoter, a general tonic to improve both the physical and mental state of the user and 
has also shown considerable success in the treatment of dysentery and cholera. 
It wasn’t until the 19th century that C. sativa was assimilated into the standard medical 
practice.  An Irish scientist and physician, O’Shaughnessy, discovered that C. sativa 
preparations were very effective anti-vomiting agents.7  Ethanolic extracts, or tinctures, 
of the resin were also given to patients to treat rheumatism, tetanus, rabies and infantile 
convulsions. 
Even with all of C. sativa’s therapeutic potential its acceptance as a common medicine 
declined in the early 20th century.  The main problem was the unavailability of the 
constituents of C. sativa in pure form and the lack of a reliable animal test that paralleled 
the activity in humans as well as the lack of controlled clinical experiments.   
Adams8 and Todd9 renewed interest in C. sativa by identifying the basic structural 
features and synthesizing compounds with cannabimimetic activity in the 1940’s.  
Efficacy was reported for the most widely tested compound, racemic synhexyl (1), as an 
antidepressant and as a treatment for alcohol or opiate withdrawal but subsequent 




Figure 1.1.1 Synhexyl and Δ9-THC. 
In 1964, the isolation and structure elucidation of (-)-Δ9-tetrahydrocannabinol (Δ9-THC, 
2), the primary psychoactive constituent of C. sativa, by Mechoulam and Gaoni of the 
Weizmann Institute of Science, opened the door for modern cannabinoid research.10  Not 
long after this discovery, the United States Drug Enforcement Agency subjected C. sativa 
to strict controls under the Controlled Substances Act of 1970 which hampered the 
advancement of C. sativa as a potential widespread therapeutic.  Even though C. sativa 
was considered a controlled substance, an enormous body of work has been published on 
the chemistry, pharmacology, behavioral effects and metabolism of natural and synthetic 
cannabinoids as well as efforts to probe the mechanisms responsible for the behavioral 
effects of cannabinoids.   
1.2 Nomenclature of Cannabinoids 
Two different numbering systems for cannabinoids with a dibenzopyran ring appear in 
the literature (Figure 1.2.1).11  Most North American publications use the dibenzopyran 
numbering system while European publications use the monoterpenoid numbering 





Figure 1.2.1 Numbering systems for cannabinoids. 
1.3 Cannabinoid Receptors 
In the early 1980’s it was speculated that cannabinoids produced their physiological and 
behavioral effects via non-specific interactions with cell membranes, instead of 
interacting with specific membrane bound receptors.  It was later determined that the 
response of cannabimimetic drugs was consistent with receptor mediation rather than 
irreversible cytopathological change or increase in cell membrane fluidity induced by 
absorption of the highly lipophilic cannabinoids.12  It was also found that cannabimimetic 
drugs cause inhibition of the enzyme adenylate cyclase, which is responsible for the 
synthesis of cyclic adenosine monophosphate (cAMP), resulting in low cAMP levels in 
neuronal cells.  The phosphorylation of key enzymes and proteins in the cell is regulated 
by cAMP, but it is unclear how this is linked to the physiological and psychological 
effects of cannabimimetic drugs.    
1.3.1 CB1 Receptor 
In 1988, Devane13 and co-workers discovered the first cannabinoid receptor, CB1, 
through the use of ligand binding assays using tritium labeled [3H]-CP-55,940 (3) with 
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P2-membranes and synaptosomes from rat brain (Figure 1.3.1).  From their work they 
determined that the receptor’s mode of action was consistent with that of a second 
messenger membrane bound G-protein receptor inhibiting adenylate cyclase in a 
reversible, competitive, enantioselective and cell specific fashion and that it is more 
responsive to psychoactive cannabinoids than non-psychoactive cannabinoids.  After the 
receptor is engaged, multiple intracellular transduction pathways are activated.  Initially, 
it was thought that the cannabinoid receptors mainly activate the G protein which inhibits 
the enzyme adenylate cyclase, which results in the inability to produce a second 
messenger molecule of cAMP, and has a positive influence on inwardly rectifying 
potassium channels.  It has also been shown that cannabinoids have other implications on 
various potassium ion channels, calcium channels, protein kinase A and C and many 
other systems.14 
 
Figure 1.3.1 Cannabinoid ligands [3H]-CP-55940 (3) and JWH-015. 
Autoradiographic techniques revealed that the CB1 receptor can be found throughout the 
brain and spinal cord, but that it is primarily concentrated in the basal ganglia, 
hippocampus and cerebellum.  The receptors can also be found in the lungs, liver and 
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kidneys but are also expressed on the pituitary gland, thyroid gland and most likely the 
adrenal gland.  CB1 is also expressed on cells relating to metabolism, such as fat, muscle 
and liver cells, and in the digestive tract and can also be found on sperm and ovarian 
cells.15 
Activation of the CB1 receptor has various functions throughout the body.  In the liver, 
activation of the receptor is known to increase de novo lipogenesis, inhibit sympathetic 
innervation of blood vessels and contribute to the suppression of the neurogenic 
vasopressor response in septic shock.  Activation of the CB1 receptor in the 
cardiovascular system contributes to hemorrhagic and endotoxin induced hypotension.16  
Activation of CB1 results in analgesic activity as well.  
1.3.2 CB2 Receptor 
Through the use of polymerase chain reaction (PCR) techniques on DNA prepared from 
human promyelocytic leukaemic line (HL60) Munro17 and co-workers at Cambridge 
discovered the second cannabinoid receptor, CB2, in 1993.  This new receptor was shown 
to have significant homology with CB1 with 44% amino acid similarity overall and 68% 
amino acid similarity in the transmembrane regions.  The CB2 receptor is comprised of 
360 amino acids while CB1 is considerably longer with 473 (Figure 1.3.2).18  The 
sequence of amino acids across human and rodent species is not as highly conserved in 
the CB2 receptor (only 81% amino acid homology) as it is in the CB1 receptor (97-99% 




Figure 1.3.2 Structures of the CB1 and CB2 receptors shown with the membrane.18 
The CB2 receptors are largely found throughout the peripheral tissues, such as the 
immune system (spleen, tonsils and thymus gland) with the greatest density in the T cells 
of the spleen.  It has recently been reported that the expression of CB2 is induced within 
the lumbar spinal cord in chronic pain models associated with peripheral nerve injury. 
The appearance of CB2 coincides with activated microglia (a type of glial cell that acts as 
the main form of active immune defense in the central nervous system).19  Recent 
research has shown that CB2 receptors are also widely distributed throughout the brain 
where their role remains unclear, and in the gastrointestinal system where they modulate 
intestinal inflammatory response.  CB2 receptor agonists make an attractive target for 
drug discovery since they lack the undesirable behavioral and psychoactive side effects 
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associated with activation of the CB1 receptor.  CB2 agonist JWH-015 (Figure 1.3.1) has 
been shown to induce macrophages to remove native beta-amyloid protein from frozen 
human tissues.20  This finding has importance in Alzheimer’s research since it is known 
that patients suffering from this disease have buildups of beta-amyloid proteins known as 
senile plaques, which disrupt neural functioning.  CB2 receptor agonists are potential 
therapeutic targets for the treatment of pain, inflammatory bowel diseases such as 
Crohn’s,21 ulcerative colitis22 and a possible treatment of Alzheimer’s.   
1.3.3 Possible Non CB1/CB2 Receptors 
The existence of non-CB1/CB2 receptors has long been suspected due to the actions of 
compounds that produce cannabinoid-like effects on blood pressure and inflammation 
without activating CB1 or CB2.  Abnormal cannabidiol (abn-CBD, 4), a synthetic 
regioisomer of cannabidiol (CBD, 5), is such a compound that has vasodilator effects, 
lowers blood pressure and induces cell migration and proliferation without psychoactive 
effects (Figure 1.3.3).  Research has shown that the actions of 4 are mediated through a 
receptor other than CB1 and CB2.  These observations suggest that the abn-CBD receptor 
is the orphan receptor GPR18, which has been shown to be a receptor for endogenous 
lipid neurotransmitters which in turn also bind to cannabinoid receptors.  In time, GPR18 
could also be termed a cannabinoid receptor. 23  Another orphan receptor, GPR55, is 
thought to be another potential cannabinoid receptor based on sequence homology at the 
binding site and its ability to respond to both exogenous and endogenous cannabinoid 




Figure 1.3.3 Cannabidiol (CBD, 5) and abnormal cannabidiol (abn-CBD, 4). 
1.4 Therapeutic Potential of Cannabinoids and Synthetic Analogs 
To date there have only been three cannabinoid receptor agonists approved for the 
treatment of specific ailments.  (-)-Δ9-THC has a broad pharmacological spectrum 
consisting of, inter alia, anticonvulsant, analgesic,25 ocular hypotensive,26 bronchodilator, 
and antiemetic effects in animals and humans.  In spite of the potential of 2 and synthetic 
analogs thereof, there has been limited success in bringing such compounds to the drug 
market.   
(-)-Δ9-THC and the synthetic analog nabilone (6) have demonstrated safety and efficacy 
as oral antiemetics in cancer chemotherapy and are commercially available as Dronabinol 
(Unimed, Inc.) and Cesamet® (Eli Lilly and Company), respectively (Figure 1.4.1).  (-)-
Δ8-THC has also been shown to be an effective antiemetic for children undergoing cancer 




Figure 1.4.1 Therapeutic cannabinoids. 
Solvay Pharmaceuticals is also marketing Marinol® (2) as a treatment for cachexia in 
AIDS patients.28  Recently, nabilone (6) has also shown to be effective for the treatment 
of pain due to fibromyalgia29 and for the treatment of nightmares associated with post-
traumatic stress disorder.29  In Canada, an oralmucosal spray consisting of a roughly 
equal parts mixture of 2 and cannabidiol 5 under the trade name Sativex was approved 
for the treatment of neuropathic pain associated with multiple sclerosis patients and 
cancer patients who showed persistent pain under maximal doses of opioid treatment.30   
Sanofi-Aventis released CB1 antagonist rimonabant (Acomplia®, 7) in 2006 to treat 
obesity.31  Unfortunately, it was removed from the market just two years after its release 
due to its users experiencing anxiety and depression which in extreme cases led to 
suicide.  Rimonabant has also shown promise as a smoking cessation aid.32  Other 
potential uses are for the treatment of addictions such as cocaine33 and ethanol,34 
12 
 
improvement of short-term memory35 and blocking the psychoactive and cardiovascular 
effects36 that are associated with 2.    
1.5 Cannabinoid Ligands and Structure Activity Realationship (SAR) 
The synthesis of natural and synthetic cannabinoid enantiomeric pairs has made it 
possible to compare their pharmacological and biological activities.  In most cases, the 
natural trans-(6aR, 10aR)-(-)-cannabinoids show significant activity while the antipode 
exhibits very little or no activity.37  The high potency of the (-)-enantiomer is consistent 
with the existence of a specific receptor for cannabinoids.  However, both enantiomers of 
5 exhibit anticonvulsant activity which suggests that this activity results from nonspecific 
membrane interactions.38 
Tentative rules for cannabimimetic activity were formulated by Mechoulam and Edery in 
1973 based on pharmacological studies carried out after the primary active constituent in 
marijuana, Δ9-THC, was identified.39  Both naturally occurring and synthetic 
cannabinoids generally follow these rules.  The term cannabimimetic refers to ligands 
that produce human subjective effects in common with Δ9-THC or that produce Δ9-THC 
like activity in laboratory animals that parallels human activity.40  To assess the 
psychoactive component of cannabinoids animal behavior is studied.41  Some common 
behaviors resulting from the treatment of laboratory animals with cannabinoids are dog 
ataxia, spontaneous activity and hypothermia in rats and mice, overt behavior in Rhesus 
monkeys and baboons, drug discrimination in rodents, pigeons or monkeys and the 
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mouse ring test.  It is not possible to  quantify the extent of separation of psychoactive 
and other side effects from therapeutic based on these tests. 
To date there have been five structurally diverse types of ligands that are classified as 
cannabinoids.  Each class of ligands will be discussed briefly as well as their structure 
activity relationships.  
1.5.1 Classical, Non-Classical and Hybrid Cannabinoids 
Classical cannabinoids are naturally occurring or synthetic cannabinoids that contain the 
tricyclic framework as seen in Δ9-THC.  Considerable effort has been devoted to the SAR 
of these cannabinoids and three key pharmacophoric features have been discovered.  The 
key pharmacophores are C9 of the cyclohexane ring as well as C1 and C342 of the 
aromatic ring.   
The identity of the alkyl group at C3 is considered the dominant factor in determining 
cannabinergic potency.  The presence of an alkyl side chain is a prerequisite for 
cannabimimetic activity.  The alkyl chain must be at least as long as the n-pentyl chain 
found in Δ9-THC and a length of seven carbon atoms appears to be optimal.  Activity is 
still observed if the C1’ carbon is replaced by an oxygen, while activity increases with the 
presence of methyl groups at the 1’- or 2’-position.  The most widely used side chain in 
synthetic cannabinoid analogs is the 1’,1’-dimethylheptyl side chain.43  Recently, it has 
been shown that groups as large as bornyl, isobornyl44 and adamantyl45 are still tolerated 
in both CB1 and CB2 binding sites.  Furthermore, considerable receptor subtype 
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selectivity was observed depending on the relative orientation of the adamantyl or bornyl 
and isobornyl group with respect to the tricyclic nucleus (Figure 1.5.1).   
 
Figure 1.5.1 C3 varied classical cannabinoids. 
The Δ9- or Δ8-double bond is not important for activity.  Substitution of the northern 
aliphatic hydroxy groups (NAH) for other groups such as a carbonyl, β-hydroxy or β-
hydroxymethyl at C9 all lead to an increase in activity (Figure 1.5.2).  The α-isomers are 
still active but to a much lesser extent.  The studies of Wilson and May using 9-nor-9β-
hydroxyhexahydrocannabinol (14) and epimeric 15 led to research in the non-classical 
cannabinoid field (Figure 1.5.2).  Both 14 and 15 produced cannabimimetic activity but 
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15 exhibited enhanced analgesic activity in rodents, with potency equal to morphine.46  
These results represented a significant step forward in the search for non-narcotic, potent 
analgesics structurally unrelated to morphine.  
Structure activity relationships have also shown that one and only one phenolic hydroxy 
group is required to maintain cannabimimetic activity and the phenolic hydroxy at C1 has 
to be free or esterified.47  Blocking of the hydroxyl group as an ether (18) leads to 
elimination of or considerable reduction of activity when compared to 9.   
 
Figure 1.5.2 C9 and C1 varied classical cannabinoids. 
Most active cannabinoids contain the dihydrobenzopyran moiety with the trans-6aR, 
10aR ring fusion to the aliphatic C ring; however, in some non-classical cannabinoids the 
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dihydropyran ring is replaced by an aliphatic chain terminating in a hydroxyl group as 
seen in 3 (Figure 1.3.1).  This functionality at C6 is termed the southern aliphatic 
hydroxy group (SAH).  The SAH can also be a simple alkyl chain, have unsaturation, be 
halogenated or be incorporated into another ring, all of which modulate binding affinity.  
In an attempt to delineate the minimum structural requirements for hexahydrocannabinol 
(15) needed to induce analgesia, it was found that the dihydropyran ring was not 
necessary for activity.48  A wide variety of these simplified analogs have been developed 
and in fact, tritiated non-classical cannabinoid [3H]-CP-55,940 (3) was used to identify 
the CB1 receptor in rat brain.  Naturally occurring cannabinoid 5, which lacks the 
dihydropyran ring, is completely devoid of cannabimimetic activity and most other major 
activity except for anticonvulsant activity.49 
Hybrid cannabinoids were introduced by Tius et al. in 1994 when they prepared tricyclic 
cannabinoids 19 and 20 (Figure 1.5.3).50  These hybrid cannabinoids incorporated all 
four key pharmacophores associated with classical and non-classical cannabinoids (NAH, 
SAH, C1 phenolic hydroxyl and C3 alkyl chain) while limiting the conformational 
mobility of the SAH bearing group.  The β-hydroxyethyl compound 19 showed 20x 
higher affinity than 20, demonstrating that the SAH-receptor interaction takes place on 
the β-face of the classical cannabinoid skeleton.  Hybrids of the highly potent 
cannabinoids HU-243 (17) and CP-55,940 were also prepared by varying the length of 
the southern β-hydroxyalkyl chain from one to three methylene units.51  As expected, 
replacing the C9 hydroxy group and the n-pentyl chain with β-hydroxymethyl and 1’,1’-
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dimethylheptyl groups respectively, greatly increased receptor affinity.  However, 
varying the length of the southern β-hydroxyalkyl chain had minimal effect on the 
affinity.  It was also observed that the presence of the new SAH in the HU-243/CP-
55,940 hybrids (21, 22 and 23) interferes with the optimal receptor interactions of the 
other pharmacophores resulting in compounds 40x less potent than the parent compound 
HU-243. 
 
Figure 1.5.3 Hybrid cannabinoids. 
1.5.2 Endocannabinoids 
With the discovery of the CB1 receptor the search for endogenous ligands, or 
endocannabinoids, began.  The first such ligand, anandamide (24), was isolated from 
porcine brain in 1992 by Mechoulam and was shown to bind strongly to the CB1 receptor 
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but only weakly to CB2 (Figure 1.5.4).52  2-Arachidonyl glycerol (2-AG, 25), the first 
endogenous ligand to be found outside of the brain, binds both receptors with similar 
affinity, acting as a full agonist at both.53  N-Arachidonyl-dopamine (NADA, 26) was 
discovered in 2000 and preferentially binds to CB1.54  2-Arachidonyl glyceryl ether (2-
AGE, 27) was also isolated from porcine brain in 2001 and was shown to bind strongly to 
CB1 causing sedation, hypothermia, intestinal mobility and mild antinociception in 
mice.55  Lastly, O-arachidonyl-ethanolamine (OAE, 28) was discovered in 2002 in the 
brain and in slightly higher concentrations in the peripheral tissues.56   
 
Figure 1.5.4 Endocannabinoids. 
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It has been shown that conservation of the ethanolamide end group is not necessary for 
receptor binding affinity and that elongation and branching of the end group can increase 
binding affinity.57  The four cis-olefins are the key feature in maintaining high activity,  
although replacement of the hydrophobic tail is tolerated as is in the case of Δ9-THC.  
Conversion of the n-pentyl tail to dimethylheptyl has been shown to improve binding.  
Through molecular modeling experiments it has been suggested that the 
endocannabinoids interact with the receptor in a similar fashion to the bicyclic and 
tricyclic cannabinoids.   
1.5.3 Aminoalkylindoles, 1,5-Diarylpyrazoles and Miscellaneous Cannabinoids 
Sterling-Winthrop Co. stumbled upon the aminoalkylindole (AAI) cannabinoid ligands in 
the 1990’s while they were developing anti-inflammatory agents.  Pravadoline (WIN-
48098, 29) was found to exhibit unexpectedly strong analgesic effects and these effects 
were not blocked by opioid antagonists (Figure 1.5.5).58  Eventually it was discovered 
that pravadoline represented the first compound in the class of AAIs.  (+)-WIN-55212-2 
(30) was another compound that showed little promise as an anti-inflammatory drug, but 
it did prove to be a very potent cannabimimetic displaying the full range of effects in 
behavioral studies.  The tritiated analog is now widely used as a radioligand standard in 
SAR studies.  The most potent AAIs contain an indole ring system, a tertiary amine 
moiety and a naphthoyl or aroyl group.  The carbonyl oxygen of AAIs was shown to be 
unnecessary for cannabinoid receptor affinity and activity.  Also, the morpholino ring can 
be replaced by an alkyl chain without loss of CB1 affinity or efficacy.  The naphthoyl 
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moiety appears to be the preferred aromatic moiety and shows increased binding affinity 
compared to the p-methoxybenzoyl present in 29, supporting the hypothesis that aromatic 
stacking interactions are important for interacting with the CB1 and CB2 receptors.59 
 
Figure 1.5.5 1, 5-Diarylpyrazoles, aminoalkylindoles and miscellaneous cannabinoids. 
In 1994 Sanofi-Aventis introduced the first selective cannabinoid antagonist, SR-141716 
(7), belonging to a family of 1,5-diarylpyrazoles.60  Most CB1 antagonists to date closely 
resemble 7 and contain a cyclic core, C, substituted by two aromatic moieties, A and B,  
















Figure 1.5.6 1,5-Diarylpyrazole skeleton system. 
SAR studies found that a para-substituted phenyl A ring is required for optimal binding 
affinity and that the A ring is involved in receptor recognition.  The para-substituent can 
be chlorine, bromine or iodine as well as an alkyl chain but iodine analogs have the 
highest affinity.  A 2,4-dichloro substituted B ring ensures high activity and receptor 
affinity while any deviation from this is detrimental.61  Having a cyclic lipophilic E 
moiety is also favorable while replacement with alkyl amides, ethers, ketones, alcohols or 
alkenes result in decreased activity.  It is interesting to note that replacement of the cyclic 
lipophilic moiety with a pentyl or heptyl chain gives the compounds agonistic properties.  
Studies have also shown that absence of the carboxamide oxygen, or hydrogen bond 
acceptor D, results in decreased affinity.  Furthermore, the presence of the carboxamide 
oxygen confers the inverse agonist properties while compounds devoid of the oxygen are 
neutral antagonists which support the hypothesis that the carboxamide oxygen forms a 
key hydrogen bond inside of the CB1 receptor.  Other examples of cannabinoid ligands 




1.6 Biological Assaying Techniques 
1.6.1 Ligand Binding Assay 
Competitive binding assays are typically used to assess the binding affinities for the CB1 
and CB2 receptor sites.  This is accomplished by the use of tritium labeled cannabinoids 
such as [3H]-CP-55,940 (3), [3H]-WIN-55212-2 (34) or [3H]-SR-141716A (35)62 which 
have well established binding profiles for both CB1 and CB2 receptors (Figure 1.6.1).   
 
Figure 1.6.1 Tritium labeled cannabinoids used in binding assays. 
The ligand, or inhibitor, is tested for a predetermined amount of time against the 
radioligand, or substrate, at several concentrations in a buffered solution containing either 
P2 membrane from homogenized male Sprague-Dawley rat brain or synaptosomes from 
the hippocampus and prefrontal cortex of rats prepared according to Dodd’s procedures.63  
The amount of displaced substrate is then measured using a scintillation counter.  The 
percentage of displaced substrate is plotted against the inhibitor concentrations and fitted 
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to a non-linear regression curve resulting in a half maximal inhibitory concentration 
(IC50) curve.  The concentration at which half of the substrate is displaced is determined 
to be the IC50 value for the inhibitor (Figure 1.6.2).   
 
Figure 1.6.2 Typical IC50 curve.   
Since IC50 values are concentration dependent the values will vary between experiments.  
The preferred value to report is the Ki value, or inhibition constant.  The inhibition 
constant is an absolute value and independent of concentration which is more useful to 
the experimentalist.  The Ki value is calculated using the Chang-Preusoff equation 
(Equation 1).64 
Ki = IC50 / (1 + [S]/Km)     (Equation 1) 
The Chang-Preusoff equation consists of the IC50 value determined for the inhibitor, 
concentration of the substrate [S] and the Michaelis-Menten constant for the substrate.  
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This equation may only be used when the substrate and inhibitor bind in a competitive 
manner.  If the substrate and inhibitor bind in a non-competitive or allosteric manner a 
different equation must be used to determine the inhibition constant. 
1.6.2 Ligand Assisted Protein Structure (LAPS) 
Ligand assisted protein structure (LAPS) is a recently developed technique combining 
molecular biology and mass spectroscopy focused proteomics.  This method is 
advantageous since it determines which amino acid residues interact with the bound 
ligand inside the reactive site.  Our collaborator, Professor Alexandros Makriyannis, uses 
this technique to help divulge information about the active binding site in the cannabinoid 
receptors, CB1 and CB2.  This is accomplished by utilizing a cannabinoid ligand 
containing a reactive functional group (i.e.: azide, isothiocyanate, etc.) which can 
undergo a reaction inside the receptor resulting in a covalent bond.  This adduct can then 
undergo partial enzymatic degradation and is analyzed using MALDI-TOF or MS/MS 
experiments.  A determination of the orientation of the ligand inside the receptor can then 
be made based on the mass fragments.  
1.7 Previous Synthetic Approaches to Cannabinoids and Analogs 
1.7.1 Approaches to Δ9-THC and Analogs 
The most common procedure for preparing cannabinoids focuses on reactions of olivetol 
(36) with an appropriately functionalized monoterpene derivative such as 37.  The major 
drawback of this approach is the formation of a 1/1 mixture of regioisomers derived from 
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substitution at C2 and C4 of olivetol.65  The byproduct, in which the hydroxyl and n-
pentyl groups are transposed, is referred to as the “abnormal” cannabinoid (38) (Scheme 
1.7.1).   
 
Scheme 1.7.1 Reagents and conditions: (a) p-TsOH·H2O, CHCl3 or PhH. 
The “abnormal” cannabinoid byproduct can be suppressed when the resorcinol has a 
bulky substituent at C5 which presumably prevents attack at C4 due to sterics.66   
Various chiral cyclic monoterpenoids have been used to synthesize Δ9-THC including 
cis- and trans-p-mentha-2,8-dien-1-ol (37),67 (+)-trans-2,3-epoxycarane,68 (-)-cis- or (-)-
trans-verbenol69 and (+)-(1R,4R)-p-menth-2-ene-1,8-diol.70  Of these, 37 and (+)-(1R, 
4R)-p-menth-2-ene-1,8-diol have the most synthetic utility.  It should be noted that since 
the cationic condensations are promoted by Lewis acids, the regiochemical outcome is 
quite sensitive to reaction conditions.  When strong protic acids are used in the 
condensation/cyclization reaction the thermodynamically more stable Δ8-THC is formed 
which requires additional steps to yield the desired Δ9-THC.71  To get around the 
undesirable isomerization, the use of catalytic BF3·Et2O in the presence of MgSO4 results 
in Δ9-THC as the major product.66   
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Another popular approach to cannabinoids, especially C9 substituted cannabinoids, uses a 
mixture of diacetates 39 and 40 derived from (-)-β-pinene (41).  An Eli Lilly Co. team led 
by Archer utilized 39 and 40 during their elegant synthesis of nabilone 6.72  Condensation 
of resorcinol 44 and diacetates 39 and 40 with p-TsOH and subsequent 
rearrangement/cyclization with SnCl4 yielded nabilone (6) in 57% yield over the two 
steps (Scheme 1.7.2).  Notably, none of the undesired abnormal cannabinoid byproduct 
or cis ring fused product was formed. 
 
Scheme 1.7.2 Reagents and conditions: (a) O3, CH2Cl2, -78 °C; Me2S, -78 °C to rt; (b) 
isopropenyl acetate, p-TsOH·H2O, reflux; (c) Pb(OAc)4, PhH, reflux, 39% over two 
steps; (d) 44, p-TsOH·H2O, CHCl3, rt, 70%; (e) SnCl4, CHCl3, rt, 84%. 
Δ9-THC is still a popular synthetic target even today, as demonstrated by the Trost group 
in 2007 (Scheme 1.7.3).73  As Trost points out, most syntheses are either not 
enantioselective or derive their chirality from the chiral pool.  Trost’s approach 
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envisioned all stereochemistry resulting from a single molybdenum catalyzed asymmetric 
alkylation reaction.  Treatment of allylic carbonate 46 with catalytic Mo(CO)3C7H8, S, S-
47 and sodium dimethyl malonate resulted in 48 in 95% yield and 94% ee.   
 
Scheme 1.7.3 Reagents and conditions: (a) 5 mol % [Mo(CO)3C7H8], 7.5 mol % S, S-47, 
sodium dimethyl malonate, THF, 65 °C; 95%, 94% ee; (b) NaCl, DMSO, H2O, 160 °C; 
83%; (c) LiHMDS, THF, -40 °C, 51; 50%. 
Alkylation of malonate 48 failed to yield any of the desired adduct 49 due to the steric 
demands of forming a quaternary carbon at the congested malonate center.  To reduce the 
steric demands a dealkoxycarbonylation of 48 was employed followed by alkylation of 
50 with triflate 51 resulting in 52 in only moderate yield (Scheme 1.7.3).  The 
elimination pathway leading to isoprene was a problem due to the slower rate of 
alkylation at reduced temperatures.  To remedy this problem the dianion from 53 was 
used and led to 55 in 84% yield as a 2.4:1 mixture of anti and syn isomers.  The C ring 
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(cyclohexane) was then installed using ring closing metathesis in 81% yield.  
Epimerization of the ester was realized with NaOMe in MeOH at 65 °C for three days 
giving 57 in 94% yield.  Addition of MeLi to 57 gave the desired tertiary alcohol 58 in 
excellent yield.  Treatment of ether 58 with BBr3 or any other acidic reagents resulted in 
a complex mixture of products.  The methyl ethers were then removed stepwise using 
NaSEt in DMF which is known to stop at the monodeprotection of aryl diethers.74  
Treatment of phenol 59 with ZnBr2 in the presence of MgSO4 resulted in formation of 
the dihydropyran ring which was resubjected to the demethylation conditions yielding Δ9-






Scheme 1.7.4 Reagents and conditions: (a) aqueous NaOH; HCl; (b) 160 °C, 97% over 
two steps; (c) LDA, THF, 54, 0 °C to rt; 84%; (d) (MeO)2SO2, K2CO3, acetone; (e) 
Grubbs II, CH2Cl2; 81% from 55; (f)  NaOMe, MeOH, 65 °C; 94%; (g) MeLi, Et2O, -78 
°C to rt; 92%; (h) NaSEt, DMF, 140 °C; 97%; (i) ZnBr2, MgSO4, CH2Cl2; (j) NaSEt, 





2 Results and Discussion* 
The work described in part I of this dissertation is concerned with the synthesis and 
receptor binding studies of a series of α-hydroxy- and β-hydroxyhexahydrocannabinol 
derivatives with a heteroadamantyl moiety at C3. 
The purpose of this study was to elucidate the SAR for the C3 appendage in cannabinoids 
by placing heteroatoms in and around the adamantyl group.  Changes in binding affinities 
of cannabinoids bearing heteroatoms might indicate the close proximity of polar amino 
acid residues within the binding pocket.  Both the α-hydroxy and β-hydroxy series were 
prepared as the northern aliphatic hydroxyl group is known to be an important 
cannabimimetic pharmacophore. 
2.1 Stereospecific Condensation of Phloroglucinol and Nopinone Derived Diacetates 
The starting material for the synthesis, diacetates 39 and 40, were easily prepared from 
readily available and inexpensive (-)-β-pinene (41) via ozonolysis to nopinone (42),75 
followed by enol acetate formation (43) and oxidation with lead (IV) acetate (Scheme 
2.1.1).  The crude diacetates were sufficiently pure (~85% pure by 1H NMR) to use in the 
following reaction without purification. 
 
   
                                                 
*  Reproduced  in part with permission from Dixon, D. D.; Sethumadhavan, D.; Benneche, T.; Banaag, A. 




Scheme 2.1.1 Reagents and conditions: (a) O3, CH2Cl2, -78 °C; thiourea, -78 °C to rt; 
75%; (b) isopropenyl acetate, p-TsOH·H2O, reflux; (c) Pb(OAc)4, PhH, reflux, 72% 42. 
In order to prepare a diverse set of cannabinoids without preparing individual resorcinols 
we envisioned an advanced common intermediate from which all analogs could be 
prepared.  Following an approach previously developed in our group by Dr. Le Goanvic, 
during the synthesis of oxazaadamantyl cannabinoids,76 we chose to employ 
phloroglucinol (61) in our acid catalyzed condensation with diacetates 39 and 40.  The 
Eli Lilly Co. team led by Archer developed this key step during their synthesis of 
nabilone.  Since phloroglucinol is sparingly soluble in CH2Cl2 a mixed solvent system of 
4/1 CH2Cl2/acetone was used to overcome this problem.  Bicyclic intermediate 62 was 
obtained in a moderate yield of 40% which can be attributed to the high reactivity of 61 
which can lead to condensation with a second molecule of 39 or 40 (Scheme 2.1.2).   
 





It should be noted that through the years of cannabinoid research conducted in the Tius 
lab, chloroform was found to be the optimal solvent for the condensation reaction and 
any deviation from this solvent results in decreased yields.  After screening various 
reaction conditions we were eventually able to devise a simple modification to overcome 
the solubility issues associated with phloroglucinol.  Exposure of phloroglucinol to 
TMSCl and TEA in CH2Cl2 led to hydrolytically sensitive persilylated phloroglucinol 63 
which was not purified and used immediately in the condensation with 39 and 40.  
Masking the phenolic hydroxyl groups as the TMS ethers drastically increased solubility 
in CHCl3 and allowed us to run the reaction in a 4/1 mixture of CHCl3/acetone with a 
slight excess of p-TsOH·H2O.  This led to a much cleaner reaction and formed 62 in 70% 
yield with negligible bis-condensation byproduct.  The separation of bicyclic adduct 62 
and excess phloroglucinol proved to be difficult so the crude reaction mixture was treated 
with Ac2O, pyridine and catalytic DMAP in CH2Cl2 yielding triacetate 64.  Separation of 
64 and acetylated 61 was straightforward and pure 62 could be isolated after hydrolytic 
cleavage of the acetates with methanolic KOH in 68% yield over the three steps (Scheme 
2.1.3).    
 
Scheme 2.1.3 Reagents and conditions: (a) TMSCl, Et3N, CH2Cl2, 0 °C to rt; (b) p-
TsOH·H2O, 4/1 CHCl3/acetone, 0 °C to rt; (b) Ac2O, CH2Cl2, DMAP (cat.), pyridine, 0 
°C to rt; (d) KOH, MeOH, 0 °C; 68% overall from 39 and 40. 
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 2.2 Synthesis of Amide Analogs 
In Le Goanvic’s synthesis of the oxazaadamantanes,76 SnCl4 was used as the Lewis acid 
to promote the rearrangement and cyclization to give 65.  On small scale this proved to 
be practical but on scale up, the formation of emulsions and tin salts resulted in 
irreproducible product yields.  After screening other Lewis acids, TMSOTf proved to be 
a much better choice than SnCl4 in terms of ease of workup as well as the yield (>95% 
vs. 84%) resulting in 65 which could be used without further purification.  Another 
improvement was the use of N-phenyltriflimide77 and TEA in CH2Cl2 over the nonaflyl 
transfer reagent 6678 and CsF in DMF in the selective sulfonylation of 65 (51% vs. 68%).  
Triflate 67 could be obtained in 68% yield in a single operation or in 57% from 62 
requiring only one purification step.  Since both diastereomers of the C9 alcohol were 
going to be investigated, ketone 68 was reduced with NaBH4 in 97% yield as a 95/5 
mixture of C9-β (equatorial) alcohol 69 to C9-α (axial) alcohol diastereomer 70.  Alcohol 
70 could be obtained as the sole diastereomer when ketone 67 was treated with L- or K-




Scheme 2.2.1 Reagents and conditions: (a) TMSOTf, MeNO2, 0 °C; (b) PhNTf2, Et3N, 
CH2Cl2, 0 °C to rt; 57% from 62; (c) CsF, DMF, 66, rt; 57%; (d) NaBH4, MeOH, 0 °C; 
97% 69 + 70, ca. 95/5; (e) L-Selectride, THF, -78 °C; rt, 90%.  
The aliphatic and phenolic hydroxy groups of 69 and 70 were simultaneously protected 
as the methoxymethyl ether, resulting in 71 and 72 in 93% and 94% respectively.  
Exposure of triflate 71 and 72 to catalytic Pd(PPh3)4 and Zn(CN)2 in DMF at 60 °C led to 
nitriles 73 and 74, respectively, in excellent yield.  The reproducibility of this reaction 
proved to be problematic, and the addition of 10 wt. % PMHS79 as an oxygen scavenger 
was required to obtain the nitriles in consistent yields of >95%.  Hydrolysis of nitriles 73 
and 74 with LiOH in aqueous methanol gave acids 75 and 76 in 91% yield for each 
isomer.  Exposure of acids 75 and 76 to EDCI and DMAP in CH2Cl2 to oxazaadamantane 
(77), 1-adamantlyamine and 2-adamantlyamine led to amides 78 (91%), 79 (88%), 80 
(90%), 81 (91%), 82 (90%) and 83 (91%) (Scheme 2.2.2).  All protected amide 




Scheme 2.2.2 Reagents and conditions: (a) MeOCH2Cl, (i-Pr)2NEt, CH2Cl2, 0 °C to rt; 
71, 93%; 72, 94%; (b) Zn(CN)2, Pd(PPh3)4 (cat.), 10 wt % PMHS, DMF, 60 °C; 73, 96%; 
74, 97%; (c) LiOH, 4/1 MeOH/H2O, 70 °C; 75, 91%; 76, 91%; (d) 77, 1-adamantylamine 
or 2-adamantylamine, EDCI, DMAP, CH2Cl2, rt; from 75: 78, 91%; 80, 90%; 82, 90%; 
from 76: 79, 88%; 81, 91%; 83, 91%; (e) n-BuSH, ZnBr2, CH2Cl2, 45 °C; 86, 77%; 87, 





Figure 2.2.1 Protected amide analogs. 
It should also be noted that the synthesis of oxazaadamantane 77 was improved.  Le 
Goanvic reported 50% yield for the photochemical oxidative closure of alcohol 84 to the 
pyran ring76, 80 and 48% yield for the reductive cleavage of the tosylate 85.  The yield for 
the oxidative ring closure can be improved drastically (75% vs. 50%) when finely 
powdered alcohol 84 and PhI(OAc)2 are used as well as focusing the light source as close 
to the reaction flask as possible with aluminum foil surrounding the flask to ensure 
maximum exposure to the light source.  Also, the yield for the reductive cleavage of the 
tosylate is greatly improved by limiting the amount of acid introduced to quench the 
reaction.  Introducing just enough saturated NH4Cl to dissipate the dark green color of the 
sodium naphthalide ensures minimal product loss.  A simple acid-base workup is then 
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used to remove excess naphthalene and to recover the pure oxazaadamantane 77 in 85% 
yield (Scheme 2.2.3).  
 
Scheme 2.2.3 Reagents and conditions: (a) PhI(OAc)2, I2, hν, C6H12, 50 °C; 75%; (b) Na, 
naphthalene, DME, -50 °C; 85%. 
Removal of the methoxymethyl ether protecting groups proved to be more challenging 
than expected.  Conventional deprotection methods (HCl, PPTS) led to diol products in 
less than 50% yield and long reaction times.  Deprotection could be realized with 
TMSBr81 in CH2Cl2 at -40 °C but the optimal conditions were treatment with ZnBr2 and 
n-BuSH in CH2Cl2 at 45 °C as described by Rawal.82  All amides prepared are shown in 




Figure 2.2.2 Amide analogs. 
2.3 Synthesis of Amine Analogs 
The next class of compounds to be synthesized was the amino analogs which 
incorporated a methylene spacer between 77 and the tricyclic cannabinoid nucleus.  Our 
initial approach involved reduction of the protected amides (78 and 79) with LAH or 
Singaram’s LAB (lithium amino borane) reagent83 followed by removal of the protecting 
groups, but this was unsuccessful.  Since reduction of the amide proved to be problematic 




Scheme 2.3.1 Reagents and conditions: (a) BH3⋅THF, THF, 0 °C; 0 °C to rt; 75, 88%; 76, 
88%; (b) MsCl, Et3N, THF, 0 °C to rt; LiBr, THF, rt; (c) 77, DMF, K2CO3, rt; 94, 75%; 
95, 72%; (d) n-BuSH, ZnBr2, CH2Cl2, 45 °C; 96, 81%; 97, 73%. 
Reduction of carboxylic acids 75 and 76 with BH3·THF or BH3·SMe2 complex led to 
benzylic alcohol diastereomers 92 and 93, each in 88% yield (Scheme 2.3.1).  Treatment 
of the diastereomeric alcohols with MsCl and immediate displacement by bromide gave 
the diastereomeric benzyl bromides which were used without purification.  Exposure of 
the diastereomeric bromides to a slight excess of 77 in the presence of K2CO3 in DMF led 
to oxazaadamantylamines 94 and 95 in 75% and 72% yield, respectively.  All attempts to 
remove the methoxymethyl ether protecting groups with TMSBr as reported by Le 
Goanvic led to very low yields.  This is quite likely due to the buffering effect of the 
basic nitrogen atom.  The conditions developed by Rawal and co-workers proved to be 
optimal for removing the methoxymethyl ethers, yielding amines 96 and 97 in 81% yield 
and 73% yield, respectively. 
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A slightly different strategy was followed for the synthesis of the secondary 
adamantylamines (98 - 101) (Scheme 2.3.2).  With the increased difficulty of removing 
the methoxymethyl ethers from 94 and 95 we wanted to devise a strategy that did not 
involve the removal of the methoxymethyl ether protecting groups in the presence of a 
secondary amine.  Removal of the methoxymethyl ethers in the presence of the aldehyde 
took place in very low yield, making the protecting group exchange necessary.  Nitriles 
73 and 74 were treated with ZnBr2 and n-BuSH at room temperature yielding 
diastereomeric alcohols 102 and 103.  The hydroxyl groups were then temporarily 
masked as triethylsilyl ethers followed by reduction of the nitrile to the aldehyde and 
fluorodesilylation to produce 104 and 105, each in 61% yield over the three steps.  
Treatment of aldehydes 104 and 105 with 1-adamantylamine or 2-adamantylamine under 
Dean-Stark conditions formed the sensitive imine which underwent catalytic 
hydrogenation with 10% Pd/C in MeOH under an atmosphere of hydrogen resulting in 







Scheme 2.3.2 Reagents and conditions: (a) n-BuSH, ZnBr2, CH2Cl2, rt; 73, 90%, 74, 
76%; (b) Et3SiCl, (i-Pr)2NEt, CH2Cl2, 0 °C to rt; (c) DIBAL, CH2Cl2, PhMe, -78 °C; (d) 
TBAF, THF, rt; 104, 61% from 102; 105, 61% from 103; (e) PhH, 1- or 2-
adamantylamine, 4Å MS, reflux, Dean-Stark; (f) Pd/C, H2, MeOH, rt; 98, 81% from 104; 
99, 78% from 105; 100, 60% from 104; 101, 84% from 105. 
2.4 Synthesis of Oxaadamantane Analogs 
The synthesis of oxaadamantanes 106 and 107 proved to be quite challenging (Scheme 
2.4.2).  Initially we had planned to utilize an approach that had served us well in the past 
involving trapping of a benzyne intermediate with a carbon nucleophile.  Ultimately, we 
were unable to define successful reaction conditions and were forced to abandon this 
approach in favor of a cross coupling process.  Suzuki-Miyaura cross coupling of triflate 
71 or 72 with an appropriate vinyl boronate would allow us to install functionality that 
would be transformed into the oxaadamantane system.  Treatment of commercially 
available 1,3-adamantanediol with benzenesulfonyl chloride84 in a mixture of pyridine 
42 
 
and benzene at 70 °C led to Grob fragmentation product 108.  Ozonolysis of crude alkene 
108 gave diketone 109 in 66% yield over the two steps.  It should be noted that the use of 
CH2Cl2 rather than CH2Cl2/MeOH resulted in consistently higher yields due to the 
formation of a methoxy hemiketal in the mixed solvent system.  The hemiketal byproduct 
can be hydrolyzed to release diketone 109 with concentrated acid in aqueous THF.  
Selective protection of one of the two carbonyl groups as the ethylene ketal formed 110 
in 94% yield.  Reaction times must be kept short in order to prevent the formation of the 
bis-ketal product.  Treatment of ketone 110 with LDA in THF at -78 °C with PhNTf2 
followed by acid catalyzed exchange of the ketal led to triflate 111 in 82% yield for the 
two steps.  Suzuki coupling of 111 with bis-pinacolato diborane led to vinyl boronate 112 
in good yield (Scheme 2.4.1).85, 86   
 
Scheme 2.4.1 Reagents and conditions: (a) PhSO2Cl, PhH, pyridine, 70 °C; (b) O3, 
CH2Cl2, -78 °C; Me2S; 66% for two steps; (c) HO(CH2)2OH, PhH, TsOH (cat.), reflux, 
Dean-Stark; 94%; (d) LDA, THF, -78 °C; PhNTf2, THF, -78 °C to 0 °C; (e) acetone, 
TsOH (cat.), rt; 82% from 110; (f) PdCl2(PPh3)2, PPh3, K2CO3, 1,4-dioxane, PinB-BPin, 
70 °C; 73%. 
Tricyclic intermediates 71 and 72 were then coupled with vinyl boronate 112.  Treatment 
of a slight excess of 112 with PdCl2(dppf)·CH2Cl2, K2CO3 and aryl triflates 71 and 72 in 
a 4/1 mixture of DMF/EtOH at 70 °C led to coupled products 113 and 114 in 87% and 
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67% yield, respectively.  Because 112 is racemic whereas 71 and 72 are homochiral, 
products 113 and 114 are formed in diastereomeric mixtures.  For the sake of simplicity, 
only one diastereomeric structure is shown in Scheme 2.4.1.  Treatment of ketones 113 
and 114 with NaBH4 led exclusively to the endo alcohols 115 and 116.  Immediate 
purification was required to obtain high yields due to the premature cyclization of the 
crude material that occurs upon standing.  Exposure of 115 and 116 to ZnBr2 and n-BuSH 
at room temperature removed the methoxymethyl ether protecting groups and induced 
cyclization forming 106 and 107 in 95% yield and 79% yield, respectively (Scheme 
2.4.2).   
 
Scheme 2.4.2 Reagents and conditions: (a) 112, PdCl2(dppf)· CH2Cl2, K2CO3, 
DMF/EtOH (4/1), 70 °C; 113, 87%; 114, 67%; (b) NaBH4, MeOH, 0 °C; 115, 90%; 116, 





3 Receptor Binding Studies and Molecular Modeling 
Receptor binding studies and molecular modeling of all final compounds were conducted 
at Northeastern University, Center for Drug Discovery under the direction of Professor 
Alexandros Makriyannis.  Competitive binding assays with the radioligand [3H]-CP-55, 
940 (3) were carried out using rat brain or membranes from HEK293 cells to assess the 
affinities for the CB1 and CB2 receptor binding sites, respectively, following previously 
described procedures.  A series of experiments were conducted for each compound at 
varying concentrations and the results of which will be discussed in detail in this chapter.  
The two oxazaadamantyl cannabinoids, 117 and 118, prepared by Dr. David Le Goanvic 
will also be discussed in this section for completeness sake (Figure 3.1).  
 
Figure 3.1 Oxazaadamantyl cannabinoids prepared by Dr. David Le Goanvic. 
Earlier work from the Makriyannis laboratory87 showed that the 1-adamantyl cannabinoid 
AM-411 exhibited preferential affinity for CB1 while the 2-adamantyl analog AM-744 
had higher affinity for CB2.  To probe the stereoelectronic properties of the adamantyl 
group and to explore potential opportunities to improve the polar properties of the 
adamantyl cannabinoid ligands we introduced heteroatoms throughout the adamantyl 
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group.  The small library of compounds that were prepared can be divided into three 
groups.  The first group includes the analogs with the 2-oxaadamantyl and 2,6-
oxazaadamantyl substituent directly attached to the C3 position of the tricyclic nucleus 
(106, 107, 117 and 118).  The second group has heteroatoms incorporated into the 
carbocyclic 1- or 2-adamantyl residue appended at C3 through a carbonyl (88-91) or 
methylene spacer (98-101).  Finally, the third group has the 2,6-oxazaadamantyl residue 
attached to C3 through a carbonyl (86 and 87) or methylene spacer (96 and 97).  Binding 

















rCB1 mCB2 hCB2 
146 0.0068 0.052 N.A. 
Group 1    
106  0.023 0.018 0.019 
107 0.55 0.54 1.3 
117 1.8 1.2 1.8 
118 22.4 17 14.9 
Group 2    
88 80 0.5 8.7 
89 375 7.5 35 
90 15 1.2 2.7 
91 100 3.7 15 
98 150 0.5 10 
99 100 5 25 
100 150 6.2 20 













Table 3.1 Continued. 
 
Group 3    
86 No binding 2.5 20 
87 No binding  8.6 25 
96 10 8.7 15 
97 125 7.5 5 
 
a Ki values for compounds 117, 118, 106 and 107 were obtained from one experiment (8 
point) run in triplicate. Ki values for compounds 88 - 91 and 98 - 101 which were all in 
the micromolar range were derived from a single experiment (2 points) run in triplicate. 
The oxazaadamantyl cannabinoids displayed reduced affinities for the CB1 and CB2 
receptors when compared to their carbocyclic counterparts, AM-411 and AM-744.  All 
analogs containing the C9 β-hydroxy showed stronger affinities to both receptors when 
compared to the C9 α-hydroxy analogs which is congruent with earlier data (For 
example: 106 and 107).  All compounds belonging to the second group (88 – 91 and 98 - 
101) had low affinities for both receptors but showed considerable selectivity for CB2 
over CB1.  This suggests that the CB2 receptors in humans and mice are capable of 
accommodating larger side chain substituents when compared to CB1.  It also suggests 
that the mouse CB2 receptor is able to accommodate larger groups compared to the 
human CB2 receptor. 
The third group displayed lower affinities than the carbocyclic counterparts while 
maintaining selectivity for CB2 (see Table 3.1).  Again, the mouse CB2 receptor showed 
slightly stronger affinities than the human CB2 receptor. 
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The analogs of the first group are the most structurally compact and similar to the potent 
cannabinoid AM-411.  We were pleased to find that 106 showed favorable affinities for 
both receptors.  Surprisingly, 106 showed a different pharmacological profile than AM-
411.  Oxaadamantane 106 showed modest selectivity for CB2 while AM-411 is CB1 
selective.  This result could be due to the presence of the oxygen atom in the adamantyl 
group which results in increased polarity (clogP) compared to AM-411 and may suggest 
that a hydrogen bond is formed in the active site of the binding pocket of the CB2 
receptor.   
To explain the observed differences of the three groups, molecular modeling was used.  
Since the only pharmacophoric variable was the substituent at C3, the focus was on the 
stereoelectronic and conformational properties as well as the available conformational 
space for the C3 substituents.  Force field methods were used and retained all conformers 
within 6 kcal/mol of the global minimum.   
The second and third groups cover a significantly larger volume which can be attributed 
to the low affinity of these compounds.  The large desolvation penalties due to the polar 
nature of the linkers as well as the bulkiness of these substituents do not allow for optimal 
interaction with the pharmacophoric site in the cannabinoid receptors.  A representative 
example from each group is shown in Figure 3.2 with accessible conformers within 6 





Figure 3.2 Pharmacophoric space for group 1 [106 (green), 117 (cyan)], group 2 [100 
(magenta)] and group 3 [97 (orange)]. 
Meanwhile, the low affinities for oxazaadamantyl cannabinoids 117 and 118 can not be 
explained using the pharmacophoric space argument since there is no striking difference 
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in the accessible conformational volumes compared to the oxaadamantyl analogs.  In 
order to explain the differences in binding affinity between the oxazaadamantyl and 
oxaadamantyl analogs, the energy barrier for rotation around the C3-C1’ bond were 
investigated.  To explore these permissible rotations of the C3 substituents a 
conformational search was performed using the OPLS force field88, 89 with the tricyclic 
moiety held fixed with minimization on the geometric parameters being performed.  All 
calculations were performed on Macromodel90 and conformers with greater than 0.5 Å 
root mean square deviation within 6 kcal/mol of the global minimum were retained.  
Also, entropic factors of 106 and 117 were of interest and calculations were performed at 
the B3LYP/6-31G** level.  A plot of the energy barriers of rotation for 106 and 117 are 
shown in Figure 3.3.  The calculations revealed that the oxaadamantyl analogs have a 
rotational barrier of approximately 6.3 kcal/mol while the oxazaadamantyl analogs have a 
significantly higher barrier of approximately 12.3 kcal/mol.  It can be argued that while 
both analogs in question occupy similar conformational spaces, entropic advantages 
associated with the more facile rotation of the oxaadamantyl moiety may improve ligand 
binding affinity.  It is also possible that the nitrogen and oxygen atoms of the 2, 6-
















4 Conclusion  
In conclusion, the design and execution of new synthetic approaches to several C3 
substituted heteroadamantyl cannabinoids and analogs thereof have been described.  The 
key steps in the synthetic scheme are the condensation of persilylated phloroglucinol with 
nopinone derived diacetates, TMSOTf catalyzed rearrangement and cyclization to form 
the dihydropyran, selective triflation of the hydroxyl at C3, stereoselective reduction at 
C9, palladium catalyzed cyanation, and Suzuki-Miyaura cross coupling between a vinyl 
boronate and aryl triflate.  All analogs showed at least micromolar affinity for the 
receptors and selectivity for CB2 over CB1. The C9 β-hydroxy 2-oxaadamantyl analog 
had the highest affinity for CB2 (Ki = 18.5 nM) and showed a slight preference for CB2 
over CB1 and will be tested in a rat behavioral model.  Molecular modeling of the 
analogs showed that the presence of a carbonyl or methylene linker at C1’ drastically 
increases the pharmacophoric space resulting in decreased binding affinity.  This work 
also confirmed that the C9 β-hydroxy analogs have higher affinities compared to the C9 
α-hydroxy analogs, that space for the adamantyl pharmacophore is most restricted at CB1 
and that there appears to be a species difference with the mouse CB2 receptor being more 
accommodating for steric bulk at C3 than human CB2.  Functionalization of the Suzuki-
Miyaura product can also be envisioned as an intermediate to form novel oxaadamantane 
derivatives with reactive functional groups present to act as covalent probes which are 




5 Experimental Section 
General: 
1H and 13C NMR spectra were recorded on a Varian Mercury Plus 300 (1H 300 MHz, 13C 
75 MHz) or a Varian Unity INOVA 500 (1H 500 MHz, 13C 126 MHz) in either 
deuterochloroform (CDCl3; 1H 7.26 ppm, 13C 77.0 ppm), deuterobenzene (C6D6; 1H 7.15 
ppm, 13C 128.0 ppm) or deuteromethanol (CD3OD; 1H 3.31 and 4.90 ppm, 13C 49.0 
ppm).  Chemical shifts are given in δ, with multiplicities given as s (singlet), br (broad 
singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or a combination thereof and J 
(coupling constants) given in hertz (Hz).  IR spectra were recorded on a Nicolet 380 FT-
IR using a NaCl plate.  Mass spectral data was collected on either an Agilent 1100 Series 
LC-MS TOF (ESI+ or APCI+ source) or VG-70SE (EI+ source).  Optical rotation data was 
collected on a JASCO DIP-370 digital polarimeter.  Melting points were collected on a 
Mel-Temp II melting point apparatus and are uncorrected.  Thin-layer chromatography 
(TLC) was performed using Sigma-Aldrich silica-gel, general-purpose TLC plates with 
UV indicator (F254).  Flash chromatography was performed using Silicycle SiliaFlash F60 
silica gel (230-400 mesh).  All solvents used were purified using a solvent purification 
system.  The purity of assayed compounds were of at least 95% and were verified using 
high performance liquid chromatography on an Agilent 1200 Series or a Beckman 
Coulter System Gold HPLC equipped with Daicel Chiralpak AD-H (4.6 x 250 mm), 




To a suspension of phloroglucinol 61 (5.50 g, 43.7 mmol) in 300 mL of CH2Cl2 at 0 °C 
was added TEA (24.3 mL, 174.6 mmol) followed by TMSCl (22.3 mL, 174.6 mmol).  
After 20 min the cooling bath was removed and the mixture was allowed to stir at room 
temperature for an additional 2 h.  The salts were removed via filtration and the filtrate 
was washed with ice cold water (3x), dried over Na2SO4 and concentrated affording 
persilylated phloroglucinol 63.  Crude 63 was then dissolved in 440 mL of a 4:1 mixture 
of CHCl3:acetone and cooled to 0 °C.  In a separate flask diacetates 39 and 40 (4.42 g, 
18.6 mmol; 5.2 g of 85% pure diacetates 39 and 40 were used) were dissolved in 150 mL 
of 4:1 CHCl3:acetone along with TsOH·H2O (4.57 g, 24.0 mmol).  The TsOH·H2O and 
diacetates mixture was then added dropwise to persilylated phloroglucinol 63 at a rate of 
approximately one drop/s via an addition funnel.  The reaction mixture was then slowly 
warmed to room temperature.  Once the diacetates were shown to be consumed 
(monitored by TLC) the reaction was quenched with saturated NaHCO3 and stirred for 45 
min.  The organic layer was separated and dried over MgSO4, while the aqueous layer 
was back-extracted with EtOAc (6x) and dried over MgSO4.  To the crude condensation 
product 62 and DMAP (100 mg, 0.82 mmol) in 200 mL of CH2Cl2 at 0 oC was added 
pyridine (13.0 mL, 160.0 mmol) followed by Ac2O (15.1 mL, 160.0 mmol).  The mixture 
was stirred for 12 h before being quenched with ice cold water, washed sequentially with 
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1 M HCl, brine then dried over MgSO4.  The crude product was then purified via flash 
column chromatography on silica gel eluting with 30% EtOAc/hexanes affording 64 
(4.90 g, 68% yield over 2 steps) as a white solid. 
mp: 138-140 °C 
1H NMR (CDCl3, 300 MHz): δ 6.83 (s, 2H), 3.63 (t, J = 8.4 Hz, 1H), 2.80 (m, 1H), 2.66-
2.57 (m, 3H), 2.29-2.25 (m, 10H), 2.13 (m, 1H), 1.37 (s, 3H), 0.95 (s, 3H) 
13C NMR (CDCl3, 75 MHz): δ 212.4, 168.5, 168.4, 149.5, 148.5, 125.0, 114.6, 57.1, 45.3, 
42.0, 38.7, 30.6, 26.0, 24.5, 21.8, 20.9 
 IR (thin film, cm-1): 2947, 1769, 1709, 1608, 1427, 1371, 1185, 1122, 1031, 903 
 HR EI+ Mass Spec. Calculated for C21H24O7: 388.1522, found: 388.1532 (2.6 ppm error) 
EI+(m/z):  388 (M+, 10), 346 (62), 304 (33), 303 (25), 262 (30), 262 (51), 244 (27),  219 
(53), 207 (20), 194 (32), 177 (34), 152 (50), 83 (100) 







To a solution of the triacetate 64 (4.90 g, 12.6 mmol) in 50 mL of MeOH at 0 °C was 
added KOH (2.48 g, 44.2 mmol) under N2. The reaction mixture was stirred at this 
temperature for an additional 2 h and then quenched with 1 N HCl.  MeOH was removed 
under reduced pressure, and the residue was diluted with EtOAc, washed with brine and 
dried over MgSO4.  The crude product was carried on without further purification.  An 
analytical sample could be purified via flash column chromatography on silica gel eluting 
with 50% EtOAc/hexanes affording 62 (3.30 g, 100% yield) as an off-white foam that 
typically entrains 10-15% ethyl acetate.  
1H NMR (MeOH-d4, 300 MHz) δ 5.85 (s, 2H), 3.95 (t, J = 8.1 Hz, 1H), 3.67 (dd, J = 18.6 
Hz, 7.5 Hz, 1H), 2.60 (m, 1H), 2.48-2.35 (m, 3H), 2.14 (t, J = 6.0 Hz, 1H), 1.35 (s, 3H), 
0.94 (s, 3H) 
13C NMR (MeOH-d4, 75 MHz) δ 220.2, 158.5, 157.3, 108.9, 95.9, 59.3, 48.8, 43.2, 38.8, 






To a solution of 62 (1.02 g, 3.89 mmol; the mass of pure ketone 62 was 1.20 g; (ethyl 
acetate was present as an impurity) in 300 mL of MeNO2 at 0 °C was added TMSOTf 
(1.76 mL, 9.73 mmol) dropwise. The resulting mixture was stirred for 2.5 h at 0 °C, then 
quenched with solid K2CO3 and stirred for 45 min at rt. The solids were filtered off and 
the solvent removed under reduced pressure.  Crude 65 was used without further 
purification in the next step. 
1H NMR (MeOH-d4, 300 MHz) δ 5.85 (d, J = 2.4 Hz, 1H), 5.76 (d, J = 2.4 Hz, 1H), 3.81 
(dd, J = 15.0 Hz, 3.0 Hz, 1H), 2.75 (m, 1H), 2.47-2.25 (m, 2H), 2.18-2.02 (m, 2H), 1.92 
(td, J = 12.3 Hz, 2.4 Hz, 1H), 1.51 (m, 1H), 1.42 (s, 3H), 1.08 (s, 3H) 
 13C NMR (MeOH-d4, 75 MHz) δ 214.6, 158.3, 156.6, 111.2, 104.3, 96.7, 96.6, 77.8, 








To crude ketone 65 (1.02 g, 3.89 mmol) in 40 mL of CH2Cl2 at 0 °C was added TEA 
(1.62 mL, 11.7 mmol) followed by dropwise addition of 
N-phenyltrifluoromethanesulfonimide (1.60 g, 4.47 mmol) in 40 mL of CH2Cl2 via 
cannula.  The reaction mixture was allowed to warm to room temperature over 12 h, was 
quenched with 1 N HCl and washed with water.   The aqueous layer was back extracted 
with CH2Cl2, washed with brine and dried over MgSO4.  The crude product was purified 
via flash column chromatography on silica gel eluting with 20, 30 and 40% 









1H NMR (CDCl3, 300 MHz):  δ 6.39 (d, J = 2.4 Hz, 1H), 6.33 (d, J = 2.4 Hz, 1H), 4.13 
(d, J = 15 Hz, 1H), 2.89 (m, 1H), 2.70 (m, 1H), 2.53 (m, 1H), 2.25-1.95 (m, 3H), 1.62-
1.49 (m, 4H), 1.29-1.12 (m, 4H) 
13C NMR (CDCl3, 75 MHz):  δ 215.9, 156.6, 155.6, 148.8, 110.7, 102.3, 100.9, 77.8, 
46.9, 44.2, 40.7, 34.7, 27.6, 26.8, 18.8 
IR (thin film, cm-1):  3415(br), 1617, 1423, 1246, 1211, 1141, 1099 
HR EI+ Mass Spec. Calculated for C16H17F3O6S:  394.0698, found: 394.0681 (4.2 ppm 
error) 
EI+(m/z):  394 (M+, 13), 279 (28), 270 (72), 243 (69), 225 (80), 207 (100), 195 (70) 










To ketone 67 (583 mg, 1.48 mmol) in 15 mL of MeOH at 0 °C was added NaBH4 (280 
mg, 7.40 mmol) in 3 portions over 5 min.  The reaction mixture was then stirred for 1 h, 
quenched with dropwise addition of 1 N HCl and diluted with EtOAc.  The organic layer 
was washed with brine and dried over MgSO4.  The crude product was then purified via 
flash column chromatography on silica gel eluting with 30% then 40% EtOAc/hexanes 
affording alcohol 69 and minor alcohol 70 (570 mg, 97% combined yield; the minor 
diastereomer is easily removed during column chromatography after the subsequent 









1H NMR (CDCl3, 300 MHz):  δ 8.19 (br s, 1H), 6.27 (s, 1H), 6.18 (s, 1H), 3.95 (m, 1H), 
3.62 (m, 1H), 2.50-2.42 (m, 2H), 2.18 (m, 1H), 1.91 (m, 1H), 1.51-1.42 (m, 2H), 1.37 (s, 
3H), 1.16 (m, 1H), 1.03 (m, 4H) 
13C NMR (CDCl3, 75 MHz):  δ 156.5, 155.9, 148.3, 119.9, 102.3, 100.6, 77.8, 71.5, 47.7, 
37.1, 35.7, 33.3, 27.6, 25.8, 18.9 (C belonging to the triflate was not observed due to its 
long relaxation time) 
IR (thin film, cm-1):  3245(br), 2937, 2873, 1597, 1420, 1245, 1213, 1141, 989, 857 
HR EI+ Mass Spec. Calculated for C16H19F3O6S: 396.0854, found: 396.0863 (2.1 ppm 
error) 
EI+(m/z):  396 (M+, 79), 378 (45), 336 (57), 335 (100), 186 (29), 69 (71) 










To ketone 67 (299 mg, 0.76 mmol) in 8 mL of THF at -78 °C was added a 1 M solution 
of L-Selectride® in THF (3.00 mL, 3.00 mmol).  The reaction was maintained at -78 °C 
for 2 h and then stirred at room temperature for 1 h.  The flask was cooled to -78 °C and 
solid NaHCO3 (930 mg, 11.1 mmol) was added followed by dropwise addition of a 30% 
aqueous solution of H2O2 (1.60 mL).  After the addition of 30% H2O2 was complete the 
cooling bath was removed and the reaction mixture was stirred for 1 h at rt. A saturated 
solution of sodium thiosulfate (5 mL) was added and the reaction mixture was stirred for 
an additional 30 min.  Ether was added and the organic layer was separated, then washed 
with brine and dried over MgSO4.  The crude product was purified via flash column 
chromatography on silica gel eluting with 40% EtOAc/hexanes affording alcohol 70 (269 








mp: 188.5-192.5 °C 
1H NMR (CDCl3, 300 MHz):  δ 7.66 (br s, 1H), 6.30 (d, J = 2.5 Hz, 1H), 6.26 (d, J = 2.5 
Hz, 1H), 4.35 (s, 1H), 3.24 (d, J = 14.1 Hz, 1H), 2.93-2.86 (m, 1H), 2.54 (br s, 1H), 1.97 
(m, 1H), 1.77-1.68 (m, 2H), 1.56-1.46 (m, 2H), 1.37-1.26 (m, 4H), 0.99 (s, 3H) 
13C NMR (CDCl3, 75 MHz):  δ 156.1, 148.3, 112.8, 102.9, 101.3, 77.7, 67.5, 48.8, 35.3, 
33.5, 28.9, 27.2, 22.5, 18.8 (C belonging to the triflate was not observed due to its long 
relaxation time) 
IR (thin film, cm-1):  3210(br), 2938, 1597, 1506, 1419, 1245, 1212, 1140, 1102, 987, 
879, 839, 735 
 HR EI+ Mass Spec. Calculated for C16H19F3O6S – H2O: 378.0749, found: 378.0743 (1.6 
ppm error) 
EI+(m/z):  396 (M+, 8), 378 (64), 335 (56), 309 (31), 202 (14), 151 (42), 101 (39), 92 
(19), 69 (100) 

















Alcohol 69 (430 mg, 1.08 mmol) was dissolved in 10 mL of CH2Cl2, was cooled to 0 °C 
and was treated with DIPEA (1.13 mL, 6.48 mmol) and dropwise addition of MOMCl 
(492 µL, 6.48 mmol).  After 45 min the cooling bath was removed and the reaction 
mixture was stirred at room temperature for another 1 h 45 min.  Saturated NaHCO3 was 
added to quench the reaction and the resulting mixture was diluted with Et2O.  The 
organic layers were washed with CuSO4 and brine, then dried over MgSO4.  The crude 
product was purified via flash column chromatography on silica gel eluting with 20% 









1H NMR (CDCl3, 300 MHz):  δ 6.56 (d, J = 2.5 Hz, 1H), 6.40 (d, J = 2.5 Hz, 1H), 5.19-
5.12 (m, 2H), 4.74-4.69 (m, 2H), 3.71 (m, 1H), 3.47 (s, 3H), 3.69 (s, 3H), 3.33 (m, 1H), 
2.44 (td, J = 11.3 Hz, 2.4 Hz, 1H), 2.19 (m, 1H), 1.89 (m, 1H), 1.55-1.37 (m, 5H), 1.19-
1.03 (m, 5H) 
13C NMR (CDCl3, 75 MHz):  δ 157.1, 155.4, 148.5, 114.2, 104.3, 99.5, 94.8, 94.6, 77.8, 
75.5, 56.3, 55.1, 48.1, 36.1, 33.7, 33.0, 27.4, 25.9, 18.8 
IR (thin film, cm-1):  3197, 3105, 2940, 2789, 1603 
HR EI+ Mass Spec. Calculated for C20H27F3O8S: 484.1379, found: 484.1354 (5.0 ppm 
error) 
EI+(m/z):  484 (M+, 7), 379 (33), 378 (100), 335 (25), 245 (19) 










Compound 72 was prepared from 70 (247 mg, 0.623 mmol) in 94% yield (284 mg) as a 
clear, colorless oil. 
1H NMR (CDCl3, 300 MHz):  δ 6.55 (d, J = 2.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 5.19-
5.12 (m, 2H), 4.81 (d, J = 6.8 Hz, 1H), 6.71 (d, J = 6.8 Hz, 1H), 4.02 (m, 1H), 3.48 (s, 
3H), 3.44 (s, 3H), 3.26 (m, 1H), 2.88 (td, J = 11.0 Hz, 2.3 Hz, 1H), 2.04 (m, 1H), 1.71-
1.43 (m, 4H), 1.38 (s, 3H), 1.18 (m, 1H), 1.08 (s, 3H) 
 13C NMR (CDCl3, 75 MHz):  δ 157.1, 155.7, 148.4, 115.0, 104.4, 99.5, 94.7, 94.2, 77.9, 
70.8, 56.3, 55.2, 48.8, 33.9, 31.3, 29.7, 27.3, 23.1, 19.0 
 IR (thin film, cm-1):  3198, 2978, 2942, 2827, 2788, 1603 
HR EI+ Mass Spec. Calculated for C20H27F3O8S: 484.1379, found: 484.1354 (5.0 ppm 
error) 
EI+(m/z):  484 (M+, 8), 439 (14), 379 (35), 378 (100), 335 (35), 245 (27), 149 (15), 69 
(31) 





To triflate 71 (435 mg, 0.90 mmol) was added Zn(CN)2 (84 mg, 0.72 mmol), Pd2(dba)3 
(82 mg, 0.090 mmol) and PPh3 (188 mg, 0.718 mmol) followed by PMHS (44 mg, 
10 wt. %) and 27 mL of DMF under an atmosphere of argon. The reaction mixture was 
further degassed by bubbling argon through the mixture for 15 min. The reaction mixture 
was heated to 60 °C and stirred for 8 h. The solvent was removed under reduced pressure 
and the residue was adsorbed onto Celite. The crude product was subjected to flash 
column chromatography on silica gel eluting with 10%, 20% and 30% EtOAc/hexanes 









1H NMR (CDCl3, 300 MHz): δ 6.90 (d, J = 1.6 Hz, 1H), 6.77 (d, J = 1.6 Hz, 1H), 5.21 (d, 
J = 6.8 Hz, 1H), 5.16 (d, J = 6.8 Hz, 1H), 4.73 (dd, J = 8.0 Hz, 7.1 Hz, 2H), 3.74 (m, 1H), 
3.49 (s, 3H), 3.40-3.30 (m, 4H), 2.49 (td, J = 11.4 Hz, 2.4 Hz, 1H), 2.21 (m, 1H), 1.92 
(m, 1H), 1.57-1.39 (m, 5H), 1.20-1.03 (m, 5H) 
13C NMR (CDCl3, 75 MHz): δ 156.7, 155.2, 119.8, 118.8, 115.6, 110.9, 108.7, 94.9, 94.5, 
77.8, 75.5, 56.4, 55.2, 48.2, 36.1, 34.1, 33.0, 27.5, 25.9, 18.7 
IR (thin film, cm-1): 2939, 2880, 2228, 1565, 1423, 1369, 1336, 1207, 1155, 1103, 1058 
HR EI+ Mass Spec. Calculated for C20H27NO5: 361.1889, found: 361.1880 (2.5 ppm 
error) 
EI+(m/z):  361 (M+, 11), 285 (19), 255 (100), 240 (25), 212 (75), 69 (10) 









Nitrile 74 was obtained from 72 (510 mg, 1.05 mmol) in 97% yield (370 mg) as a 
colorless oil.  
1H NMR (CDCl3, 300 MHz): δ 6.86 (s, 1H), 6.74 (s, 1H), 5.17 (d, J = 6.6 Hz, 1H), 5.12 
(d, J = 6.6 Hz, 1H), 4.79 (d, J = 6.8 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 4.01 (bs, 1H), 3.46 
(s, 3H), 3.42 (s, 3H), 3.23 (m, 1H), 2.93 (app t, J = 9.6 Hz, 1H), 2.02 (m, 1H), 1.70 -1.32 
(m, 7H), 1.15 (m, 1H), 1.04 (s, 3H) 
13C NMR (CDCl3, 75 MHz): δ 156.5, 155.3, 120.6, 118.7, 115.4, 110.4, 108.4, 94.4, 94.0, 
77.6, 70.5, 56.2, 55.0, 48.6, 33.7, 31.1, 30.0, 27.1, 23.0, 18.7 
IR (thin film, cm-1): 2938, 2229, 1564, 1413, 1339, 1224, 1150, 1101, 1048, 1003 
HR EI+ Mass Spec. Calculated for C20H27NO5: 361.1889, found: 361.1880 (2.5 ppm 
error) 
EI+(m/z):  361 (M+, 7), 284 (16), 255 (100), 212 (63), 77 (22) 













73 75  
To nitrile 73 (52 mg, 0.15 mmol) in a screw cap vial was added MeOH:H2O (4:1, 1 mL) 
and LiOH (61 mg, 1.45 mmol) and the mixture was heated to 70 °C in an oil bath for 3 
days.  Conc. HCl was added to the reaction mixture and the resultant milky solution was 
extracted with CHCl3, washed with saturated brine and dried over Na2SO4.  Acid 75 was 
obtained as a clear, colorless oil (50 mg, 91% yield).  No purification was necessary. 
1H NMR (CDCl3, 300 MHz):  δ 7.29 (s, 1H), 7.24 (s, 1H), 5.26 (d, J = 6.6 Hz, 1H), 5.20 
(d, J = 6.6 Hz, 1H), 4.74 (dd, J = 9.3 Hz, 6.9 Hz, 2H), 3.76 (m, 1H), 3.51 (s, 3H), 3.47-
3.40 (m, 4H), 2.51 (td, J = 11.1 Hz, 1.8 Hz, 1H), 2.25-2.18 (m, 1H), 1.90 (m, 1H), 1.60-
1.40 (m, 5H), 1.25-1.04 (m, 5H) 
13C NMR (CDCl3, 75 MHz):  δ 171.2, 156.3, 154.8, 128.7, 120.1, 113.7, 106.5, 94.8, 
94.5, 77.4, 75.7, 56.4, 55.2, 48.4, 36.2, 34.3, 33.1, 27.6, 26.1, 18.7 
IR (thin film, cm-1):  2939, 1719, 1690, 1574, 1424, 1375, 1211, 1149, 1100, 1051 
HR EI+ Mass Spec. Calculated for C20H28O7: 380.1835, found: 380.1827 (2.1 ppm error) 
EI+(m/z):  380 (M+, 3), 293 (11), 149 (100), 71 (26) 




Acid 76 was obtained from 74 (68 mg, 0.19 mmol) in 91% yield (65 mg) as a semi solid.  
1H NMR (CDCl3, 300 MHz): δ 7.28 (d, J = 1.7 Hz, 1H), 7.24 (d, J = 1.7 Hz, 1H), 5.25 (d, 
J = 6.6 Hz, 1H), 5.19 (d, J = 6.6 Hz, 1H), 4.85 (d, J = 6.9 Hz, 1H), 4.73 (d, J = 6.9 Hz, 
1H), 4.04 (br s, 1H), 3.50 (s, 3H), 3.45 (s, 3H), 3.33 (m, 1H ), 2.94 (td, J = 11.0 Hz, 2.2 
Hz, 1H ), 2.04 (m, 1H), 1.70 (m, 1H), 1.60-1.40 (m, 5H), 1.25-1.13 (m, 2H), 1.08 (s, 3H) 
13C NMR (CDCl3, 75 MHz): δ 171.4, 156.3, 155.0, 128.6, 121.0, 113.7, 106.5, 94.5, 94.0, 
77.3, 70.7, 56.4, 55.2, 48.9, 33.8, 31.3, 30.3, 27.4, 23.2, 18.9 
IR (thin film, cm-1): 2936, 1688, 1570, 1418, 1296, 1212, 1149, 1046 
HR EI+ Mass Spec. Calculated for C20H28O7: 380.1835, found: 380.1824 (2.9 ppm error) 
EI+(m/z):  380 (M+, 15), 274 (100), 259 (24), 231 (56), 191 (10) 





To a solution of 75 (30 mg, 0.079 mmol) in 2 mL CH2Cl2 was added amine 77 (30 mg, 
0.12 mmol) followed by DMAP (39 mg, 0.32 mmol) and EDCI (30 mg, 0.16 mmol). The 
flask was sealed with a Teflon cap and stirred overnight at rt. The mixture was diluted 
with EtOAc, washed with 1 N HCl, brine and dried over MgSO4.  The crude product was 
directly adsorbed onto Celite and purified via flash column chromatography eluting with 











1H NMR (CDCl3, 300 MHz): δ 6.66 (s, 1H), 6.49 (s, 1H), 5.21 (d, J = 6.6 Hz, 1H), 5.12 
(d, J = 6.6 Hz, 1H), 5.05 (br s, 1H), 4.72 (dd, J = 9.6 Hz, 6.9 Hz, 2H), 4.24-4.18 (m, 3H), 
3.73 (m, 1H), 3.47 (s, 3H), 3.43-3.34 (m, 4H), 2.47 (td, J = 11.2 Hz, 2.0 Hz, 1H), 2.21-
1.75 (m, 10H), 1.57-1.37 (m, 5H), 1.21-1.02 (m, 5H) 
13C NMR (CDCl3, 75 MHz): δ 169.1, 156.6, 154.8, 135.4, 115.5, 109.4, 103.9, 94.7, 94.5, 
77.2, 75.6, 66.7, 56.2, 55.1, 49.0, 48.4, 42.9, 36.3, 35.1, 34.3, 33.9, 33.1, 27.6, 26.0, 18.8 
IR (thin film, cm-1): 2937, 1626, 1566, 1424, 1370, 1148, 1101, 1048 
HR EI+ Mass Spec. Calculated for C28H39NO7: 501.2727, found: 501.2702 (5.0 ppm 
error) 
EI+(m/z):  501 (M+, 28), 457 (23), 395 (100), 380 (13), 352 (20), 257 (30), 167 (17), 149 
(44), 95 (21), 71 (24), 69 (30) 





















Amide 79 was obtained from 76 (30 mg, 0.079 mmol) in 88% yield (35 mg) as a 
colorless oil.  
1H NMR (CDCl3, 300 MHz): δ 6.63 (d, J = 1.2 Hz, 1H), 6.48 (d, J = 1.2 Hz, 1H), 5.19 (d, 
J = 6.6 Hz, 1H), 5.09 (d, J = 6.6 Hz, 1H), 5.04 (br s, 1H), 4.81 (d, J = 6.9 Hz, 1H), 4.70 
(d, J = 6.9 Hz, 1H), 4.25-4.18 (m, 3H), 4.01 (br s, 1H), 3.45 (s, 3H), 3.42 (s, 3H), 3.27 
(m, 1H), 2.88 (m, 1H), 2.17-1.74 (m, 9H), 1.71-1.35 (m, 7H), 1.17 (m, 1H), 1.05 (s, 3H) 
13C NMR (CDCl3, 75 MHz): δ 169.2, 156.6, 155.0, 135.2, 116.3, 109.4, 103.9, 94.5, 94.0, 
77.3, 70.7, 66.8, 56.2, 55.2, 49.1, 42.9, 35.1, 34.3,  34.2, 34.0, 31.4, 29.9, 27.4, 23.2, 19.0 
IR (thin film, cm-1): 2937, 1626, 1566, 1424, 1370, 1148, 1101, 1048 
HR EI+ Mass Spec. Calculated for C28H39NO7: 501.2727, found: 501.2710 (3.4 ppm 
error) 
EI+(m/z):  501 (M+, 28), 424 (18), 395 (65), 321 (26), 293 (29), 167 (46), 149 (100), 104 
(19), 85 (55), 71 (54), 69 (49) 

















Amide 80 was obtained from 75 (30 mg, 0.079 mmol) in 90% yield (36 mg) as a 
colorless oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.06 (d, J = 2.0 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 5.73 
(s, 1H), 5.25 (d, J = 6.5 Hz, 1H), 5.18 (d, J = 6.5 Hz, 1H), 4.73 (dd, J = 12.5 Hz, 6.5 Hz, 
2H), 3.74 (m, 1H), 3.49 (s, 3H), 3.43-3.39 (m, 4H), 2.49 (td, J = 11.3 Hz, 2.3 Hz, 1H), 
2.21 (m, 1H), 2.12-2.08 (m, 9H), 1.91 (m, 1H), 1.73-1.67 (m, 6H), 1.55-1.40 (m, 5H), 
1.18-1.04 (m, 5H) 
13C NMR (CDCl3, 126 MHz):  δ 166.1, 156.7, 154.5, 135.8, 117.1, 109.0, 104.7, 94.8, 
94.5, 77.3, 75.6, 56.5, 55.2, 52.1, 48.5, 41.6, 36.4, 36.3, 34.1, 33.1, 29.5, 27.7, 26.1, 18.8 
IR (thin film, cm-1):  2907, 1654, 1570, 1522, 1057 
HR EI+ Mass Spec. Calculated for C30H43NO6:  513.3090, found: 513.3082 (1.6 ppm 
error) 
EI+(m/z):  513 (M+, 8), 407 (100), 135 (76) 





Amide 81 was prepared from 76 (25 mg, 0.066 mmol) in 91% yield (31 mg) as a 
colorless oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.05 (d, J = 1.5 Hz, 1H), 6.70 (d, J = 1.5 Hz, 1H), 5.73 
(br s, 1H), 5.24 (d, J = 6.3 Hz, 1H), 5.16 (d, J = 6.3 Hz, 1H), 4.83 (d, J = 6.8 Hz, 1H), 
4.72 (d, J = 6.8 Hz, 1H), 4.04-4.01 (m, 1H), 3.48 (s, 3H), 3.44 (s, 3H), 3.32 (m, 1H), 2.91 
(td, J = 11.1 Hz, 2.7 Hz, 1H), 2.11-2.01 (m, 9H), 1.74-1.66 (m, 7H), 1.63-1.42 (m, 4H), 
1.39 (s, 3H), 1.15 (m, 1H), 1.06 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 166.1, 156.7, 154.7, 135.5, 118.0, 109.0, 104.7, 94.5, 
94.1, 77.4, 70.7, 56.4, 55.2, 52.1, 49.1, 41.6, 36.4, 34.0, 31.4, 30.0, 29.5, 27.4, 23.2, 19.0 
IR (thin film, cm-1):  2907, 2850, 1651, 1570, 1522, 1050 
HR EI+ Mass Spec. Calculated for C30H43NO6: 513.3090, found: 513.3117 (5.0 ppm 
error) 
EI+(m/z):  513 (M+, 6), 407 (25), 318 (19), 274 (100), 259 (28), 231 (59), 207 (22), 167 
(34), 149 (91), 135 (60), 87 (29), 71 (26), 69 (28) 


















1H NMR (CDCl3, 500 MHz):  δ 7.10 (d, J = 1.5 Hz, 1H), 6.77 (d, J = 1.5 Hz, 1H), 6.34 
(d, J = 3.0 Hz, 1H), 5.27 (d, J = 6.5 Hz, 1H), 5.20 (d, J = 6.5 Hz, 1H), 4.73 (dd, J = 12.3 
Hz, 6.8 Hz, 2H), 4.20 (br m, 1H), 3.75 (m, 1H), 3.50 (s, 3H), 3.44-3.38 (m, 4H), 2.50 (td, 
J = 11.3 Hz, 2.3 Hz, 1H), 2.22-2.19 (m, 1H), 2.02-1.98 (m, 2H), 1.94-1.75 (m, 10H), 
1.71-1.65 (m, 3H), 1.57-1.51 (td, J = 11.5 Hz, 2.2 Hz, 1H), 1.50-1.41 (m, 4H), 1.19-1.05 
(m, 5H) 
13C NMR (CDCl3, 126 MHz):  δ 166.2, 156.7, 154.6, 135.1, 117.3, 109.0, 104.8, 94.8, 
94.6, 77.4, 75.6, 37.5, 37.1, 36.3, 34.1, 33.1, 32.0 (2), 31.9 (2), 27.6, 27.2, 27.1, 26.1, 
18.8 
IR (thin film, cm-1):  2906, 2853, 1653, 1570, 1057 
HR EI+ Mass Spec. Calculated for C30H43NO6:  513.3090, found: 513.3096 (1.1 ppm 
error) 
EI+(m/z):  513 (M+, 18), 407 (16), 150 (100), 135 (27) 





















1H NMR (MeOH- d4, 500 MHz):  δ 7.09 (d, J = 1.5 Hz, 1H), 6.76 (d, J = 1.5 Hz, 1H), 
6.34 (d, J = 2.5 Hz, 1H), 5.25 (d, J = 6.0 Hz, 1H), 5.17 (d, J = 6.0 Hz, 1H), 4.83 (d, J = 
6.8 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.20 (br m, 1H), 4.03 (br s, 1H), 3.49 (s, 3H), 3.44 
(s, 3H), 3.33 (m, 1H), 2.92 (td, J = 11.0 Hz, 2.5 Hz, 1H), 2.04-1.98 (m, 2H), 1.91-1.74 
(m, 10H), 1.72-1.43 (m, 7H), 1.40 (s, 3H), 1.17 (m, 1H), 1.09 (s, 3H) 
13C NMR (MeOH- d4, 126 MHz):  δ 166.3, 156.7, 154.8, 134.9, 118.2, 109.0, 104.8, 
94.6, 94.1, 77.4, 70.6, 56.5, 55.2, 53.5, 49.1, 37.5, 37.1, 34.0, 32.0 (2), 31.9, 31.4, 30.0, 
27.4, 27.2, 27.1, 23.2, 19.0 
IR (thin film, cm-1):  2908, 2851, 1653, 1570, 1521, 1471, 1049 
HR EI+ Mass Spec. Calculated for C30H43NO6: 513.3090, found: 513.3102 (2.2 ppm 
error) 
EI+(m/z):  513 (M+, 18), 407 (44), 364 (24), 257 (22), 207 (51), 150 (100), 135 (40), 69 
(17) 






General Procedure for Deprotection of MOM Ethers.   
 To a solution of amide 78 (36 mg, 0.072 mmol) and n-BuSH (180 µL, 1.68 mmol) in 2 
mL of CH2Cl2 was added ZnBr2 (81 mg, 0.36 mmol) all in one portion.  The reaction 
flask was placed in an oil bath and heated at 45 °C for 8 h.  The flask was then cooled to 
room temperature, diluted with EtOAc and quenched with saturated NaHCO3.  The 
organic layer was washed with brine and dried over Na2SO4.  The crude product was 
adsorbed onto Celite and subjected to column chromatography on silica gel using a 
gradient elution of 2.5, 5, 10% MeOH/CH2Cl2.  Amide 86 is a white glass obtained in 









Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 7.50 min and 98.6% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 6.33 (d, J = 1.8 Hz, 1H), 6.29 (d, J = 1.8 Hz, 1H), 
4.96 (br s, 1H), 4.20 (br s, 3H), 3.74 (m, 1H), 3.51 (m, 1H), 2.50 (td, J = 11.3 Hz, 2.5 Hz, 
1H), 2.18-2.09 (m, 3H), 2.06-2.00 (m, 2H), 1.93-1.80 (m, 5H), 1.46 (td, J = 11.8 Hz, 2.3 
Hz, 1H), 1.42-1.33 (m, 4H), 1.20 (m, 1H), 1.04 (s, 3H), 0.95 (m, 1H) 
13C NMR (MeOH- d4, 126 MHz):  δ 171.7, 158.4, 156.7, 136.0, 115.4, 107.7, 105.8, 
78.4, 71.3, 68.2(2), 51.0, 50.1, 44.8, 39.6, 36.6, 36.0, 35.9, 35.2, 35.1, 28.1, 27.2, 19.1 
IR (thin film, cm-1):  3454(br), 2932, 1738, 1727, 1604, 1572, 1441, 1381, 1240, 1057 
HR EI+ Mass Spec. Calculated for C24H31NO5: 413.2202, found: 413.2214 (2.8 ppm 
error) 
EI+(m/z):  413 (M+, 100), 395 (26), 352 (20), 275 (30), 149 (56) 







Compound 87 was prepared from 79 (15 mg, 0.030 mmol) in 89% yield (11 mg) as a 














Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 16.47 min and 98.7% chemical purity. 
1H NMR (MeOH- d 4, 500 MHz):  6.32 (d, J = 1.8 Hz, 1H), 6.28 (d, J = 1.8 Hz, 1H), 4.96 
(br s, 1H), 4.20 (br m, 3H), 4.13 (br m, 1H), 3.42-3.37 (m, 1H), 3.00 (td, J = 11.3, 2.3 Hz, 
1H), 2.18-2.10 (m, 2H), 2.06-1.99 (m, 2H), 1.95-1.81 (m, 5H) 1.68-1.60 (m, 2H), 1.56-
1.46 (m, 2H), 1.36 (s, 3H), 1.19 (m, 1H), 1.08 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 171.8, 158.4, 156.9, 135.8, 116.2, 107.7, 105.8, 
78.2, 68.2 (2), 67.5, 51.0, 50.6, 44.8, 37.4, 36.0, 35.9, 35.2 (2), 34.2, 30.6, 27.9, 23.7, 
19.3 
IR (thin film, cm-1):  3454(br), 1642, 1442, 1382, 1194, 1104, 1060 
HR EI+ Mass Spec. Calculated for C24H31NO5: 413.2202, found: 413.2214 (2.8 ppm 
error) 
EI+(m/z):  413 (M+, 10), 149 (51), 142 (100), 109 (73), 101 (95) 






Amide 88 was prepared from 80 (15 mg, 0.029 mmol) in 89% yield (11 mg) as a 














Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 6.70 min and 98.6% chemical purity. 
1H NMR (MeOH- d 4, 300 MHz):  δ 7.21 (br s, 1H), 6.70 (d, J = 1.8 Hz, 1H), 6.65 (d, J = 
1.8 Hz, 1H), 3.75 (m, 1H), 3.51 (m, 1H), 2.49 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.15-2.05 
(m, 10H), 1.90 (m, 1H), 1.78-1.72 (m, 6H), 1.50-1.12 (m, 6H), 1.03 (s, 3H), 0.94 (m, 1H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 170.3, 158.1, 156.3, 135.7, 116.9, 108.7, 106.9, 
78.2, 71.2, 56.1, 50.1, 39.5, 38.6, 38.3, 36.6, 35.2, 33.0, 32.7, 28.7, 28.1, 27.1, 19.1 
IR (thin film, cm-1):  3447(br), 2909, 2854, 1636, 1555, 1451, 1366, 1275, 1112, 1056 
HR EI+ Mass Spec. Calculated for C26H35NO4 –H2O: 407.2460, found: 407.2459 (0.4 
ppm error) 
EI+(m/z):  407 (M+, 5), 207(37), 163(17), 150(40), 149(19), 134(16), 105(56), 91(20), 
82(86), 80(100), 77(27), 69(19) 







Amide 89 was prepared from 81 (38 mg, 0.074 mmol) in 92% yield (29 mg) as a 













Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 7.00 min and 98.4% chemical purity. 
1H NMR (MeOH- d 4, 300 MHz):  δ 6.61 (d, J = 1.8 Hz, 1H), 6.59 (d, J = 1.8 Hz, 1H), 
4.13 (m, 1H), 3.40 (m, 1H), 2.97 (td, J = 11.2 Hz, 7.5 Hz, 1H), 2.15-2.05 (m, 10H), 1.93 
(m, 1H), 1.75 (br s, 6H), 1.70-1.42 (m, 4H), 1.36 (m, 3H), 1.17 (m, 1H), 1.07 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 170.1, 158.0, 156.4, 136.4, 117.4, 108.6, 106.9, 
78.0, 67.5, 53.3, 50.6, 42.3, 37.5, 37.4, 34.1, 31.0, 30.7, 27.9, 23.7, 19.3 
IR (thin film, cm-1):  3393(br), 2986, 2907, 2850, 1636, 1577, 1420, 1359, 1247, 1134, 
1046 
HR EI+ Mass Spec. Calculated for C26H35NO4: 425.2566, found: 425.2545 (5.0 ppm 
error) 
EI+(m/z):  425 (M+, 4), 207(48), 192(79), 163(32), 149(33), 105(83), 103(100), 102(28), 
87(20), 83(22), 77(36), 69(22) 






Amide 90 was prepared from 82 (17 mg, 33.1 µmol) in 91% yield (13 mg) as a colorless 














Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 6.90 min and 98.9% chemical purity. 
1H NMR (MeOH- d 4, 500 MHz):  δ 6.69 (d, J = 1.8 Hz, 1H), 6.64 (d, J = 1.8 Hz, 1H), 
4.06 (br s, 1H), 3.74 (m, 1H), 3.51 (m, 1H), 2.49 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.12 (m, 
1H), 2.06-2.00 (m, 4H), 1.95-1.79 (m, 9H), 1.69-1.63 (m, 2H), 1.49-1.33 (m, 5H), 1.20 
(m, 1H), 1.04 (s, 3H), 0.95 (m, 1H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 170.3, 158.1, 156.3, 135.7, 117.0, 108.8, 106.9, 
78.2, 71.3, 56.1, 50.1, 39.6, 38.6, 38.3, 36.6, 35.2, 33.0, 32.8, 28.7, 28.1, 27.1, 19.1 
IR (thin film, cm-1):  3365(br), 2907, 2854, 1733, 1717, 1576, 1507, 1055 
HR EI+ Mass Spec. Calculated for C26H35NO4: 425.2566, found: 425.2555 (2.6 ppm 
error) 
EI+(m/z):  425 (M+, 6), 207(45), 163(40), 149(64), 105(100), 95(22), 91(18), 77(45), 
73(51), 69(15) 






Amide 91 was prepared from 83 (30 mg, 58 µmol) in 90% yield (22 mg) as a colorless 














Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 6.33 min and 97.7% chemical purity. 
1H NMR (MeOH- d 4, 300 MHz):  δ 6.68 (d, J = 1.8 Hz, 1H), 6.63 (d, J = 1.8 Hz, 1H), 
4.13 (m, 1H), 4.07 (br s, 1H), 3.42 (m, 1H), 2.99 (td, J = 11.0 Hz, 2.5 Hz, 1H), 2.08-1.79 
(m, 13H), 1.72-1.42 (m, 6H), 1.37 (s, 3H), 1.18 (m, 1H), 1.09 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 170.3, 158.2, 156.6, 135.4, 117.7, 108.7, 107.0, 
78.1, 67.5, 56.0, 49.2, 38.6, 38.3, 37.3, 34.1, 33.0, 32.8, 30.7, 28.8, 27.9, 23.7, 19.3 
IR (thin film, cm-1):  3314(br), 2982, 2909, 2846, 1651, 1574, 1449, 1375, 1242, 1131, 
1046 
HR EI+ Mass Spec. Calculated for C26H35NO4: 425.2566, found: 425.2558 (2.0 ppm 
error) 
EI+(m/z):  425 (M+, 1), 207(23), 192(55), 163(26), 150(14), 149(17), 105(100), 103(82), 
91(22), 87(25), 69(16) 






 To carboxylic acid 75 (12 mg, 0.032 mmol) in 0.1 mL THF was added excess BH3·THF 
(100 µL, 1 mmol, 1 M) at 0 °C and the mixture was allowed to warm to room temperature 
overnight.  6 N HCl was added slowly and carefully at 0 oC and the mixture was diluted 
with CHCl3.  The organic layers were washed with brine and dried over Na2SO4.  The 
crude product was purified via flash column chromatography on silica gel using 50% 











1H NMR (CDCl3, 500 MHz):  δ 6.63 (s, 1H), 6.50 (s, 1H), 5.21 (d, J = 6.3 Hz, 1H), 5.16 
(d, J = 6.3 Hz, 1H), 4.72 (dd, J = 13.3 Hz, 6.8 Hz, 2H), 4.57 (br s, 2H), 3.74 (m, 1H), 
3.50 (s, 3H), 3.44-3.39 (m, 4H), 2.47 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.20 (m, 1H), 1.91 
(m, 1H), 1.56-1.40 (m, 2H), 1.39 (s, 3H), 1.18-1.06 (m, 2H), 1.04 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 156.7, 154.9, 140.8, 113.3, 109.8, 104.2, 94.8, 94.4, 
76.9, 75.7, 65.2, 56.3, 55.2, 48.6, 36.5, 33.9, 33.2, 27.7, 26.1, 18.8 
IR (thin film, cm-1):  3409(br), 2918, 2849, 1577, 1431, 1056, 1042 
HR EI+ Mass Spec. Calculated for C20H30O6: 366.2042, found: 366.2035 (2.0 ppm error) 
EI+(m/z):  366 (M+, 26), 260 (100), 245 (28), 217 (34), 177 (10) 


















76 93  
Alcohol 93 was prepared from 76 (12 mg, 0.032 mmol) in 88% yield (10 mg) as a 
colorless oil. 
1H NMR (CDCl3, 300 MHz):  δ 6.61 (d, J = 1.5 Hz, 1H), 6.50 (s, 1H), 5.17 (d, J = 6.8 
Hz, 1H), 5.14 (d, J = 6.8 Hz, 1H), 4.84 (d, J = 6.8 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.56 
(br s, 2H), 4.02 (m, 1H), 3.48 (s, 3H), 3.43 (s, 3H), 3.32 (m, 1H), 2.88 (td, J = 11.1 Hz,  
2.5 Hz, 1H), 2.02 (m, 1H), 1.71-1.42 (m, 4H), 1.38 (s, 3H), 1.17 (ddd, J = 13.8 Hz, 11.5 
Hz, 2.3 Hz, 1H), 1.08 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 156.7, 155.1, 140.6, 114.1, 109.8, 104.2, 94.4, 94.1, 
76.9, 70.9, 65.2, 56.2, 55.2, 49.2, 34.1, 31.4, 29.8, 27.5, 23.3, 18.9 
IR (thin film, cm-1):  3400(br), 2955, 1620, 1579, 1432, 1367 1186, 1085, 925 
HR EI+ Mass Spec. Calculated for C20H30O6: 366.2042, found: 366.2029 (3.7 ppm error) 
EI+(m/z):  366 (M+, 21), 266 (100), 245 (19), 217 (38) 




Alcohol 92 (55 mg, 0.15 mmol) was dissolved in 2 mL of THF under N2, was cooled to 
-40 °C and was treated with NEt3 (125 µL, 0.90 mmol) and MsCl (50 µL, 0.65 mmol).  
The reaction mixture was allowed to stir at this temperature for 45 min then was warmed 
to 0 °C and stirred for an additional 30 min.  A solution of LiBr (130 mg, 1.50 mmol) in 2 
mL of THF was added via cannula and the reaction mixture was allowed to warm to 
room temperature and was stirred for 4 h.  The reaction mixture was quenched with ice 
cold saturated NaHCO3, extracted with Et2O, washed with brine and dried over Na2SO4.  
The crude bromide and amine 77 (24 mg, 0.17 mmol) were dissolved in 1 mL of DMF 
under N2. K2CO3 (124 mg, 0.90 mmol) was added and the mixture was stirred overnight.  
The solvent was removed under vacuum then diluted with EtOAc, washed with water, 
brine and dried over Na2SO4.  The crude product was subjected to column 
chromatography on silica gel eluting with 50% then 80% EtOAc/hexanes affording 






1H NMR (MeOH- d 4, 300 MHz):  δ 6.70 (d, J = 1.5 Hz, 1H), 6.47 (d, J = 1.5 Hz, 1H), 
5.21 (d, J = 6.5 Hz, 1H), 5.16 (d, J = 6.5 Hz, 1H), 4.71 (s, 2H), 4.22-4.06 (m, 3H), 3.80 
(s, 2H), 3.78-3.67 (m, 1H), 3.51-3.43 (m, 4H), 3.37 (s, 3H), 3.06-3.00 (m, 2H), 2.49 (td, J 
= 11.3 Hz, 2.4 Hz, 1H), 2.24-2.03 (m, 5H), 1.96-1.85 (m, 5H), 1.52-1.36 (m, 5H), 1.20 
(td, J = 12.6 Hz, 3.5 Hz, 1H), 1.02 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.0, 156.0, 114.5, 112.9, 107.7, 95.9, 95.8, 77.9, 
77.4, 68.9, 57.7, 56.6, 55.5, 50.9, 50.3, 38.2, 35.2, 34.4, 33.5, 32.8, 28.1, 27.1, 19.0 
IR (thin film, cm-1):  2930, 1573, 1429, 1335, 1154, 1106, 1057 
HR EI+ Mass Spec. Calculated for C28H41NO6:  487.2934, found: 487.2950 (3.3 ppm 
error) 
EI+(m/z):  487 (M+, 61), 364 (19), 258 (100), 215 (62), 152 (35), 95 (51), 69 (73) 









Amine 95 was prepared from 93 (12 mg, 0.033 mmol) in 72% yield over the 2 steps (12 
mg) as a colorless oil. 
1H NMR (MeOH- d 4, 500 MHz):  δ 6.68 (d, J = 1.3 Hz, 1H), 6.46 (d, J = 1.3 Hz, 1H), 
5.17 (dd, J = 13.8 Hz, 6.8 Hz, 2H), 4.82 (d, J = 6.5 Hz, 1H), 4.70 (d, J = 6.5 Hz, 1H), 
4.09 (br s, 2H), 3.99 (m, 1H), 3.81 (s, 2H), 3.46 (s, 3H), 3.42 (s, 3H), 3.35 (m, 1H), 3.04 
(br s, 2H), 2.87 (td, J = 11.1 Hz, 2.2 Hz, 1H), 2.05 (m, 5H), 1.92-1.86 (m, 4H), 1.70 (m, 
1H), 1.60 (m, 1H), 1.53-1.39 (m, 2H), 1.35 (s, 3H), 1.15 (ddd, J = 13.8 Hz, 11.6 Hz, 2.1 
Hz, 1H), 1.04 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.0, 156.2, 145.3, 118.4, 112.9, 112.2, 107.7, 
95.7, 95.3, 77.8, 72.6, 68.9, 57.8, 56.6, 55.6, 50.9, 50.7, 35.5, 32.9, 32.4, 31.1, 27.9, 24.3, 
19.2 
IR (thin film, cm-1):  2927, 1573, 1462, 1428, 1051 
HR EI+ Mass Spec. Calculated for C28H41NO6:  487.2934, found: 487.2919 (3.1 ppm 
error) 
EI+(m/z):  487 (M+, 7), 277 (23), 258 (29), 149 (83), 69 (100) 


















HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both containing 0.1% 
HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 8.56 min and 95.1% chemical 
purity. 
1H (MeOH- d 4, 500 MHz):  δ 6.35 (d, J = 1.5 Hz, 1H), 6.25 (d, J = 1.5 Hz, 1H), 4.07 (br 
s, 2H), 3.77-3.70 (m, 3H), 3.53 (m, 1H), 3.00 (br s, 2H), 2.44 (td, J = 11.1 Hz, 2.2 Hz, 
1H), 2.13-2.04 (m, 5H), 1.91-1.83 (m, 5H), 1.42-1.31 (m, 5H), 1.28 (m, 1H), 1.02 (s, 3H), 
0.93 (m, 1H) 
13C (MeOH- d 4, 126 MHz):  δ 170.3, 156.1, 139.5, 112.3, 110.0, 109.1, 77.7, 71.4, 69.2, 
57.8, 50.6, 50.3, 39.9, 36.7, 35.1, 32.9, 28.2, 27.2, 19.1 
IR (thin film, cm-1):  3301(br), 2976, 2934, 2856, 1576, 1427, 1056, 997 
HR EI+ Mass Spec. Calculated for C24H33NO4:  399.2410, found: 399.2427 (4.4 ppm 
error) 
EI+(m/z):  399 (M+, 100), 340 (39), 261 (50), 152 (26) 






Amine 97 was prepared from 95 (20 mg, 0.041 mmol) in 73% yield (12 mg) as a 













HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both containing 0.1% 
HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 7.59 min and 96.9% chemical 
purity. 
1H NMR (MeOH- d 4, 500 MHz):  δ 6.48 (d, J = 1.8 Hz, 1H), 6.45 (d, J = 1.8 Hz, 1H), 
4.35 (d, J = 13.0 Hz, 1H), 4.33 (d, J = 13.0 Hz, 1H), 4.16-4.10 (m, 3H), 3.72 (br s, 2H), 
3.38 (m, 1H), 2.96 (td, J = 11.3 Hz, 2.8 Hz, 1H), 2.32-2.24 (m, 4H), 2.22-2.15 (m, 4H), 
1.93 (m, 1H), 1.68-1.42 (m, 4H), 1.35 (s, 3H), 1.15 (ddd, J = 14.0 Hz, 11.8 Hz, 2.3 Hz, 
1H), 1.07 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.7, 157.3, 130.0, 116.0, 111.9, 110.1, 78.2, 67.4, 
65.9, 56.6, 53.8, 50.6, 37.3, 34.1, 31.6, 30.5, 27.9, 23.6, 19.3 
IR (thin film, cm-1):  3334(br), 2980, 2934, 2874, 1576, 1426, 1336, 1045, 999 
HR EI+ Mass Spec. Calculated for C24H33NO4:  399.2410, found: 399.2418 (2.1 ppm 
error) 
EI+(m/z):  399 (M+, 47), 207 (100) 






To nitrile 73 (132 mg, 0.365 mmol) in 3.5 mL of CH2Cl2 at rt was added n-BuSH (390 
µL, 3.65 mmol) followed by ZnBr2 (544 mg, 2.41 mmol) all at once.  The reaction 
mixture was stirred for 15 min then diluted with EtOAc, washed with saturated NaHCO3, 
brine and dried over Na2SO4.  The crude product was subjected to flash column 
chromatography on silica gel eluting with 50% then 80% EtOAc/hexanes resulting in 











mp: 212.1 °C  (dec.) 
1H NMR (MeOH- d 4, 300 MHz):  δ 6.55 (s, 2H), 4.62 (br s, 1H), 3.75 (m, 1H), 3.48 (m, 
1H), 2.50 (td, J = 11.2 Hz, 2.4 Hz, 1H), 2.13 (m, 1H), 1.90 (m, 1H), 1.52-1.31 (m, 5H), 
1.19 (m, 1H), 1.03 (s, 3H), 0.95 (m, 1H) 
13C NMR (MeOH- d 4, 75 MHz):  δ 158.7, 157.0, 119.8, 119.6, 113.6, 111.3, 110.6, 78.8, 
71.1, 49.7, 39.2, 36.4, 35.2, 28.0, 27.0, 19.1 
IR (thin film, cm-1):  3234(br), 2982, 2972, 2864, 2224, 1711, 1568, 1424, 1344, 1270, 
1057 
HR EI+ Mass Spec. Calculated for C16H19NO3:  273.1365, found:  273.1360 (1.8 ppm 
error) 
EI+(m/z):  273 (M+, 72), 240 (53), 212 (100), 186 (18), 69 (36) 









Nitrile 103 was prepared from 74 (127 mg, 0.351 mmol) in 76% yield (73 mg) as a fluffy 
white solid. 
mp: 192.5-195.0 °C 
1H NMR (CDCl3, 300 MHz):  δ 6.53 (s, 2H), 4.13 (br s, 1H), 3.41-3.29 (m, 2H), 3.00 (td, 
J = 10.9 Hz, 2.6 Hz, 1H), 1.93 (m, 1H), 1.70-1.44 (m, 3H), 1.37 (s, 3H), 1.17 (ddd, J = 
13.7 Hz, 11.6 Hz, 2.1 Hz, 1H), 1.07 (s, 3H) 
13C NMR (CDCl3, 75 MHz):  δ 158.8, 157.3, 120.5, 119.9, 113.5, 111.1, 110.6, 78.6, 
67.3, 50.2, 37.0, 34.0, 30.8, 27.7, 23.6, 19.2 
 IR (thin film, cm-1):  3435(br), 3135, 2932, 2234, 1736, 1575, 1421, 1344, 1284, 1064 
HR EI+ Mass Spec. Calculated for C16H19NO3:  273.1365, found:  273.1378 (4.7 ppm, 
error) 
EI+(m/z):  273 (M+, 12), 255 (40), 212 (100), 149 (24) 





To an ice cold solution of nitrile 102 (140 mg, 0.51 mmol) in 5 mL of CH2Cl2 was added 
DIPEA (460 µL, 2.56 mmol) followed by dropwise addition of TESCl (300 µL, 1.31 
mmol). The reaction mixture was stirred for 20 min, quenched with ice cold saturated 
NaHCO3, diluted with Et2O, washed with brine and dried over Na2SO4. The crude nitrile 
was dissolved in 5 mL of CH2Cl2, cooled to -78 °C and stirred for 10 min.  DIBAL in 
PhMe (1.10 mL, 1.32 mmol, 1.2 M) was added dropwise and the resulting mixture was 
stirred for 1 h.  Excess DIBAL was quenched with acetone at -78 °C and the reaction 
mixture was stirred with saturated Rochelle’s salt at room temperature until the biphasic 
mixture was clear.  EtOAc was added and the organic layer was separated, washed with 
brine and dried over Na2SO4.  The crude product was purified on a plug of silica gel 
eluting with 5% EtOAc/hexanes with 2% TEA present.  The silylated aldehyde was 
dissolved in 5 mL of THF, treated with TBAF (550 mg, 1.74 mmol) at rt and stirred until 
the reaction was shown to be complete by TLC analysis.  Solid CaCO3 was added to the 
flask and stirred for 15 min.  EtOAc was added and the organic layer was separated, 
washed with brine and dried over Na2SO4.  The crude product was purified via flash 
column chromatography on silica gel eluting with 50% then 80% EtOAc/hexanes 
resulting in aldehyde 104 (44 mg, 61% yield over 3 steps) as a white foam. 
107 
 
1H NMR (CDCl3, 300 MHz):  δ  9.76 (s, 1H), 6.85 (d, J = 1.4 Hz, 1H), 6.79 (d, J = 1.4 
Hz, 1H), 3.96 (m, 1H), 3.65 (m, 1H), 2.55 (td, J = 11.1 Hz, 2.1 Hz, 1H), 2.21 (m, 1H), 
1.92 (m, 1H), 1.57-1.41 (m, 5H), 1.25-1.15 (m, 2H), 1.07 (s, 3H) 
13C NMR (MeOH- d 4, 75 MHz):  δ 193.9, 158.7, 157.0, 137.4, 120.8, 112.5, 107.2, 78.4, 
71.2, 49.9, 39.3, 36.5, 35.5, 28.1, 27.1, 19.1 
IR (thin film, cm-1):  3338(br), 2976, 2934, 2872, 1716, 1684, 1577, 1558, 1338, 1144, 
1057 
HR EI+ Mass Spec. Calculated for C16H20O4:  276.1362, found: 276.1375 (4.8 ppm error) 
EI+(m/z):  276 (M+, 75), 258 (42), 243 (33), 215 (100), 189 (54), 142 (66) 











Aldehyde 105 was prepared from 103 (55 mg, 0.20 mmol) in 61% yield over 3 steps (34 
mg) as a colorless oil. 
1H NMR (MeOH- d 4, 300 MHz):  δ 9.72 (d, J = 0.9 Hz, 1H), 6.79 (s, 1H), 6.76 (s, 1H), 
4.14 (br s, 1H), 3.46-3.39 (m, 1H), 3.02 (td, J = 11.0 Hz, 2.5 Hz, 1H), 1.97-1.90 (m, 1H), 
1.71-1.46 (m, 4H), 1.38 (s, 3H), 1.24-1.13 (m, 1H), 1.09 (s, 3H) 
13C NMR (MeOH- d 4, 75 MHz):  δ 194.0, 158.8, 157.2, 137.3, 121.7, 112.5, 107.2, 78.3, 
67.4, 50.4, 37.1, 34.1, 31.1, 27.9, 23.7, 19.3 
IR (thin film, cm-1):  3373(br), 2979, 2940, 2874, 1684, 1576, 1334, 1138, 1046 
HR EI+ Mass Spec. Calculated for C16H20O4:  276.1362, found: 276.1357 (1.6 ppm error) 
EI+(m/z):  276 (M+, 23), 258 (62), 215 (100), 207 (32) 






General Procedure for Reductive Amination  
To a round bottom flask equipped with a stir bar, reflux condenser and Dean-Stark trap 
was added aldehyde 104 (10 mg, 0.036 mmol), 1-adamantanamine (6 mg, 0.040 mmol) 
and two 4Å molecular sieve beads in benzene.  The reaction mixture was heated at reflux 
overnight.  The progress of the reaction was followed by IR, monitoring the 
disappearance of the carbonyl absorption.  The solvent was removed under vacuum and 
the crude imine was dissolved in dry MeOH and was treated with a spatula tip of 10% 
Pd/C.  The reaction flask was purged with H2 gas three times and the mixture was 
allowed to stir at room temperature overnight.  The Pd/C was filtered off through a plug 
of Celite.  The crude product was purified on silica gel using 2.5, 5, 10% MeOH/ CH2Cl2 







HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both containing 0.1% 
HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 15.87 min and 96.1% 
chemical purity. 
1H NMR (MeOH- d 4, 500 MHz):  δ  6.26 (d, J = 1.0 Hz, 1H), 6.24 (d, J = 1.0 Hz, 1H), 
3.74 (m, 1H), 3.52 (br s, 3H), 2.44 (td, J = 11.2 Hz, 2.3 Hz, 1H), 2.14-2.06 (m, 4H), 1.90 
(m, 1H), 1.81-1.63 (m, 13H), 1.47-1.29 (s, 5H), 1.19 (td, J = 12.8 Hz, 3.3 Hz, 1H), 1.01 
(s, 3H), 0.92 (m, 1H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.1, 156.3, 140.8, 112.2, 109.8, 108.6, 77.7, 71.3, 
52.4, 50.3, 45.3, 42.8, 40.0, 37.7, 36.7, 35.0, 31.0, 28.2, 27.2, 19.1 
IR (thin film, cm-1):  3282(br), 2976, 2906, 2844, 1576, 1363, 1232, 1134, 1054 
HR EI+ Mass Spec. Calculated for C26H37NO3: 411.2773, found: 411.2760 (3.3 ppm 
error) 
EI+(m/z):  411 (M+, 10), 207 (23), 151 (82), 135 (28), 94 (100), 77 (30), 67 (23) 








Amine 99 was prepared from 105 (12 mg, 0.043 mmol) in 78% yield (14 mg) over 2 













Chiral HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both 
containing 0.1% HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 16.72 min 
and 98.5% chemical purity. 
1H NMR (MeOH- d 4, 500 MHz):  δ 6.30 (d, J = 1.5 Hz, 1H), 6.28 (d, J = 1.5 Hz, 1H), 
4.12 (m, 1H), 3.66 (s, 2H), 3.39 (m, 1H), 2.94 (td, J = 11.7 Hz, 2.3 Hz, 1H), 2.13 (br s, 
3H), 1.93 (m, 1H), 1.85-1.81 (m, 6H), 1.78-1.59 (m, 8H), 1.56-1.42 (m, 2H), 1.35 (s, 3H), 
1.14 (ddd, J = 14.0 Hz, 11.8 Hz, 2.3 Hz, 1H), 1.06 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.3, 156.8. 113.7, 110.3, 108.8, 77.8, 67.5, 50.8, 
45.1, 41.6, 37.6, 37.3, 34.2, 30.9, 30.5, 28.0, 23.7, 19.3 
IR (thin film, cm-1):  3276(br), 2975, 2911, 2850, 1621, 1578, 1451, 1429, 1134 
HR EI+ Mass Spec. Calculated for C26H37NO3: 411.2773, found: 411.2791 (4.2 ppm 
error) 
EI+(m/z):  411 (M+, 3), 151 (23), 97 (11), 95 (24), 94 (100), 83 (13), 81 (12), 71 (13), 69 
(19) 






Amine 100 was prepared from 104 (10 mg, 0.036 mmol) in 60% yield (9 mg) over 2 














Chiral HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both 
containing 0.1% HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 16.47 min 
and 94.7% chemical purity.   
1H NMR (CDCl3, 500 MHz):  δ  6.28 (d, J = 1.5 Hz, 1H), 6.24 (d, J = 1.5 Hz, 1H), 3.74 
(m, 1H), 3.56 (br s, 2H), 3.54-3.50 (m, 1H), 2.77 (br s, 1H), 2.45 (td, J = 11.2 Hz, 2.3 Hz, 
1H), 2.11 (m, 1H), 2.04-1.97 (m, 2H), 1.96-1.69 (m, 11H), 1.59-1.53 (m, 2H), 1.47-1.33 
(m, 5H), 1.18 (m, 1H), 1.03 (s, 3H), 0.95 (m, 1H) 
13C NMR (CDCl3, 126 MHz):  δ 158.1, 156.3, 140.8, 112.2, 109.8, 108.6, 77.7, 71.3, 
52.4, 50.3, 45.4, 42.8, 40.0, 37.7, 35.0, 31.0, 28.2, 27.2, 19.1 
IR (thin film, cm-1):  23291(br), 2980, 2904, 2844, 1576, 1371, 1241, 1134, 1056 
HR EI+ Mass Spec. Calculated for C26H37NO3: 411.2773, found: 411.2756 (4.2 ppm 
error) 
EI+(m/z):  411 (M+, 17), 207 (19), 135 (21), 94 (100) 






Compound 101 was prepared from 105 (10 mg, 36 µmol) in 84% yield (12.5 mg) over 2 
steps as a colorless oil.   
Chiral HPLC (0.10 cm x 25 cm Luna C8(2) 5µ, 20 - 60% MeCN in water (both 
containing 0.1% HCO2H) over 30 min, 3 mL/min, UV detection at 280 nm) 17.09 min 
and 96.9% chemical purity. 
1H NMR (MeOH- d 4, 500 MHz):  δ 6.37-6.35 (m, 2H), 4.14-4.11 (m, 1H), 3.89 (br s, 
2H), 3.39(m, 1H), 3.16 (br s, 1H), 2.96 (td, J = 11.1 Hz, 2.5 Hz, 1H), 2.10 (br s, 2H), 
2.00-1.87 (m, 7H), 1.82-1.73 (m, 4H), 1.71-1.60 (m, 4H), 1.57-1.44 (m, 2H), 1.36 (s, 
3H), 1.16 (ddd, J = 14.0 Hz, 11.9 Hz, 2.2 Hz, 1H), 1.07 (s, 3H) 
13C NMR (MeOH- d 4, 126 MHz):  δ 158.5, 157.1, 110.9, 109.2, 78.0, 67.5, 62.7, 50.7, 
50.3, 38.3, 38.1, 37.5, 34.2, 31.5, 31.2, 30.5, 28.6, 28.4, 27.9, 23.7, 19.3 
IR (thin film, cm-1):  3329(br), 2918, 1619, 1584, 1458, 1431, 1135 
HR EI+ Mass Spec. Calculated for C26H37NO3: 411.2773, 411.2762 (2.7 ppm error) 
EI+(m/z):  391 (M+, 9), 262 (24), 207 (19), 151 (17), 150 (100), 69 (15) 













71 113  
A 4:1 solution of DMF/EtOH(abs.) over 4Å molecular sieves was degassed by bubbling 
Ar through the solution for 20 min.  In a separate flask equipped with a stir bar was added 
triflate 71 (65 mg, 0.13 mmol), boronate 112 (45 mg, 0.17 mmol), K2CO3 (62 mg, 0.45 
mmol) and PdCl2(dppf)· CH2Cl2 (12 mg, 0.015 mmol).  The reaction flask was evacuated 
and purged with Ar three times, then 2 mL of the DMF/EtOH mixture was added and the 
reaction mixture was heated at 70 °C for 6 h.  The flask was cooled to room temperature; 
the mixture was filtered through Celite and concentrated directly onto Celite.  The crude 
product was purified via flash column chromatography on silica gel eluting with 10, 20, 
30 and 40% EtOAc/hexanes resulting in ketone 113 as a clear, colorless oil as a mixture 








1H NMR (CDCl3, 300 MHz):  δ  6.63 (d, J = 6.0 Hz, 1H), 6.51-6.47 (m, 1H), 6.12 (d, J = 
5.7 Hz, 1H), 5.22-5.12 (m, 2H), 4.73  (dd, J = 10.5 Hz, 6.9 Hz, 1H), 3.74 (m, 1H), 3.49 
(s, 3H), 3.43-3.34 (m, 4H), 2.87 (br s, 1H), 2.80-1.84 (m, 13H), 1.55-1.25 (m, 5H), 1.20-
1.03 (m, 5H) 
IR (thin film, cm-1):  2924, 2853, 1712, 1608, 1564, 1422, 1367, 1209, 1141, 1105, 1056, 
1041 
HR EI+ Mass Spec. Calculated for C28H38O6: 470.2668, found:  470.2667 (0.3 ppm error) 











Compound 114 was prepared from 72 (65 mg, 0.13 mmol) in 67% yield (42 mg) as a 
colorless oil and a mixture of diastereomers. 
1H NMR (C6D6, 300 MHz):  δ  6.90-6.84 (m, 2H), 6.02 (m, 1H), 4.99-4.83 (m, 3H), 4.67 
(d, J = 6.6 Hz, 1H), 3.96 (br s, 1H), 3.51 (m, 1H), 3.32 (s, 3H), 3.21-3.12 (m, 4H), 2.43 
(m, 1H), 2.30-1.89 (m, 8H), 1.58-1.25 (m, 8H), 1.18-1.04 (m, 5H) 
IR (thin film, cm-1):  2972, 2931, 2813, 1712, 1610, 1563, 1153, 1049, 921 
HR EI+ Mass Spec. Calculated for C28H38O6:  470.2668, found: 470.2679 (2.3 ppm error) 
EI+(m/z):  470 (M+, 12), 408 (23), 376 (47), 364(69), 363(34), 361(11), 321(20), 








Ketone 113 (55 mg, 0.117 mmol) in 2 mL of MeOH was cooled to 0 °C and NaBH4 (22 
mg, 0.58 mmol) was added all at once and stirred for 30 min.  The reaction was quenched 
with brine and the crude product was extracted with EtOAc and dried over Na2SO4.   The 
crude product was quickly purified via flash column chromatography eluting with 50% 
EtOAc/hexanes affording a diastereomeric mixture of endo-alcohol 115 as a clear, 
colorless oil (50 mg, 90% yield). 
1H NMR (C6D6, 300 MHz):  δ  6.99-6.95 (m, 2H), 6.43 (d, J = 6.0 Hz, 1H), 5.02 (m, 1H), 
4.92-4.90 (d, J = 6.6 Hz, 1H), 4.77-4.70 (dd, J = 14.6 Hz, 6.8 Hz, 2H), 3.93 (br s, 1H), 
3.74-3.67 (m, 2H), 3.28-3.23 (m, 7H), 2.60-2.48 (m, 4H), 2.20-1.81 (m, 5H), 1.68 (dt, J = 
14.7 Hz, J = 5.1 Hz, 1H), 1.57-1.22 (m, 8H), 0.96 (s, 3H), 0.75 (m, 1H) 
IR (thin film, cm-1):  3566(br), 2974, 2923, 2825, 1610, 1561, 1153, 1106, 1055, 1042 
HR EI+ Mass Spec. Calculated for C28H40O6:  472.2825, found: 472.2823 (0.4 ppm error) 






Alcohol 116 was prepared from 114 (34 mg, 0.072 mmol) in 82% yield (28 mg) as a 
colorless oil and a mixture of diastereomers.   
1H NMR (CDCl3, 300 MHz):  δ  6.779 (m, 1H), 6.57-6.53 (m, 2H), 5.23-5.14 (m, 2H), 
4.84 (d, J = 6.8 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.02 (br s, 1H), 3.95 (br s, 1H), 3.49 (s, 
3H), 3.44 (s, 3H), 3.31 (m, 1H), 2.88 (app t, J = 10.4 Hz, 1H), 2.81-2.50 (m, 2H), 2.38 (br 
s, 1H), 2.05-1.96 (m, 4H), 1.83-1.45 (m, 8H), 1.38 (s, 3H), 1.28-1.08 (m, 4H) 
IR (thin film, cm-1):  3566(br), 2982, 2923, 2822, 2786, 1610, 1559, 1363, 1155, 1046, 
921 
 HR EI+ Mass Spec. Calculated for C28H40O6:  472.2825, found: 472.2816 (1.8 ppm 
error) 
EI+(m/z):  472 (M+, 62), 366 (100), 348 (32), 246 (41), 200 (21), 121 (25), 120 (23), 105 






To alcohol 115 (26 mg, 0.055 mmol) in 2 mL of CH2Cl2 was added n-BuSH (135 µL, 
1.27 mmol) at rt followed by ZnBr2 (62 mg, 0.28 mmol) all at once.  The reaction 
mixture was stirred for 20 min and then diluted with EtOAc and saturated NaHCO3.  The 
organic layer was washed with brine and dried over Na2SO4.  The crude product was 
purified via flash column chromatography eluting with 40% then 50% EtOAc/hexanes 











Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 7.50 min and 98.1% chemical purity. 
1H NMR (C6D6, 500 MHz):  δ  8.51 (br s, 1H, OH), 6.87 (s, 1H), 6.79 (s, 1H), 4.24 (br s, 
1H), 4.00 (m, 1H), 3.83 (m, 1H), 2.56 (br t, J = 10.8 Hz, 1H), 2.15-1.87 (m, 8H), 1.63-
1.15 (m, 12H), 0.97 (s, 3H), 0.78 (m, 1H) 
13C NMR (C6D6, 126 MHz):  δ 156.8, 155.6, 147.6, 111.0, 105.8, 104.3, 76.6, 73.0, 71.6, 
69.2, 48.5, 42.3, 41.9, 38.6, 35.8, 35.7, 35.2, 34.2, 28.0, 26.4, 19.3 
IR (thin film, cm-1):  3336(br), 2975, 2928, 2852, 1622, 1577, 1418, 1051 
HR ESI+ Mass Spec. Calculated for C24H32O4 + H+:  385.2380, found: 385.2379 (0.3 
ppm error) 









Oxaadamantane 107 was prepared from 116 (28 mg, 0.059 mmol) in 79% yield (18 mg) 
as a white glass.   
Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 16.93 min and 98.6% chemical purity. 
1H NMR (MeOH-d4, 300 MHz):  δ  6.40 (d, J = 1.8 Hz, 1H), 6.31 (d, J = 1.8 Hz, 1H), 
4.19-4.10 (m, 2H), 3.40 (m, 1H), 2.93 (td, J = 11.4 Hz, 2.9 Hz, 1H), 2.21 (br s, 2H), 2.07-
1.89 (m, 8H), 1.78-1.70 (m, 2H), 1.69-1.40 (m, 4H), 1.34 (s, 3H), 1.21-1.11 (m, 2H), 1.06 
(s, 3H) 
13C NMR (MeOH-d4, 75 MHz):  δ 157.5, 156.1, 148.3, 112.4, 105.9, 104.5, 77.6, 73.9, 
70.8, 67.6, 50.9, 43.0, 37.6, 36.5, 36.0, 34.2, 30.4, 29.0, 28.0, 23.7, 19.3 
IR (thin film, cm-1):  3502(br), 2926, 2851, 1623, 1418, 1138 
HR ESI+ Mass Spec. Calculated for C24H32O4 + H+:  385.2380, found: 385.2362 (4.7 
ppm error) 





To 1,3-adamantanediol (3.35 g, 19.9 mmol) in 80 mL of 1:1 pyridine/benzene was added 
benzenesulfonyl chloride (8.90 mL, 69.7 mmol) which was then heated to 75 °C 
overnight.  The mixture was cooled to room temperature and solvent was removed under 
reduced pressure.  The crude oil was then dissolved in EtOAc, washed with CuSO4 and 
dried over MgSO4.  The crude ketone 108 was then carried on to the next step.  A pure 
sample could be obtained by flash column chromatography on silica gel eluting with 
30-80% EtOAc/hexanes.  Spectral data was identical to that reported in the literature.84   











108 109  
Crude ketone 108 was dissolved in 60 mL of CH2Cl2 and ozone was bubbled through at 
-78 °C until the solution became blue in color.  Oxygen was bubbled through for 15 min 
followed by N2 for an additional 15 min. Dimethylsulfide (10 eq) was then added and 
allowed to warm gradually to room temperature overnight.  Solvent was removed under 
vacuum and the crude product was subjected to flash column chromatography on silica 
gel eluting with 50-80% EtOAc/hexanes affording 109 (2.00 g, 66% over 2 steps) as a 
white solid which was identical to the reported spectral data.84  
1H NMR (CDCl3, 300 MHz):  δ 2.85 (br s, 2H), 2.61-2.53 (m, 4H), 2.41-2.35 (m, 4H), 














109 110  
To diketone 109 (1.70 g, 11.2 mmol) in 30 mL of benzene was added ethylene glycol 
(2.77 g, 44.7 mmol) and TsOH·H2O (212 mg, 1.12 mmol) at room temperature.  The 
reaction flask was then equipped with a stir bar and Dean-Stark apparatus and heated to 
reflux for 6 h.  The flask was cooled to room temperature, washed with water, saturated 
NaHCO3, brine and dried over Na2SO4.  The crude product was then subjected to flash 
column chromatography on silica gel eluting with 70% EtOAc/hexanes affording 110 












To a freshly prepared solution of LDA (made from diisopropylamine (540 µL, 3.83 
mmol) and n-BuLi in hexanes (1.37 mL, 3.57 mmol, 2.60 M) stirred at 0 °C for 30 min) 
in 10 mL of THF at -78 °C was added the ketone 110 (500 mg, 2.55 mmol) dropwise via 
cannula over 10 min.  After 1.5 h at -78 °C PhNTf2 (1.55 g, 4.33 mmol) in 5 mL of THF 
was added dropwise via cannula and gradually warmed to room temperature overnight. 
The reaction was quenched with saturated NaHCO3, diluted with Et2O, washed with brine 
and dried over MgSO4.  The crude product was then passed through a plug of silica 
eluting with 50% EtOAc/hexanes.  The crude triflate was then dissolved in 10mL of 
acetone and TsOH·H2O (49 mg, 0.26 mmol) was added at room temperature and stirred 
for 2 h.  The reaction mixture was diluted with Et2O, washed with saturated NaHCO3, 
brine and dried over MgSO4.  The crude triflate 111 was purified via flash column 
chromatography on silica gel eluting with 40-50% EtOAc/hexanes resulting in 111 as a 






1H NMR (CDCl3, 300 MHz):  δ 5.83 (d, J = 6.3 Hz, 1H), 2.97 (br s, 1H), 2.78-2.71 (m, 
2H), 2.62-2.37 (m, 4H), 2.24-1.98 (m, 3H) 
IR (thin film, cm-1):  2937, 1716, 1685, 1417, 1211, 1141, 1069, 1035, 969 
HR EI+ Mass Spec. Calculated for C10H11F3O4S:  284.0330, found: 284.0335 (1.6 ppm 
error) 













To the triflate 111 (130 mg, 0.457 mmol) in a round bottom flask charged with a stir bar 
was added flame dried K2CO3 (95 mg, 0.69 mmol), bispinacolboronate (128 mg, 0.50 
mmol), PdCl2(PPh3)2 (32 mg, 0.046 mmol) and PPh3 (24 mg, 0.092 mmol).  The flask 
was then equipped with a reflux condenser and the system was evacuated and purged 
with Ar three times.  Anhydrous and deoxygenated 1,4-dioxane (Ar bubbled through for 
20 min) was then added and the reaction mixture was heated to 70 °C for 7 h.  The black 
reaction mixture was then cooled to rt, filtered through a pad of Celite and adsorbed onto 
Celite.  The crude product was then purified via flash column chromatography on silica 
gel eluting with 20% EtOAc/hexanes affording 112 (87 mg, 73%) as a white waxy solid. 
1H NMR (CDCl3, 300 MHz):  δ 6.54 (d, J = 5.1 Hz, 1H), 2.74 (br s, 1H), 2.58-2.26 (m, 
6H), 2.14-1.94 (m, 3H), 1.24 (s, 12H) 
IR (thin film, cm-1):  2978, 2928, 1716, 1632, 1456, 1386, 1320, 1145 







To a solution of powdered alcohol 84 (650 mg, 2.20 mmol) and finely powdered 
iodobenzene diacetate (1.10 g, 3.41 mmol) in 16.5 mL of cyclohexane under Ar was 
added I2 (838 mg, 3.30 mmol) at room temperature. The mixture was stirred in a 
preheated oil bath set at 60 °C and irradiated (light source: slide projector ELMO 
omnigraphic 301AF, projection lamp: 120V-300W ANSI Code ELH; 3 cm from the flask 
and surrounded in Al foil to trap the light) for 1.5 h. The reaction was then quenched with 
10% Na2S2O3, extracted with EtOAc, washed with brine and dried over Na2SO4.  The 
crude product was then purified using flash column chromatography on silica gel eluting 
with 30% then 50% EtOAc/hexanes resulting in 85 (485 mg, 75%) as a white solid.  
1H NMR NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 








Freshly washed Na (200 mg, 8.70 mmol) was added to naphthalene (1.33 g, 10.4 mmol) 
in 5 mL of DME under nitrogen at room temperature and stirred for 1.5 h resulting in a 
dark green solution. The green solution was then added dropwise via cannula to 
sulfonamide 85 (200 mg, 0.68 mmol) in 5 mL of DME at -50 °C until the dark green 
color persisted followed by an additional 15 min of stirring.  The mixture was quenched 
with the dropwise addition of saturated NH4Cl solution until the green color dissipated. 
The reaction mixture was then diluted with Et2O, acidified to pH 1 with conc. HCl, 
organic layer separated, the aqueous layer was then basified with solid KOH until 
strongly basic, extracted with Et2O, washed with brine and dried over Na2SO4.  The crude 
amine was then dissolved in hot hexanes and filtered using a Buchner funnel and 
concentrated resulting in amine 77 (80 mg, 85%) as a white solid.  The TFA salt could be 
prepared from dissolving 77 in 1:1 CH2Cl2:TFA at 0 °C and then removing the solvent 
under vacuum resulting in a white solid which could be stored for months without any 
decomposition. 
1H NMR (300 MHz, C6D6) δ 4.05 (m, 2H), 2.95 (m, 1H), 1.88-1.83 (m, 4H), 1.53- 
1.47 (m, 4H), 0.92 (br s, 1H) 




















































































































































































































































































































































































































































































































































































































































































































The goal of this project was to further investigate the pharmacophoric properties of the 
C3 substituent and to probe the spatial requirements of the two cannabinoid receptors.  
By installing a heteroaroyl group at C3 (Figure 6.1 green box), we also hoped to discover 
important polar interactions between the ligand and key amino acids in the receptor.  If a 
high affinity ligand were to be discovered, these C3 heteroaroyl cannabinoids could 
potentially be used as irreversible photoaffinity labels for the receptor(s) potentially 
resulting in discovery of the key amino acids that interact with the ligand in the active 
binding site as well as determining the orientation of the ligand within the active site.    
The inspiration for this design was provided by our earlier studies of the structural 
homology between the aminoalkylindoles (e.g. WIN-55212-2, 30) and classical 
cannabinoids (e.g. (-)-HHC, 14).91  Through the use of 2D NMR techniques and 
computational molecular modeling, it was suggested that the naphthoyl, morpholino and 
3-keto groups of the aminoalkylindoles correspond to the C3 side chain, cyclohexyl ring 






Figure 6.1 Structural homology between (-)-HHC (14) and WIN-55212-2 (30). 
The synthesis of C3 naphthoyl and naphthylmethyl tricyclic cannabinoids (118 and 119), 
which were shown to be good ligands for CB1, supported this hypothesis (Figure 6.2).92  
 
Figure 6.2 Makriyannis’ C3 naphthoyl and naphthylmethyl cannabinoids. 
Recently, the Makriyannis group93 has shown that bicyclic analogs with a benzoyl unit at 
C3 such as 120, are selective for CB2 while Moore94 has shown that the tricyclic Δ8-THC 











Ki = 2045 nM CB1
Ki = 22 nM CB2
Ki = 297 nM CB1
Ki = 23.6 nM CB2  
Figure 6.3 CB2 selective C3 aroyl cannabinoids. 
6.1 Probes for the Cannabinoid Receptors 
In order to gain new SAR information, molecular level interactions between the ligand 
and cannabinoid receptor(s) have been studied using covalent probes.  A 3D model95 of 
the CB1 receptor has been constructed based on the comparison of the amino acid 
sequence of numerous other GCPR’s whose structure is known in greater detail.  Based 
on these comparisons, the receptor was predicted to consist of seven linked α-helices and 
their relative positions were calculated using an array of molecular modeling techniques.  
The proposed helix bundle resembles that of the G-protein coupled visual pigment, 
rhodopsin, whose structure is known from a 2.8 Å resolution crystal structure.96  In order 
to determine the structure and location of the binding site(s), experiments with 
irreversible covalent probes have been conducted.   
The first such photoaffinity label, 5’-N3-Δ8-THC (122), was prepared by the Makriyannis 
group in 1992 (Figure 6.1.1).97  Binding experiments revealed that 122 has a two-fold 










Ki = 47.6 nM CB1  
Figure 6.1.1 The first CB1 selective photoaffinity label 122. 
of 122 to inactivate the CB1 receptor, photoirradiation experiments were conducted.  Rat 
forebrains were saturated with 122 to ensure receptor occupancy was greater than 98% 
and then irradiated with shortwave ultraviolet light.  After irradiation was complete, the 
membranes were washed extensively to remove any unbound 122 and then retested for 
cannabinoid binding.  The membrane that was equilibrated with 122 and irradiated 
resulted in no specific binding of [3H]-CP-55,940.  It should also be noted that exposure 
of the membrane preparations to ultraviolet light did not result in any damage to the 
membranes as irradiated control membranes did not exhibit reduced binding affinity. 
In 1994, the Makriyannis group reported (-)-11-hydroxy-7’-isothiocyanato-1’,1’-
dimethylheptyl-Δ8-THC (123) as the first irreversible covalent probe for the CB1 receptor 
(Figure 6.1.2).98  The isothiocyanate group was chosen because it is inert to neutral water 
but capable of nucleophilic reactions with amino, hydroxyl and sulfhydryl groups under 
physiological conditions.99  Also, isothiocyanate containing ligands have been used for 
the study and characterization of a series of receptors including the opioid,100, 101 




Figure 6.1.2 CB1 selective high affinity covalent probe 123. 
Rat forebrain membranes were used to assess the binding affinity of 123 via a filtration 
assay using [3H]-CP-55,940 as the radioligand resulting in an apparent Ki of 3.2 nM.  
Because the ligands undergo irreversible binding the apparent Ki must be reported.  The 
ligand (123) was then evaluated for its ability to irreversibly label the receptor by treating 
rat forebrain membranes with varying amounts of the ligand.  When a large amount (over 
ten times its apparent IC50) of 123 was used, complete labeling of the receptor was 
achieved after five minutes of incubation, indicating a rapid reaction between the ligand 
and receptor.  The success of these experiments clearly showed that high-affinity 
classical cannabinoid ligands can covalently attach themselves to the active site of the 
receptor and also suggested that there is a thiol, amino or hydroxyl amino acid residue at 
or in the vicinity of the active binding site of the receptor.   
The first two high affinity covalent anandamide probes for the CB1 receptor (Figure 
6.1.3) were also recently prepared by the Makriyannis group.105  To impart optimal CB1 




Figure 6.1.3 High affinity covalent anandamide probes. 
Until recently, a high affinity covalent probe for the CB2 receptor had not been 
developed.  The Makriyannis group recently published results on two such compounds 
















Figure 6.1.4 High affinity CB2 selective covalent probes. 
The first compound, 126, is based on the classical cannabinoid tricyclic framework.  
Through the use of LAPS and site directed mutagenesis, the Makriyannis group were able 
to determine that cysteine residue, C6.47(257) residing in transmembrane helix six, is the 




Figure 6.1.5 Schematic reputation of the human CB2 receptor.  Amino acids subjected to 
mutation, C6.47(257), C7.38(248) and C7.42(288) are circled in bold.107 
Of the five cysteine residues modeled in the ligand-binding pocket of the human CB2 
receptor, C6.47(257) is located most deeply within the pocket, near the center of the lipid 
bilayer.109 On the assumption that the NCS functional group of AM-841 reacts with the 
first cysteine residue with which it comes into contact in the human CB2 receptor’s 
ligand-binding pocket, identification of C6.47(257) as the site for covalent attachment of 
AM-841 to the human CB2 receptor suggests that the tail of AM-841 enters the 
receptor’s binding pocket at great depth.  
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Diarylpyrazole 127 was also studied using LAPS and site directed mutagenesis.  
Experiments involving mutant CB2 receptors revealed that the 1,5-diarylpyrazole class of 
compounds interact with a different cysteine residue when compared to the classical 
cannabinoids.  Cysteine residues C7.38(284) and C7.42(288) in transmembrane helix 
seven were shown to be critical for optimal binding interaction and ligand recognition 
(Figure 6.1.6).     
 
Figure 6.1.6 Schematic reputation of the human CB2 receptor.  The key amino acids 
critical for optimal binding and ligand recognition, C7.38(284) and C7.42(288),  are 





With our recent success in the synthesis of C3 heteroadamantyl cannabinoids,110 we 
chose to utilize the same approach to synthesize C3 heteroaroyl analogs preparing all 
compounds from an advanced intermediate such as 71 (Scheme 7.1).  Only the C9 β-
hydroxy series were of interest since they typically show enhanced binding affinity 
compared to their C9 α-hydroxy counterparts. 
 
Scheme 7.1 Reagents and conditions: (a) TsOH·H2O, 4/1 CHCl3/acetone, 0 °C to rt; (b) 
Ac2O, CH2Cl2, DMAP (cat.), pyridine, 0 °C to rt; (c) KOH, MeOH, 0 °C; 68% overall 
from 39 and 40; (d) TMSOTf, MeNO2, 0 °C; (e) PhNTf2, NEt3, CH2Cl2, 0 °C to rt; 57% 
from 62; (f) NaBH4, MeOH, 0 °C; 97% 69 + 70, ca. 95/5; (g) MeOCH2Cl, (i-Pr)2NEt, 
CH2Cl2, 0 °C to rt, 2.5 h; 93%. 
Initially, we envisioned the efficient conversion of aryl triflate 71 to nitrile 73 followed 
by addition of aryl Grignard reagents and subsequent hydrolysis leading to the desired 
phenones (Scheme 7.2).  To our surprise, we did not observe any of the desired phenone 
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when nitrile 73 was treated with excess aryl Grignard reagent.  Instead, only recovered 
starting material was obtained.  We believe this can be attributed to the decreased 
nucleophilicity of aryl magnesium reagents and nitrile 73 being a poor electrophile.   
 
Scheme 7.2 Reagents and conditions:  (a) THF, ArLi or ArMgBr, Reflux, additives; (b) 
H3O+. 
To circumvent this problem, we sought to exploit the aryl triflate 71 by using a 
carbonylative Stille process.  This approach was very attractive since it increased the 
overall efficiency of the synthesis and a wide variety of heteroaroyl stannanes are 
commercially available or easily prepared from their respective aryl bromides or iodides.  
Exposure of triflate 71 to a slight excess of heteroaryl stannane, LiCl, 4 Å molecular 
sieves, BHT, and catalytic PdCl2(dppf)·CH2Cl2 in DMF at 110 °C under an atmosphere 
of CO for 24 h led to protected heteroaroyl cannabinoids 128 - 142 in moderate to 
excellent yields (Scheme 7.3)  It should be noted that under these reaction conditions 




Scheme 7.3 Reagents and conditions:  (a) DMF, CO, LiCl, BHT, 4Å MS, 110 °C, 
ArSnBu3, PdCl2(dppf)·CH2Cl2, 24 h. 
In cases in which the aryl stannane was either not commercially available or unreactive, a 
slightly modified synthetic procedure was used in order to prepare the heteroaroyl 
compounds.  Since we had shown nitrile 73 to be unreactive towards aryl Grignard 
reagents, we believed that a two step process involving nucleophilic addition of aryl 
lithium reagents to aldehyde 143 and subsequent oxidation would yield the desired 
phenones.  Reduction of nitrile 73 to aldehyde 143 with DIBAL took place in 96% yield.  
Nucleophilic addition of aryl lithium reagents derived from 3-bromofluorobenzene and 3-
bromobenzotrifluoride to 143 followed by oxidation of the respective benzylic alcohols 
with manganese oxide led to phenones 144 and 145 in 74% and 81% yield, respectively 
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(Scheme 7.4).  Oxidation of the benzylic alcohols with Dess-Martin periodinane (DMP) 
was also attempted but none of the desired phenone product was observed.   
Scheme 7.4 Reagents and conditions:  (a)  CH2Cl2, DIBAL, -78 °C; 96%; (b) ArBr, n-
BuLi, THF, -78 °C; (c) MnO2, CH2Cl2; 144, 74% from 143; 145, 81% from 143.   
Exposure of 143 to indole in methanolic KOH followed by oxidation with manganese 
dioxide led to 146 in 52% yield over the two steps (Scheme 7.5).   
 
Scheme 7.5 Reagents and conditions:  (a) KOH, MeOH, indole; (e) MnO2, CH2Cl2; 52% 
from 143. 
Treatment of indole 146 with NaH and iodomethane in DMF furnished the N-methylated 




Scheme 7.6 Reagents and conditions:  (a) DMF, NaH, MeI; 97%. 
Once again, removal of the methoxymethyl ether protecting groups proved to be slightly 
problematic.  Treatment of protected phenones 128 - 142 and 144 - 147 with TMSBr in 
CH2Cl2 at -40 °C for 1.5 h and then 0 °C for 1 h led to diols 148 - 166 in moderate to 
good yields (Scheme 7.7).  The low yield for deprotection of the furyl and thiophenyl 
compounds can be attributed to the high nucleophilicity of the electron rich aromatic ring.  
Reaction with the methoxymethyl bromide that is generated under these reaction 
conditions may be responsible for the appearance of byproducts.  Low yields were also 
observed in the presence of the acid scavenger poly(4-vinylpyridine), which rules out that 
the low yields of the deprotected products are due to the presence of strong acid.  Other 
common conditions to remove methoxymethyl ethers such as methanolic HCl or 












8 Receptor Binding Studies 
Receptor binding studies of all final compounds were conducted at Northeastern 
University, Center for Drug Discovery under the direction of Professor Alexandros 
Makryiannis.  Competitive binding assays with the radioligand [3H]-CP-55,940 (3) were 
carried out using rat brain or membranes from HEK293 cells to assess the affinities for 
CB1 and CB2 receptor binding sites, respectively, following previously described 
procedures.  A series of experiments were conducted for each compound at varying 
concentrations and the results of which will be discussed in detail in this chapter.  All 
compounds that showed binding affinities of greater than 1000 nM from the two point 
data experiments (run in triplicate) were not subjected to the human CB2 assay.  
Compounds having binding affinities of less than 1000 nM from the two point data 
experiments (run in triplicate) were subjected to eight point data experiments (run in 
triplicate) and were also subjected to the human CB2 assay. 
Studies from the Makriyannis lab93 have shown that bicyclic analog 120 containing a C3 
benzoyl substituent exhibited high affinity for the human CB2 receptor (22 nM) with 
significant selectivity over the CB1 receptor (93 fold).  The Moore lab94 has reported 
tetrahydrocannabinol analog 121 with a C3 benzoyl substituent to be a high affinity CB2 
selective ligand with moderate selectivity (12.6 fold).  The presence of the 1’-keto 
functionality seems to impart selectivity for the CB2 receptor.  However, further SAR 
data needed to improve the pharmacological profile of these cannabinoid analogs are 
lacking.  To probe the stereoelectronic requirements of the C3 side chain and 
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simultaneously improve the polar properties, three groups of C3 heteroaroyl compounds 
were designed and synthesized.   
The first group includes analogs containing a five membered heteroaromatic ring 


































Figure 8.1 Analogs belonging to group one. 
In the second group, a six membered aromatic ring, substituted aromatic ring and a 




Figure 8.2 Analogs belonging to group two. 
Finally, the third group consisted of a fused heteroaromatic rings attached to C3 through 
a carbonyl linker (151, 152, 155, 156, 165 and 166).  The SAR of all the analogs was 
examined by measuring their respective affinities for the rat CB1 receptor (rCB1), mouse 


































156 165 166  
















rCB1 mCB2 hCB2 
Group 1    
 149 >1000 >1000 >1000 
150 >1000 >1000 N.A. 
153 >1000 >1000 N.A. 
154 1037 525 1551 
157 >1000 >1000 >1000 
158 >1000 >1000 N.A. 
Group 2    
148 968 247 587 
159 >1000 >1000 >1000 
160 >1000 >1000 >1000 
161 >1000 >1000 >1000 
162 >1000 >1000 N.A. 
163 460 370 N.A. 










Table 8.1 Continued. 
 
Group 3    
151 1356 163.3 209.4 
152 2880 169.2 118.2 
155 156.6 152.1 113.1 
156 1254 34.2 124.8 
165 2400 60.4 158.6 
166 3270 406 3006 
 
a Affinities for CB1 and CB2 were determined using rat brain (CB1) or membranes from 
HEK293 cells expressing mouse or human CB2 and [3H]CP-55,940 as the radioligand 
following previously described procedures. Ki values for these compounds were obtained 
from one experiment (8 point) run in triplicate when the two point data (run in triplicate) 
was less than 1000 nM.      
All analogs belonging to group one (149, 150, 153, 154, 157 and 158) exhibited 
significantly diminished activity at both the CB1 and CB2 receptors (compared to 164).  
This could be attributed to the to the lack of sufficient hydrophobic interaction of the five 
membered heteroaromatic ring with the hydrophobic pocket of the receptor which, in 
general, is the key factor for the affinity, potency and selectivity for the classical 
cannabinoids.111  The reduced activity could also be due to the large desolvation penalties 
due to the polar nature of these rings.  In the second group (148, 159 – 164), benzoyl 
analog 148 showed reduced affinity and selectivity compared to Moore’s 
tetrahydrocannabinol analog 120.  The reason for this observation is still unclear.  One 
possibility is that the additional interaction of the C9 β-hydroxy group results in an 
unfavorable orientation of the C3 benzoyl group in the hydrophobic pocket of the 
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receptor.  To further probe the interactions of the C3 aroyl group, a nitrogen atom was 
incorporated into the 2-, 3- and 4- positions of the aromatic ring (159 - 162).  All of the 
pyridyl analogs exhibited a further decrease in activity at both the CB1 and CB2 
receptors which could be a result from unfavorable electronic interactions within the 
receptor site.  Incorporation of a fluorine atom at the meta position of the benzoyl group 
(163) improved binding at the CB1 receptor while slightly decreasing binding affinity at 
mCB2 (compared to 148).  Introduction of a lipophilic trifluoromethyl group (164) in the 
meta position of the benzoyl substituent yielded encouraging results.  Binding affinities 
improved significantly for both receptors (rCB1 = 61.7 nM, mCB2 = 45.8 nM and hCB2 
= 37.3 nM) compared to 148 and 163 and also showed a slight preference for CB2 over 
CB1 (1.7 fold).  This is consistent with what the Moore group112 observed with 
cannabinoid analogs containing a substituted phenyl ring at the 1’ position. The meta 
substituted series resulted in higher affinities for both CB1 and CB2 when compared to 
their para substituted counterparts.  Also, the presence of a meta electron withdrawing 
group enhanced CB1 binding affinities while the CB2 affinities were equivalent or 
slightly enhanced.   
The third group (151, 152, 155, 156, 165 and 166) which incorporated fused bicyclic 
heteroaromatic groups connected to C3 through a carbonyl linker showed significant 
improvements in both affinity and selectivity for the CB2 receptor.  The benzofuran 
series (151 and 152) displayed an eight fold and seventeen fold selectivity respectively 
for mCB2 over rCB1.   The 2-benzofuran analog 151 displayed species selectivity for 
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mCB2 over hCB2 (1.3 fold) while the 3-benzofuran analog 152 slightly favored hCB2 
over mCB2 (1.4 fold) but was 24.4 fold more selective for hCB2 over rCB1.  Also, the 
binding affinity for rCB1 of 152 was two fold lower when compared to 151.  This 
observation can be attributed to the larger conformational space required by the 3-
benzofuran analog (152) compared to the 2-benzofuran analog (151).  Previous research 
in the Makriyannis group has shown that the space available in the receptor for 
interaction at the C3 site is larger for the CB2 receptor compared to that of the CB1 
receptor.45  Interestingly, the 2-benzothiophene analog 155 exhibited slight species 
selectivity for hCB2 which is the opposite of the 2-benzofuran analog 151.  The 3-
benzothiophene analog 156 also showed the opposite species selectivity when compared 
to its 3-benzofuran counterpart 152 (3.6 fold for mCB2 over hCB2).  Analog 156 was the 
most CB2 selective compound (36.7 fold more selective for mCB2 over rCB1) and 
exhibited an eight fold decrease in affinity for rCB1 when compared to 155.  To further 
probe the interaction of the heteroatom in the receptor, the O- or S-atom was replaced 
with a hydrogen bond donor/acceptor NH group.  The presence of the indole nitrogen in 
165 resulted in a slight reduction in affinity for mCB2 compared to that of 156 with a 17 
fold selectivity for mCB2 over rCB1 and 2.6 fold species selectivity for mCB2 over 
hCB2.  Capping of the indole nitrogen with a methyl group resulted in significantly 
diminished affinity at both rCB1 (>1000 nM) and mCB2 (406 nM).  Arguably, this may 
be due to the inability of the nitrogen atom to interact with its counterpart amino acid 
residue due to the steric interactions of the introduced methyl group, signifying the 




In conclusion, the synthesis of nineteen C3 heteroaroyl cannabinoids has been described.  
The key steps in the synthesis were the carbonylative Stille reaction between an aryl 
triflate and heteroaroyl stannanes, addition of heteroaryl groups to the aromatic aldehyde, 
and protecting group removal with TMSBr.  All analogs showed at least micromolar 
affinity for the receptors and selectivity for CB2 over CB1. The 3-benzothiophene (Ki = 
34.2 nM), 3-trifluoromethylbenzene (Ki = 45.8 nM) and 3-indole (Ki = 60.4 nM) analogs 
proved to be the most potent compounds as well as the most selective towards CB2.  This 
work also confirmed that the presence of a keto group at 1’ imparts selectivity for the 
CB2 receptor, 5-membered heteroaromatic ring substituents at 1’ are poor ligands, meta 
substituted phenyl rings at 1’ are CB2 selective, 3-substituted fused bicyclic 
heteroaromatic rings favor CB2 over CB1 and the presence of a hydrogen bond acceptor 
heteroatom is important for strong binding.  Functionalization of the phenyl or fused 
bicyclic heteroaromatic systems can also be envisioned to further probe the structural and 
electronic requirements of the CB2 receptor as well as introduction of an azide or 







10 Experimental Section 
General: 
1H and 13C NMR spectra were recorded on a Varian Mercury Plus 300 (1H 300 MHz, 13C 
75 MHz) or a Varian Unity INOVA 500 (1H 500 MHz, 13C 126 MHz) in either 
deuterochloroform (CDCl3; 1H 7.26 ppm, 13C 77.0 ppm), deuterobenzene (C6D6; 1H 7.15 
ppm, 13C 128.0 ppm) or deuteromethanol (CD3OD; 1H 3.31 and 4.90 ppm, 13C 49.0 
ppm).  Chemical shifts are given in δ, with multiplicities given as s (singlet), br (broad 
singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or a combination thereof and J 
(coupling constants) given in hertz (Hz).  IR spectra were recorded on a Nicolet 380 FT-
IR using a NaCl plate.  Mass spectral data was collected on either an Agilent 1100 Series 
LC-MS TOF (ESI+ or APCI+ source) or VG-70SE (EI+ source).  Optical rotation data was 
collected on a JASCO DIP-370 digital polarimeter.  Thin-layer chromatography (TLC) 
was performed using Sigma-Aldrich silica-gel, general-purpose TLC plates with UV 
indicator (F254).  Flash chromatography was performed using Silicycle SiliaFlash F60 
silica gel (230-400 mesh).  All solvents used were purified using a solvent purification 
system.  The purity of assayed compounds were of at least 95% and were verified using 
high performance liquid chromatography on an Agilent 1200 Series or a Beckman 
Coulter System Gold HPLC equipped with Daicel Chiralpak AD-H (4.6 x 250 mm), 





General procedure for the carbonylative Stille coupling. 
To a round bottom flask charged with a stir bar and triflate 71 (110 mg, 0.23 mmol) was 
added tributyl(phenyl)stannane (100 mg, 0.27 mmol), three 4 Å molecular sieve beads, 
three crystals of BHT, PdCl2(dppf)·CH2Cl2 (ca. 7.5 mg, 0.01 mmol) and freshly flame 
dried LiCl (30 mg, 0.70 mmol).  The flask was then sealed with a septum and placed 
under an atmosphere of CO followed by the addition of 1.2 mL of DMF.  CO was 
bubbled through the mixture for 5 min and then the septum was quickly replaced with a 
three way tap equipped with a balloon of CO.  The reaction mixture was warmed to 110 
°C in an oil bath for 24 h.  The black solution was then cooled to room temperature, 
adsorbed onto Celite and purified directly via flash column chromatography on silica gel 
eluting with 10%, 20% then 30% EtOAc/hexanes resulting in phenone 128 (66 mg, 66% 






1H NMR (CDCl3, 500 MHz):  δ 7.79 (d, J = 7.5 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.45 (t, 
J = 7.5 Hz, 2H), 7.11 (d, J = 1.5 Hz, 1H), 6.86 (d, J = 1.5 Hz, 1H), 5.27 (d, J = 6.5 Hz, 
1H), 5.20 (d, J = 6.5 Hz, 1H), 4.74 (dd, J = 13.3 Hz, 6.8 Hz, 2H), 3.77 (m, 1H), 3.50 (s, 
3H), 3.44 (m, 1H), 3.40 (s, 3H), 2.54 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.22 (m, 1H), 1.92 
(m, 1H), 1.58 (m, 1H), 1.46 (m, 1H), 1.39 (s, 3H), 1.20-1.11 (m, 2H), 1.04 (s, 3H) 
 13C NMR (CDCl3, 126 MHz):  δ 195.9, 156.4, 154.4, 137.6, 136.9, 132.1, 129.9, 128.1, 
118.9, 114.4, 106.2, 94.8, 94.5, 77.3, 75.6, 56.5, 55.2, 48.5, 36.3, 34.3, 33.1, 27.6, 26.1, 
18.8 
IR (thin film, cm-1): 2934, 1658, 1597, 1567, 1336, 1057 
HR EI+ Mass Spec. Calculated for C26H32O6: 440.2199, found: 440.2200 (0.2 ppm error) 
EI+(m/z):  440 (M+, 35), 334 (100), 319 (24), 291 (39), 105 (29) 








Ketone 129 was prepared from triflate 71 (40 mg, 0.083 mmol) and tributyl(furan-2-
yl)stannane (33 mg, 0.091 mmol) in 84% yield (30 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.69 (dd, J = 1.8 Hz, 0.6 Hz, 1H), 7.25 (dd, J = 3.6 Hz, 
0.6 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 6.57 (dd, J = 3.6 Hz, 1.8 
Hz, 1H), 5.29 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 1H), 4.75 (dd, J = 9.3 Hz, 6.9 Hz, 
2H), 3.77 (m, 1H), 3.51 (s, 3H), 3.46-3.40 (m, 4H), 2.54 (td, J = 11.3 Hz, 2.5 Hz, 1H), 
2.23 (m, 1H), 1.94 (m, 1H), 1.62-1.42 (m, 5H), 1.23-1.06 (m, 5H) 
13C NMR (CDCl3, 126 MHz):  δ 181.7, 156.4, 154.7, 152.0, 147.0, 136.6, 120.6, 119.0, 
113.1, 112.1, 105.8, 94.8, 94.5, 77.4, 75.6, 56.4, 55.2, 48.4, 36.2, 34.2, 33.1, 27.6, 26.1, 
18.8 
IR (thin film, cm-1):  2938, 1650, 1566, 1464, 1336, 1302, 1105, 1057 
HR EI+ Mass Spec. Calculated for C24H30O7: 430.1992, found: 430.1982 (2.3 ppm error) 
EI+(m/z): 430 (M+, 17), 364 (18), 324 (22), 258 (100), 243 (35), 215 (49), 149 (37)  





Ketone 130 was prepared from triflate 71 (55 mg, 0.11 mmol) and tributyl(furan-3-
yl)stannane (45 mg, 0.12 mmol) in 64% yield (31 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.96 (d, J = 0.5 Hz, 1H), 7.47 (m, 1H), 7.11 (d, J = 1.5 
Hz, 1H), 6.99 (d, J = 1.5 Hz, 1H), 6.89 (m, 1H), 5.26 (d, J = 6.5 Hz, 1H), 5.20 (d, J = 6.5 
Hz, 1H), 4.74 (dd, J = 12.5 Hz, 7.0 Hz, 2H), 3.76 (m 1H), 3.51 (s, 3H), 3.44-3.40 (m, 
4H), 2.53 (td, J = 11.2 Hz, 2.5 Hz. 1H), 2.22 (m, 1H), 1.95-1.90 (m, 1H), 1.57 (m, 1H), 
1.51-1.40 (m, 4H), 1.20-1.05 (m, 5H) 
13C NMR (CDCl3, 126 MHz):  δ 188.5, 156.5, 154.8, 148.5, 143.7, 138.1, 126.2, 118.8, 
112.6, 110.2, 105.4, 94.8, 94.4, 77.4, 75.6, 56.4, 55.2, 48.4, 36.2, 34.2, 33.1, 27.6, 26.1, 
18.8 
IR (thin film, cm-1): 3131, 2935, 2876, 1651, 1567, 1508, 1402, 1336, 1158, 1105, 1078 
HR ESI+ Mass Spec. Calculated for (C24H30O7 + Na+): 453.1884, found: 453.1891 (1.5 
ppm error) 





Ketone 131 was prepared from triflate 71 (41 mg, 0.085 mmol) and (benzofuran-2-
yl)tributylstannane (38 mg, 0.094 mmol) in 76% yield (31 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.71 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.55 
(s, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.32 (t, J = 7.8 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1H), 7.19 
(d, J = 1.5 Hz, 1H), 5.31 (d, J = 6.5 Hz, 1H), 5.23 (d, J = 6.5 Hz, 1H), 4.75 (dd, J = 12.5 
Hz, 7.0 Hz, 2H), 3.78 (m, 1H), 3.53 (s, 3H), 3.47-3.41 (m, 4H), 2.56 (td, J = 11.3 Hz, 2.5 
Hz, 1H), 2.24 (m, 1H), 1.95 (m, 1H), 1.60 (m, 1H), 1.52-1.41 (m, 4H), 1.21-1.12 (m, 2H), 
1.08 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 183.6, 156.5, 156.0, 154.7, 152.0, 136.6, 128.2, 127.0, 
123.8, 123.3, 119.4, 116.6, 113.2, 112.6, 105.9, 94.8, 94.5, 77.5, 75.6, 56.5, 55.2, 48.4, 
36.2, 34.3, 33.1, 27.6, 26.1, 18.8 
IR (thin film, cm-1): 2931, 1653, 1559, 1541, 1338, 1154, 1057 
HR EI+ Mass Spec. Calculated for C28H32O7: 480.2148, found: 480.2161 (2.7 ppm error) 
EI+(m/z): 480 (M+, 23), 420 (18), 374 (47), 314 (48), 288 (27), 269 (41), 258 (100), 215 
(56), 145 (27) 




Ketone 132 was prepared from triflate 71 (46 mg, 0.095 mmol) and (benzofuran-2-
yl)tributylstannane (43 mg, 0.11 mmol) in 68% yield (31 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.26-8.24 (m, 1H), 8.16 (s, 1H), 7.55 (m, 1H), 7.41-7.37 
(m, 2H), 7.16 (d, J = 1.5 Hz, 1H), 7.03 (d, J = 1.5 Hz, 1H), 5.29 (d, J = 6.5 Hz, 1H), 
5.21(d, J = 6.5 Hz, 1H), 4.75 (dd, J = 12.8 Hz, 6.8 Hz, 2H), 3.81-3.74 (m, 1H), 3.51 (s, 
3H), 3.47-3.40 (m, 4H), 2.55 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.23 (m, 1H), 1.94 (m, 1H), 
1.59 (td, J = 12.3 Hz, 2.5 Hz, 1H), 1.52-1.42 (m, 4H), 1.21-1.11 (m, 2H), 1.07 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 189.3, 156.6, 155.5, 154.8, 152.2, 138.5, 125.7, 125.3, 
124.4, 122.9, 120.8, 118.8, 112.5, 111.4, 105.5, 94.8, 94.4, 77.4, 75.6, 56.4, 55.2, 48.4, 
36.2, 34.2, 33.1, 27.6, 26.1, 18.8 
IR (thin film, cm-1): 2983, 2935, 2880, 2815, 1647, 1567, 1547, 1450, 1423, 1401, 1367, 
1155, 1056 
HR EI+ Mass Spec. Calculated for C28H32O7: 480.2148, found: 480.2135 (2.7 ppm error) 
EI+(m/z): 480 (M+, 26), 374 (91), 331 (50), 145 (100) 




Ketone 133 was prepared from triflate 71 (32 mg, 0.066 mmol) and tributyl(thiophen-2-
yl)stannane (27 mg, 0.073 mmol) in 80% yield (24 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.71-7.67 (dd, J = 4.0 Hz, 1.0 Hz, 1H), 7.14-7.10 (m, 
2H), 7.00 (d, J = 1.5 Hz, 1H), 5.27 (d, J = 6.5 Hz, 1H), 5.20 (d, J = 6.5 Hz, 1H), 4.75 (dd, 
J = 9.3 Hz, 6.9 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.44 (m, 1H), 3.39 (s, 3H), 2.54 (td, J 
= 11.2 Hz, 2.3 Hz, 1H), 2.22 (m, 1H), 1.93 (m, 1H), 1.65-1.55 (m, 2H), 1.46 (m, 1H), 
1.40 (s, 3H), 1.16 (m, 1H), 1.05 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 187.3, 156.4, 154.6, 143.4, 137.4, 134.7, 133.9, 127.8, 
118.6, 113.0, 105.9, 94.8, 94.5, 77.3, 75.6, 56.4, 55.2, 48.4, 36.2, 34.2, 33.1, 27.6, 26.1, 
18.8 
IR (thin film, cm-1):  2934, 2880, 2824, 1636, 1559, 1507, 1418, 1339, 1218, 1155 
HR EI+ Mass Spec. Calculated for C24H30O6S: 446.1763, found: 446.1755 (2.7 ppm 
error) 
EI+(m/z):  446 (M+, 26), 340 (77), 325 (18), 297 (33), 271 (41), 269 (100), 267 (69), 180 
(22), 11 (37), 69 (75) 




Ketone 134 was prepared from triflate 71 (73 mg, 0.15 mmol) and tributyl(thiophen-3-














1H NMR (CDCl3, 500 MHz):  δ 7.96 (dd, J = 2.8 Hz, 1.3 Hz, 1H), 7.58 (dd, J = 5.3 Hz, 
1.3 Hz, 1H), 7.10 (d, J = 1.5 Hz, 1H), 6.96 (d, J = 1.5 Hz, 1H), 5.27 (d, J = 6.5 Hz, 1H), 
5.19 (d, J = 6.5 Hz, 1H), 4.73 (dd, J = 12.8 Hz, 6.8 Hz, 2H), 3.79-3.73 (m, 1H), 3.50 (s, 
3H), 3.43 (m, 1H), 3.39 (s, 3H), 2.53 (td, J = 11.2 Hz, 2.3 Hz, 1H), 2.21 (m, 1H), 1.92 
(m, 1H), 1.57 (m, 1H), 1.51-1.39 (m, 5H), 1.14 (m, 1H), 1.04 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 189.1, 156.3, 154.5, 141.0, 137.8, 133.8, 128.6, 125.9, 
118.6, 113.3, 105.8, 94.8, 94.4, 77.3, 75.6, 56.4, 55.1, 48.4, 36.2, 34.2, 33.0, 27.6, 26.0, 
18.8 
IR (thin film, cm-1):  3106, 2935, 2879, 2824, 1651, 1567, 1510, 1401, 1334, 1105, 923, 
751 
 HR EI+ Mass Spec. Calculated for C24H30O6S: 446.1763, found: 446.1776 (2.9 ppm 
error) 
EI+(m/z): 446 (M+, 3), 273 (18), 269 (100), 265 (38), 207 (26) 






Ketone 135 was prepared from triflate 71 (65 mg, 0.13 mmol) and (benzo[b]thiophen-2-
yl)tributylstannane (62 mg, 0.15 mmol) in 64% yield (40.5 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 7.94 (s, 1H), 7.89 (app t, J = 8.5 Hz, 2H), 7.48 (t, J = 7.8 
Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 1.5 Hz, 1H), 7.07 (d, J = 1.5 Hz, 1H), 5.29 
(d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 1H), 4.75 (dd, J = 12.8 Hz, 6.5 Hz, 2H), 3.78 (m, 
1H), 3.51 (s, 3H), 3.48-3.41 (m, 4H), 2.56 (td, J = 11.3 Hz, 2.2 Hz, 1H), 2.24 (m, 1H), 
1.95 (m, 1H), 1.61 (m, 1H), 1.53-1.43 (m, 4H), 1.17 (m, 1H), 1.08 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 188.7, 156.5, 154.7, 142.9, 142.6, 139.1, 137.1, 132.1, 
127.3, 126.1, 124.9, 122.8, 118.9, 113.1, 105.9, 94.8, 94.5, 77.5, 75.6, 56.5, 55.2, 48.5, 
36.3, 34.3, 33.1, 27.6, 26.1, 18.8 
IR (thin film, cm-1): 2933, 1636, 1567, 1508, 1338, 1156, 1057 
HR EI+ Mass Spec. Calculated for C28H32O6S: 496.1920, found: 496.1909 (2.2 ppm 
error) 
EI+(m/z): 496 (M+, 55), 390 (100), 347 (30), 267 (36), 161 (47) 




Ketone 136 was prepared from triflate 71 (83 mg, 0.17 mmol) and (benzo[b]thiophen-3-
yl)tributylstannane (80 mg, 0.19 mmol) in 69% yield (58 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.55 (dd, J = 7.5 Hz, 0.5 Hz, 1H), 8.08 (s, 1H), 7.88 (d, J 
= 7.5 Hz, 1H), 7.49 (dt, J = 8.3 Hz, 1.3 Hz, 1H(, 7.42 (dt, J = 8.3 Hz, 1.3 Hz, 1H), 7.16 
(d, J = 1.5 Hz, 1H), 6.98 (d, J = 1.5 Hz, 1H), 5.28 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 
1H), 4.75 (dd, J = 12.8 Hz, 6.8 Hz, 2H), 3.81-3.74 (m, 1H), 3.51 (s, 3H), 3.46 (m, 1H), 
3.40 (s, 3H), 2.55 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.23 (m, 1H), 1.93 (m, 1H), 1.59 (m, 
1H), 1.50-1.40 (m, 4H), 1.20-1.11 (m, 2H), 1.06 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 189.9, 156.4, 154.5, 139.9, 138.5, 138.1, 137.4, 134.4, 
125.5, 125.4, 125.1, 122.2, 118.7, 113.5, 106.0, 94.8, 94.4, 77.3, 75.6, 56.4, 55.1, 48.4, 
36.2, 34.2, 33.0, 27.6, 26.0, 18.7 
IR (thin film, cm-1):  3099, 2934, 2878, 1645, 1567, 1056, 1043 
HR EI+ Mass Spec. Calculated for C28H32O6S: 496.1920, found: 496.1904 (3.2 ppm 
error) 
EI+(m/z): 496 (M+, 35), 390 (70), 314 (100), 272 (42), 257 (42), 207 (41), 161 (48) 




Ketone 137 was prepared from triflate 71 (52 mg, 0.11 mmol) and 4-
(tributylstannyl)thiazole (44 mg, 0.12 mmol) in 76% yield (36.5 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.88 (d, J = 2.0 Hz, 1H), 8.24 (d, J = 2.0 Hz, 1H), 7.36 
(d, J = 1.5 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), 5.28 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 
1H), 4.73 (dd, J = 6.8 Hz, 1.8 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.42 (m, 1H), 3.38 (s, 
3H), 2.53 (td, J = 11.2 Hz, 1.5 Hz, 1H), 2.22 (m, 1H), 1.91 (m, 1H), 1.56 (m, 1H), 1.49-
1.39 (m, 4H), 1.19-1.11 (m, 2H), 1.04 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 186.4, 156.3, 155.2, 154.5, 152.7, 136.5, 127.5, 119.5, 
114.4, 106.5, 94.8, 94.5, 77.2, 75.6, 56.4, 55.1, 48.4, 36.2, 34.3, 33.0, 27.6, 26.0, 18.8 
IR (thin film, cm-1):  3101, 2934, 2877, 2824, 1653, 1567, 1400, 1369, 1154, 1057 
HR EI+ Mass Spec. Calculated for C23H29NO6S: 447.1716, found: 447.1719 (0.7 ppm 
error) 
EI+(m/z):  447 (M+, 34), 354 (22), 341 (100), 326 (30), 298 (47), 273 (46), 271 (66), 212 
(37), 208 (20), 177 (53), 153 (24), 149 (41), 112 (57) , 69 (32) 




Ketone 138 was prepared from triflate 71 (67 mg, 0.14 mmol) and 5-
(tributylstannyl)thiazole (57 mg, 0.15 mmol) in 44% yield (27 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 9.03 (s, 1H), 8.41 (s, 1H), 7.13 (d, J = 1.5 Hz, 1H), 7.02 
(d, J = 1.5 Hz, 1H), 5.27 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 1H), 4.74 (dd, J = 12.0 
Hz, 7.0 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.44-3.39 (m, 4H), 2.54 (td, J = 10.8 Hz, 2.5 
Hz. 1H), 2.22 (m, 1H), 1.92 (m, 1H), 1.58 (td, J = 11.7 Hz, 2.3 Hz, 1H), 1.51-1.39 (m, 
4H), 1.20-1.05 (m, 5H) 
13C NMR (CDCl3, 126 MHz):  δ 186.4, 158.9, 156.6, 154.9, 148.9, 139.1, 136.7, 119.5, 
113.0, 105.6, 94.8, 94.4, 77.5, 75.6, 56.4, 55.2, 48.3, 36.1, 34.2, 33.0, 27.6, 26.0, 18.8 
IR (thin film, cm-1):  2936, 2880, 2825, 1647, 1569, 1338, 1154, 1057 
HR EI+ Mass Spec. Calculated for C23H29NO6S: 447.1716, found: 447.1708 (1.8 ppm 
error) 
EI+(m/z): 447 (M+, 1), 149 (13), 97 (14), 95 (19), 83 (24), 81 (43), 69 (100) 





Ketone 139 was prepared from triflate 71 (60 mg, 0.12 mmol) and 2-
(tributylstannyl)pyridine (50 mg, 0.14 mmol) in 58% yield (32 mg) as a pale yellow oil 
which turns green upon standing. 
1H NMR (CDCl3, 500 MHz):  δ 8.89 (d, J = 2.0 Hz, 1H), 8.24 (d, J = 2.0 Hz, 1H), 7.36 
(d, J = 1.5 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), 5.28 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 
1H), 4.73 (dd, J = 12.3 Hz, 6.8 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.44-3.38 (m, 4H), 
2.53 (td, J = 11.2 Hz, 2.5 Hz, 1H), 2.21 (m, 1H), 1.91 (m, 1H), 1.56 (m, 1H), 1.49-1.39 
(m, 4H), 1.19-1.07 (m, 2H), 1.04 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 186.4, 156.3, 155.2, 154.5, 152.7, 136.5, 127.5, 119.5, 
114.4, 106.5, 94.8, 94.5, 77.2, 75.6, 56.4, 55.1, 48.4, 36.2, 34.3, 33.0, 27.6, 26.0, 18.8 
IR (thin film, cm-1): 3101, 2934, 2877, 2824, 1653, 1567, 1337, 1154, 1057 
HR EI+ Mass Spec. Calculated for C25H31NO6: 441.2151, found: 441.2158 (1.6 ppm 
error) 
EI+(m/z): 441 (M+, 3), 274 (33), 272 (60), 269 (100), 267 (68), 253 (36), 231 (74) 




Ketone 140 was prepared from triflate 71 (65 mg, 0.13 mmol) and 3-
(tributylstannyl)pyridine (54 mg, 0.15 mmol) in 83% yield (49 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.99 (bs, 1H), 8.78 (bs, 1H), 8.09 (d, J = 7.5 Hz, 1H), 
7.42 (dd, J = 7.5 Hz, 5.0 Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 6.85 (d, J = 1.5 Hz, 1H), 5.27 
(d, J = 6.8 Hz, 1H), 5.21 (d, J = 6.8 Hz, 1H), 4.74 (dd, J = 12.3 Hz, 6.8 Hz, 2H), 3.77 (m, 
1H), 3.50 (s, 3H), 3.43 (m, 1H), 3.40 (s, 3H), 2.54 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.22 (m, 
1H), 1.93 (m, 1H), 1.58 (m, 1H), 1.51-1.31 (m, 4H), 1.20-1.10 (m, 2H), 1.05 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 194.1, 156.6, 154.7, 152.6, 150.8, 137.1, 136.0, 123.2, 
119.7, 114.4, 106.0, 94.8, 94.4, 77.5, 75.6, 56.5, 55.2, 48.4, 36.2, 34.3, 33.1, 27.6, 26.0, 
18.8 
IR (thin film, cm-1):  2933, 1653, 1559, 1339, 1154 
HR EI+ Mass Spec. Calculated for C25H31NO6: 441.2151, found: 441.2137 (3.2 ppm 
error) 
EI+(m/z): 441 (M+, 21), 380 (20), 335 (100), 320 (22), 292 (40), 106 (25) 




Ketone 141 was prepared from triflate 71 (54 mg, 0.11 mmol) and 4-
(tributylstannyl)pyridine (45 mg, 0.12 mmol) in 84% yield (41 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.77 (d, J = 4.5 Hz, 2H), 7.56 (d, J = 6.0 Hz, 2H), 7.15 
(d, J = 1.5 Hz, 1H), 6.81 (d, J = 1.5 Hz, 1H), 5.27 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 6.5 Hz, 
1H), 4.74 (dd, J = 11.8 Hz, 6.8 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.44-3.39 (m, 4H), 
2.54 (dt, J = 11.3 Hz, 2.3 Hz, 1H), 2.22 (m, 1H), 1.93 (m, 1H), 1.57 (m, 1H), 1.51-1.39 
(m, 4H), 1.19-1.06 (m, 2H), 1.04 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 194.4, 156.7, 154.7, 150.2, 144.5, 135.2, 122.8, 120.1, 
114.6, 105.9, 94.8, 94.4, 77.6, 75.6, 56.5, 55.2, 48.4, 36.2, 34.3, 33.1, 27.6, 26.0, 18.8 
IR (thin film, cm-1): 2936, 2879, 2824, 1669, 1569, 1424, 1405, 1338, 1155, 1057 
HR EI+ Mass Spec. Calculated for C25H31NO6: 441.2151, found: 441.2137 (3.2 ppm 
error) 
EI+(m/z): 441 (M+, 19), 365 (11), 335 (100), 320 (23), 292 (50), 106 (37) 





Ketone 142 was prepared from triflate 71 (77 mg, 0.16 mmol) and 4-(tributylstannyl)-3-
fluoropyridine (68 mg, 0.18 mmol) in 51% yield (36 mg) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz):  δ 8.59 (s, 1H), 8.54 (d, J = 4.5 Hz, 1H), 7.35 (t, J = 5.3 Hz, 
1H), 7.23 (d, J = 1.5 Hz, 1H), 6.74 (s, 1H), 5.27 (d, J = 6.8 Hz, 1H), 5.21 (d, J = 6.8 Hz, 
1H), 4.73 (dd, J = 11.5 Hz, 7.0 Hz, 2H), 3.76 (m, 1H), 3.50 (s, 3H), 3.42-3.39 (m, 4H), 
2.52 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.22 (m, 1H), 1.92 (m, 1H), 1.54 (td, J = 11.6 Hz, 2.2 
Hz, 1H), 1.45 (m, 1H), 1.38 (s, 3H), 1.18-1.07 (m, 2H), 1.03 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 190.5, 155.9 (d, JCF = 251.0 Hz), 145.8 (d, JCF = 5.4 
Hz), 139.3 (d, JCF = 26.5 Hz), 135.1, 134.0, 133.9, 123.0, 121.2, 114.8, 104.9, 94.8, 94.5, 
77.6, 75.5, 56.5, 55.2, 48.3, 36.1, 34.3, 33.0, 27.5, 26.0, 18.7 
IR (thin film, cm-1): 2931, 2879, 1671, 1570, 1412, 1338, 1154, 1105, 1057 
HR EI+ Mass Spec. Calculated for C25H30FNO6: 459.2057, found: 459.2051 (1.3 ppm 
error) 
EI+(m/z): 459 (M+, 18), 353 (100), 338 (17), 310 (45), 124 (25) 




Nitrile 73 (530 mg, 1.47 mmol) was dissolved in 10 mL of CH2Cl2, cooled to -78 °C and 
stirred for 10 min.  DIBAL (520 µL, 2.93 mmol) was then added drop wise and stirred 
for 45 min.  Excess DIBAL was quenched with acetone at -78 °C and then the reaction 
mixture was stirred with saturated Rochelle’s salt at room temperature until the emulsion 
subsided.  EtOAc was added; organic layer was washed with brine and dried over 
Na2SO4.  The crude product was then purified on silica gel eluting with 30% then 40% 










1H NMR (CDCl3, 300 MHz):  δ 9.81 (s, 1H), 7.10 (s, 1H), 6.97 (s, 1H), 5.26 (d, J = 6.5 
Hz, 1H), 5.20 (d, J = 6.5 Hz, 1H), 4.72 (m, 2H), 3.74 (m, 1H), 3.49 (s, 3H), 3.42-3.37 (m, 
4H), 2.51 (td, J = 11.3 Hz, 2.1 Hz, 1H), 2.20 (m, 1H), 1.91 (m, 1H), 1.59-1.38 (m, 5H), 
1.26-1.03 (m, 5H) 
13C NMR (CDCl3, 75 MHz):  δ 191.7, 156.9, 155.3, 136.1, 120.9, 114.3, 104.6, 94.8, 
94.4, 77.4, 75.6, 56.4, 55.1, 48.3, 36.1, 34.4, 33.0, 27.5, 26.0, 18.7 
IR (thin film, cm-1): 2938, 2879, 2726, 1698, 1576, 1433, 1385, 1154, 1056 
HR EI+ Mass Spec. Calculated for C20H28O6: 364.1886, found: 364.1890 (1.1 ppm error) 
EI+(m/z):  364 (M+, 19), 288 (13), 258 (100), 243 (31), 215 (70), 69 (25) 









To 1-bromo-3-fluorobenzene (140 mg, 0.80 mmol) in 1.6 mL of THF at -78 °C under 
nitrogen was added n-BuLi in hexanes (340 µL, 0.77 mmol) and this reaction mixture 
was stirred for 1 h.  Aldehyde 143 (62 mg, 0.17 mmol) in 2 mL of THF was then added 
via cannula at -78 °C and stirred for an additional 1 h at this temperature.  The reaction 
was quenched with saturated brine, extracted with Et2O, washed with brine and dried 
over Na2SO4.  The crude product was then purified on silica gel eluting with 20, 30, 40% 
EtOAc/hexanes resulting in the benzylic alcohol.  This mixture was then treated with 
MnO2 (131 mg, 1.51 mmol) in 8 mL of CH2Cl2 at rt for 24 h.  The solids were removed 
by filtering through Celite and then the solvent was removed under reduced pressure 








1H NMR (CDCl3, 500 MHz):  δ 7.56 (d, J = 7.5 Hz, 1H), 7.49-7.47 (m, 1H), 7.44-7.40 (m 
1H), 7.26-7.22 (m, 1H), 7.10 (d, J = 1.5 Hz, 1H), 6.83 (d, J = 1.5 Hz, 1H), 5.26 (d, J = 
6.8 Hz, 1H), 5.19 (d, J = 6.8 Hz, 1H), 4.74 (dd, J = 12.8 Hz, 6.8 Hz. 2H), 3.76 (m, 1H), 
3.50 (s, 3H), 3.43 (m, 1H), 3.39 (s, 3H), 2.53 (td, J = 11.2 Hz, 2.5 Hz, 1H), 2.21 (m, 1H), 
1.92 (m, 1H), 1.57 (m, 1H), 1.45 (m, 1H), 1.39 (s, 3H), 1.19-1.07 (m, 2H), 1.04 s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 194.4, 162.3 (d, JCF = 247.7 Hz), 156.4, 154.4, 139.6 (d, 
JCF = 6.2 Hz), 136.2, 129.8 (d, JCF = 7.8 Hz), 125.6, 119.2, 119.0, 116.6 (d, JCF = 22.4 
Hz), 114.2, 106.1, 94.8, 94.4, 77.4, 75.5, 56.4, 55.1, 48.4, 36.2, 34.2, 33.0, 27.5, 26.0, 
18.7 
IR (thin film, cm-1): 2935, 2879, 1653, 1568, 1558, 1338, 1155, 1057 
HR EI+ Mass Spec. Calculated for C26H31FO6: 458.2105, found: 458.2120 (3.3 ppm 
error) 
EI+(m/z):  458 (M+, 34), 352 (100), 309 (48), 219 (26), 149 (52), 123 (94), 71 (32), 69 
(33) 






Ketone 145 was prepared from aldehyde 143 (62 mg, 0.17 mmol) and 1-bromo-3-
(trifluoromethyl)benzene (180 mg, 0.80 mmol) in 81% yield (65 mg) over the 2 steps as a 













1H NMR (CDCl3, 500 MHz):  δ 8.05 (s, 1H), 7.97 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 7.5 
Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.09 (d, J = 1.5 Hz, 1H), 6.84 (d, J = 1.5 Hz, 1H), 5.26 
(d, J = 6.8 Hz, 1H), 5.19 (d, J = 6.8 Hz, 1H), 4.74 (dd, J = 12.5 Hz, 7.0 Hz, 2H), 3.77 (m, 
1H), 3.50 (s, 3H), 3.43 (m, 1H), 3.39 (s, 3H), 2.54 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.25 (m, 
1H), 1.93 (m, 1H), 1.58 (m, 1H), 1.47 (m, 1H), 1.39 (s, 3H), 1.19-1.11 (m, 2H), 1.05 (s, 
3H) 
13C NMR (CDCl3, 126 MHz):  δ 194.4, 156.5, 154.7, 138.3, 136.0, 133.0, 130.7 (q, JCF = 
32.7 Hz), 128.8, 128.5 (q, JCF = 3.1 Hz), 126.6 (q, JCF = 3.5 Hz), 124.0 (q, JCF = 272.5 
Hz), 119.5, 114.1, 106.3, 94.8, 94.3, 77.5, 75.6, 56.4, 55.2, 48.3, 36.2, 34.2, 33.1, 27.5, 
26.0, 18.8 
IR (thin film, cm-1): 2979, 2942, 2882, 1653, 1569, 1340, 1296, 1129, 1057 
HR EI+ Mass Spec. Calculated for C27H31F3O6: 508.2073, found: 508.2079 (1.2 ppm 
error) 
EI+(m/z): 508 (M+, 4), 402 (22), 319 (100), 215 (36), 173 (95), 145 (29) 





















143 146  
To aldehyde 143 (99 mg, 0.27 mmol) and indole (35 mg, 0.30 mmol) in 500 µL of 
MeOH at 0 °C was added 30 µL of 50% KOH dropwise.  The reaction flask was then 
sealed with a Teflon cap and stirred overnight gradually warming to room temperature.  
Saturated NH4Cl was then added, extracted with EtOAc, washed with brine and dried 
over MgSO4.  The crude addition product was purified via flash column chromatography 
on silica gel eluting with 30%, 50% then 80% EtOAc/hexanes.  The alcohol was then 
treated with MnO2 (283 mg, 3.26 mmol) in 10 mL of CH2Cl2 at rt for 12 h.  The solids 
were removed by filtering through Celite and then the solvent was removed under 
reduced pressure.  The crude ketone was then purified via flash column chromatography 
on silica gel eluting with 30% then 50% EtOAc/hexanes resulting in pure ketone 146 (67 







1H NMR (MeOH-d4, 500 MHz):  δ 8.28 (dd, J = 6.5 Hz, 2.0 Hz, 1H), 7.85 (s, 1H), 7.48 
(dd, J = 6.8 Hz, 1.8 Hz, 1H), 7.28-7.23 (m, 2H), 7.07 (d, J = 1.5 Hz, 1H), 6.86 (d, J = 1.5 
Hz, 1H), 5.29 (d, J = 6.8 Hz, 1H), 5.22 (d, J = 6.8 Hz, 1H), 4.72 (s, 2H), 3.74 (m, 1H), 
3.50-3.48 (m, 4H), 3.37 (s, 3H), 2.56 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.19 (m, 1H), 1.92 
(m, 1H), 1.53 (m, 1H), 1.46-1.36 (m, 4H), 1.18 (m, 1H), 1.09-1.02 (m, 4H) 
13C NMR (CDCl3, 126 MHz):  δ 193.0, 157.7, 155.9, 141.3, 138.5, 137.2, 127.8, 124.6, 
123.4, 123.0, 119.0, 116.9, 113.1, 113.0, 107.2, 96.0, 95.7, 78.4, 77.4, 56.7, 55.5, 50.0, 
37.9, 35.4, 34.3, 28.0, 27.0, 19.1 
IR (thin film, cm-1): 3246(br), 2978, 2934, 2875, 2816, 1737, 1604, 1563, 1519, 1433, 
1371, 1244, 1153, 1056, 1045 
HR EI+ Mass Spec. Calculated for C28H33NO6: 479.2308, found: 479.2291 (3.5 ppm 
error) 
EI+(m/z): 479 (35, M+), 373 (84), 330 (21), 144 (100), 130 (46) 






To ketone 146 (24 mg, 0.05 mmol) in 500 µL DMF under N2 at room temperature was 
added a spatula tip of NaH and stirred for 10 minutes.  MeI (56 mg, 25 µL) was then 
added and stirred overnight.  The reaction mixture was then directly absorbed onto Celite 
and purified via flash column chromatography on silica gel eluting with 60% 











1H NMR (CDCl3, 500 MHz):  δ 8.46-8.44 (m, 1H), 7.64 (s, 1H), 7.37-7.32 (m, 3 H), 7.09 
(d, J = 1.3 Hz, 1H), 6.95 (d, J = 1.3 Hz, 1H), 5.28 (d, J = 6.5 Hz, 1H), 5.19 (d, J = 6.5 Hz, 
1H), 4.75 (dd, J = 13.8, 6.8 Hz, 2H), 3.84 (s, 3H), 3.78 (m, 1H), 3.51 (s, 3H), 3.47 (m, 
1H), 3.41 (s, 3H), 2.55 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.26-2.20 (m, 1H), 1.95 (m, 1H), 
1.59 (td, J = 11.6 Hz, 2.3 Hz, 1H), 1.52-1.42 (m, 4H), 1.21-1.12 (m, 2H), 1.07 (s, 3H) 
13C NMR (CDCl3, 126 MHz):  δ 189.9, 156.3, 154.4, 140.3, 138.0, 137.5, 127.3, 123.5, 
122.8, 122.6, 117.2, 115.2, 112.2, 109.5, 105.8, 94.8, 94.5, 75.6, 56.4, 55.2, 48.6, 36.4, 
34.2, 33.5, 33.1, 27.7, 26.1, 18.8 
IR (thin film, cm-1): 3114, 3053, 2935, 2824, 1623, 1565, 1525, 1464, 1369, 1215, 1057 
HR EI+ Calculated for C29H35NO6: 493.2464, found: 493.2446 (3.6 ppm error) 
EI+(m/z): 493 (M+, 64), 387 (86), 344 (29), 207 (61), 158 (100), 144 (83) 









General Experimental for the Removal of the Methoxymethyl ether Group 
TMSBr was prepared by adding Br2 (100 µL, 1.95 mmol) dropwise to a solution of 
hexamethyldisilane (420 µL, 2.05 mmol) in 5 mL of CH2Cl2 at -78 °C under N2, stirred 
for 5 min then warmed to room temperature where the reaction mixture changed color 
from orange to clear and colorless (sometimes the solution has a slight orange or yellow 
color to it but it does not affect the yield of the following reaction). 
To ketone 128 (33 mg, 0.075 mmol) in 1 mL of CH2Cl2 at -40 oC was added a 0.35 M 
solution of  TMSBr in CH2Cl2 (0.43 mL, 0.15 mmol) via syringe and stirred for 45 min.  
Additional TMSBr (0.43 mL, 0.15 mmol) was added at -40 °C and stirred for 45 min.  
The reaction mixture was then warmed to 0 °C followed by the addition of TMSBr (0.43 
mL, 0.15 mmol) and stirred for 1 h.  The reaction was quenched with saturated NaHCO3, 
extracted with EtOAc, washed with brine and dried over Na2SO4.  The crude product was 
then purified via flash column chromatography on silica gel eluting with 2.5% then 5% 





Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 3.95 min and 98.4% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 7.75 (d, J = 7.0 Hz, 2H), 7.62 (t, J = 7.3 Hz, 1H), 7.51 
(t, J = 7.8 Hz, 2H), 6.73 (d, J = 1.5 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 3.78 (m, 1H), 3.57 
(m, 1H), 2.55 (td, J = 11.3 Hz, 2.3 Hz, 1H), 2.14 (m, 1H), 1.93 (m, 1H), 1.52 (m, 1H), 
1.44-1.36 (m, 4H), 1.22 (m, 1H), 1.07 (s, 3H), 0.99 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 198.4, 158.2, 156.2, 139.1, 137.7, 133.5, 130.9, 
129.3, 118.8, 112.0, 109.3, 78.4, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3253(br), 2931, 2861, 1641, 1568, 1417, 1056 
HR EI+ Mass Spec. Calculated for C22H24O4: 352.1675, found: 352.1675 (0.0 ppm error) 
EI+(m/z): 352 (M+, 61), 334 (32), 291 (55), 265 (29), 105 (100), 91 (4), 77 (32) 








Prepared in 42% yield as a beige glass. 
Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 4.00 min and 95.3% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 7.88 (d, J = 1.0 Hz, 1H), 7.31 (d, J = 3.5 Hz, 1H), 
6.89 (d, J = 1.8 Hz, 1H), 6.85 (d, J = 1.8 Hz, 1H), 6.69 (dd, J = 3.5 Hz, 2.0 Hz, 1H), 3.77 
(m, 1H), 3.56 (m, 1H), 2.55 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.14 (m, 1H), 1.93 (m, 1H), 
1.51 (td, J = 11.5 Hz, 2.3 Hz, 1H), 1.44-1.36 (m, 4H), 1.22 (m, 1H), 1.07 (s, 3H), 0.99 
(m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 183.9, 158.1, 156.4, 153.3, 149.2, 137.4, 122.3, 
118.9, 113.4, 111.2, 108.4, 78.4, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3218(br), 2931, 2863, 1632, 1563, 1463, 1341, 1057 
HR EI+ Mass Spec. Calculated for C20H22O5: 342.1467, found: 342.1469 (0.6 ppm error) 
EI+(m/z): 342 (M+, 74), 324 (66), 281 (69), 255 (39), 149 (74), 95 (100) 



















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 3.85 min and 98.4% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.11 (dd, J = 1.3 Hz, 0.8 Hz, 1H), 7.65-7.64 (m, 1H), 
6.86 (dd, J = 1.8 Hz, 0.8 Hz, 1H), 6.80 (d, J = 1.8 Hz, 1H), 6.73 (d, J = 1.8 Hz, 1H), 3.77 
(m, 1H), 3.55 (m, 1H), 2.54 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.16-2.12 (m, 1H), 1.93 (m, 
1H), 1.51 (td, J = 11.6 Hz, 2.2 Hz, 1H), 1.40 (m, 4H), 1.24 (m, 1H), 1.07 (s, 3H), 0.98 (m, 
1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 191.0, 158.2, 156.5, 150.5, 145.6, 139.0, 127.5, 
118.7, 110.9, 110.7, 108.1, 78.4, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3367 (br), 2932, 2870, 1734, 1717, 1635, 1571, 1508, 1419, 1340, 
1047 
HR EI+ Mass Spec. Calculated for C20H22O5: 342.1467, found: 342.1470 (0.9 ppm error) 
EI+(m/z):  342 (M+, 31), 324 (71), 281 (32), 269 29), 255 (24), 217 (24), 129 (18), 95 
(100), 84 (80) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 4.19 min and 97.4% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 7.80 (d, J = 8.0 Hz, 1H), 7.66-7.64 (m, 2H), 7.54 
(ddd, J = 8.8 Hz, 7.5 Hz, 1.0 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 6.98 (d, J = 1.8 Hz, 1H), 
6.95 (d, J = 1.8 Hz, 1H), 3.81-3.75 (m, 1H), 3.57 (m, 1H), 2.57 (td, J = 11.3 Hz, 2.5 Hz, 
1H), 2.15 (m, 1H), 1.53 (td, J = 11.6 Hz, 2.2 Hz, 1H), 1.45-1.37 (m, 4H), 1.24 (m, 1H), 
1.09 (s, 3H), 1.01 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 185.5, 158.2, 157.4, 156.5, 153.4, 137.3, 129.7, 
128.4, 125.2, 124.7, 119.4, 117.9, 113.1, 111.4, 108.6, 78.5, 71.3, 50.0, 39.4, 36.6, 35.4, 
28.1, 27.2, 19.2 
IR (thin film, cm-1): 3420 (br), 1636, 1572, 1544, 1419, 1363, 1339, 1055 
HR EI+ Mass Spec. Calculated for C24H24O5: 392.1624, found: 392.1621 (0.8 ppm error) 
EI+(m/z): 392 (M+, 32), 331 (10), 310 (14), 279 (25), 167 (26), 149 (100), 129 (13), 112 
(10), 71 (24) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 4.17 min and 97.7% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.36 (s, 1H), 8.15 (dd, J = 7.8 Hz, 1.3 Hz, 1H), 7.60 
(d, J = 7.5 Hz, 1H), 7.43 (td, J = 7.6 Hz, 1.6 Hz, 1H), 7.39 (td, J = 7.6 Hz, 1.2 Hz, 1H), 
6.84 (d, J = 2.0 Hz, 1H), 6.78 (d, J = 2.0 Hz, 1H), 3.78 (m, 1H), 3.57 (m, 1H), 2.56 (td, J 
= 11.4 Hz, 2.3 Hz, 1H), 2.16 (m, 1H), 1.93 (m, 1H), 1.52 (td, J = 11.6 Hz, 2.2 Hz, 1H), 
1.45-1.36 (m, 4H), 1.23 (m, 1H), 1.08 (s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 191.7, 158.3, 157.0, 156.6, 154.5, 139.5, 126.9, 
126.5, 125.5, 123.6, 122.0, 118.6, 112.5, 110.7, 108.1, 78.5, 71.3, 50.0, 39.5, 36.6, 35.4, 
28.1, 27.2, 19.2 
IR (thin film, cm-1): 3405 (br), 2979, 2937, 2871, 1735, 1641, 1573, 1547, 1419, 1373, 
1277, 1247, 1137, 1048 
HR EI+ Mass Spec. Calculated for C24H24O5: 392.1624, found: 392.1617 (1.8 ppm error) 
EI+(m/z): (M+, 100), 331 (20), 145 (46) 





















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 7.63 min and 98.8% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 7.89 (dd, J = 5.3 Hz, 1.3 Hz, 1H), 7.74 (dd, J = 3.8 
Hz, 1.3 Hz, 1H), 7.22 (dd, J = 5.0 Hz, 4.0 Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 6.72 (d, J = 
2.0 Hz, 1H), 3.78 (m, 1H), 3.57 (m, 1H), 2.55 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.14 (m, 1H), 
1.93 (m, 1H), 1.52 (td, J = 11.8 Hz, 2.3 Hz, 1H), 1.43-1.36 (m, 4H), 1.22 (m, 1H), 1.07 
(s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 189.6, 158.3, 156.3, 144.1, 138.3, 136.4, 135.8, 
129.2, 118.5, 110.9, 108.5, 78.4, 71.3, 50.0, 39.5, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3379(br), 2981, 2934, 2856, 1734, 1635, 1570, 1508, 1419, 1341, 
1246, 1055 
HR EI+ Mass Spec. Calculated for C20H22O4S: 358.1239, found: 358.1245 (1.7 ppm 
error) 
EI+(m/z): 358 (M+, 6), 207 (57), 149 (70), 122 (20), 107 (29), 101 (100), 98 (35), 85 
(25), 71 (46) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 260 nm) 7.73 min and 96.0% chemical purity. 
mp:  >230 °C 
1H NMR (MeOH-d4, 500 MHz):  δ 8.07 (app t, J = 2.0 Hz, 1H), 7.53 (s, 1H), 7.52 (s, 
1H), 6.77 (d, J = 1.5 Hz, 1H), 6.69 (d, J = 1.5 Hz, 1H), 3.79-3.73 (m, 1H), 3.56 (m, 1H), 
2.54 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.13 (m, 1H), 1.92 (m, 1H), 1.50 (td, J = 11.6 Hz, 2.2 
Hz, 1H), 1.44-1.33 (m, 4H), 1.22 (m, 1H), 1.06 (s, 3H), 0.99 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 191.7, 158.1, 156.3, 142.3, 138.8, 135.6, 129.3, 
127.6, 118.6, 111.4, 108.7, 78.4, 71.3, 50.0, 39.5, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3378(br), 2932, 2857, 1652, 1634, 1574, 1511, 1419, 1341, 1246, 
1178, 1136, 1055 
HR EI+ Mass Spec. Calculated for C20H22O4S: 358.1239, found: 358.1248 (2.5 ppm 
error) 
EI+(m/z): 358 (M+, 89), 297 (68), 271 (37), 149 (51), 111 (100) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 212 nm) 4.40 min and 98.8% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.00 (s, 1H), 7.97 (d, J = 9.3 Hz, 1H), 7.95 (d, J = 9.3 
Hz, 1H), 7.51 (ddd, J = 9.5 Hz, 7.5 Hz, 1.0 Hz, 1H), 7.44 (ddd, J = 9.5 Hz, 7.5 Hz, 1.0 
Hz, 1H), 6.85 (d, J = 1.5 Hz, 1H), 6.79 (d, J = 1.5 Hz, 1H), 3.78 (m, 1H), 3.58 (m, 1H), 
2.57 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.15 (m, 1H), 1.94 (m, 1H), 1.53 (td, J = 11.5 Hz, 2.3 
Hz, 1H), 1.45-1.37 (m, 4H), 1.24 (m, 1H), 1.09 (s, 3H), 1.01 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 190.9, 158.2, 156.4, 143.9, 140.6, 138.0, 133.8, 
128.8, 127.4, 126.2, 123.8, 118.8, 111.1, 108.5, 78.5, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 
27.2, 19.2 
IR (thin film, cm-1): 3420 (br), 2978, 2933, 2869, 1734, 1716, 1634, 1571, 1511, 1418, 
1343, 1265, 1047 
HR EI+ Mass Spec. Calculated for C24H24O4S: 408.1395, found: 408.1390 (1.2 ppm 
error) 
EI+(m/z): 408 (M+, 25), 390 (37), 347 (24), 167 (19), 161 (61), 149 (100), 83 (21), 71 
(21), 69 (21) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 212 nm) 8.47 min and 98.1% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.41 (d, J = 7.8 Hz, 1H), 8.23 (s, 1H), 7.97 (d, J = 7.8 
Hz, 1H), 7.50-7.43 (m, 2H), 6.81 (br s, 1H), 6.72 (d, J = 1.5 Hz, 1H), 3.78 (m, 1H), 3.57 
(m, 1H), 2.56 (td, J = 11.4 Hz, 1.7 Hz, 1H), 2.15 (m, 1H), 1.93 (m, 1H), 1.52 (td, J = 11.5 
Hz, 1.8 Hz, 1H), 1.44-1.36 (m, 4H), 1.22 (m, 1H), 1.07 (s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 192.4, 158.2, 156.4, 141.5, 140.1, 139.5, 138.7, 
135.6, 118.6, 111.5, 108.8, 78.4, 71.3, 50.0, 39.5, 36.6, 35.4, 28.1, 27.2, 19.2 
IR (thin film, cm-1):  3395 (br), 2976, 2931, 2869, 1734, 1637, 1571, 1420, 1199, 1138, 
1047 
HR EI+ Mass Spec. Calculated for C24H24O4S: 408.1395, found: 408.1394 (0.3 ppm 
error) 
EI+(m/z): 408 (M+, 37), 347 (23), 281 (65), 269 (35), 267 (30), 221 (36), 207 (100), 161 
(50), 72 (59) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 212 nm) 8.07 min and 98.1% chemical purity. 
mp: >220 °C (dec.); 
1H NMR (MeOH-d4, 500 MHz):  δ 9.09 (d, J = 2.0 Hz, 1H), 8.36 (d, J = 2.0 Hz, 1H), 
7.00 (d, J = 1.5 Hz, 1H), 6.96 (d, J = 1.5 Hz, 1H), 3.79-3.73 (m, 1H), 3.56 (m, 1H), 2.53 
(td, J = 11.33 Hz,  2.3 Hz, 1H), 2.12 (m, 1H), 1.90 (m, 1H), 1.49 (td, J = 11.3 Hz, 2.3 Hz, 
1H), 1.42-1.34 (m, 4H), 1.20 (m, 1H), 1.05 (s, 3H), 0.97 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 188.5, 158.0, 156.3, 155.8, 155.7, 137.5, 129.8, 
119.3, 112.3, 109.2, 78.4, 71.3, 50.0, 39.4, 36.5, 35.4, 28.1, 27.1, 19.2 
IR (thin film, cm-1): 3392(br), 2925, 2854, 1720, 1652, 1460, 1419, 1375, 1274, 1135, 
1055 
HR EI+ Mass Spec. Calculated for C19H21NO4S: 359.1191, found: 359.1185 (1.7 ppm 
error) 
EI+(m/z): 359 M+, 24), 341 (89), 298 (50), 272 (43), 112 (100) 






Prepared in 66% yield as a brown oil. 
Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 4.30 min and 96.8% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 9.29 (s, 1H), 8.41 (s, 1H), 6.84 (d, J = 1.5 Hz, 1H), 
6.78 (d, J = 1.5 Hz, 1H), 3.78 (m, 1H), 3.56 (m, 1H), 2.56 (td, J = 11.3 Hz, 2.0 Hz, 1H), 
2.15 (m, 1H), 1.94 (m, 1H), 1.53 (td, J = 11.6 Hz, 1.8 Hz, 1H), 1.45-1.36 (m, 4H), 1.23 
(m, 1H), 1.08 (s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 188.1, 161.5, 158.4, 156.6, 149.6, 140.5, 137.8, 
119.4, 111.0, 108.3, 78.6, 71.3, 49.9, 39.4, 36.6, 35.4, 28.1, 27.1, 19.1 
IR (thin film, cm-1): 3397 (br), 2977, 2932, 2869, 1732, 1637, 1572, 1505, 1419, 1342, 
1242, 1055 
HR EI+ Mass Spec. Calculated for C19H21NO4S: 359.1191, found: 359.1181 (2.8 ppm 
error) 
EI+(m/z): 359 (M+, 5), 337 (42), 253 (24), 199 (100), 91 (17), 77 (15), 68 (13) 



















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 4.67 min and 97.4% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.66-8.64 (m, 1H), 8.01 (dt, J = 7.6 Hz, 1.7 Hz, 1H), 
7.86 (d, J = 7.6 Hz, 1H), 7.61 (ddd, J = 7.5 Hz, 5.0 Hz, 1.0 Hz, 1H), 6.91 (d, J = 1.5 Hz, 
1H), 6.79 (d, J = 1.5 Hz, 1H), 3.76 (m, 1H), 3.56 (m, 1H), 2.54 (td, J = 11.1 Hz, 2.2 Hz, 
1H), 2.14 (m, 1H), 1.92 (m, 1H), 1.50 (td, J = 11.6 Hz, 2.0 Hz, 1H), 1.43-1.35 (m, 4H), 
1.21 (m, 1H), 1.06 (s, 3H), 0.98 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 195.0, 158.0, 156.6, 156.2, 149.6, 138.9, 136.3, 
127.6, 125.6, 119.6, 113.0, 109.6, 78.4, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 27.1, 19.1 
IR (thin film, cm-1): 3272(br), 2978, 2935, 2870, 1735, 1660, 1571, 1419, 1341, 1275, 
1141, 1047 
HR EI+ Mass Spec. Calculated for C21H23NO4: 353.1627, found: 353.1616 (3.1 ppm 
error) 
EI+(m/z): 353 (M+, 78), 335 (41), 292 (55), 266 (30), 106 (58), 78 (100) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 212 nm) 7.03 min and 97.7% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.85 (s, 1H), 8.73 (d, J = 4.0 Hz, 1H), 8.16-8.13 (m, 
1H), 7.57 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.74 (d, J = 1.8 Hz, 1H), 6.61 (d, J = 1.8 Hz, 1H), 
3.76 (m, 1H), 3.55 (m, 1H), 2.53 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.12 (m, 1H), 1.90 (m, 
1H), 1.49 (td, J = 11.6 Hz, 2.2 Hz, 1H), 1.43-1.34 (m, 4H), 1.19 (m, 1H), 1.04 (s, 3H), 
0.98 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 195.6, 158.5, 156.4, 153.0, 150.9, 139.0, 136.8, 
135.3, 125.0, 119.6, 112.0, 109.2, 78.5, 71.2, 49.9, 39.3, 36.5, 35.4, 28.1, 27.1, 19.1 
IR (thin film, cm-1): 3235(br), 2977, 2934, 2869, 1735, 1657, 1572, 1418, 1342, 1263, 
1140, 1057 
HR EI+ Mass Spec. Calculated for C21H23NO4: 353.1627, found: 353.1634 (2.0 ppm 
error) 
EI+(m/z): 353 (M+, 24), 207 (100), 149 (30), 101 (28) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 7.00 min and 98.4% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.71 (d, J = 4.8 Hz, 2H), 7.62 (d, J = 4.8 Hz, 2H), 
6.76 (d, J = 1.8 Hz, 1H), 6.62 (d, J = 1.8 Hz, 1H), 3.79-3.71 (m, 1H), 3.54 (m, 1H), 2.53 
(td, J = 11.3 Hz, 2.3 Hz, 1H), 2.12 (m, 1H), 1.90 (m, 1H), 1.48 (td, J = 11.5 Hz, 2.2 Hz, 
1H), 1.42-1.33 (m, 4H), 1.20 (m, 1H), 1.03 (s, 3H), 0.96 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 195.8, 158.6, 156.5, 150.7, 147.2, 136.0, 124.4, 
120.0, 112.1, 109.2, 78.5, 71.2, 49.9, 39.3, 36.5, 35.4, 28.1, 27.1, 19.1 
IR (thin film, cm-1): 3228(br), 2933, 2866, 1661, 1573, 1419, 1342, 1141, 1059 
HR EI+ Mass Spec. Calculated for C21H23NO4: 353.1627, found: 353.1611 (4.5 ppm 
error) 
EI+(m/z): 353 (M+, 43), 335 (22), 292 (38), 279 (21), 207 (81), 165 (35), 149 (100), 106 
(39), 69 (48) 





















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 280 nm) 4.02 min and 98.6% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.63 (s, 1H), 8.55 (d, J = 4.5 Hz, 1H), 7.49 (t, J = 5.8 
Hz, 1H), 6.78 (d, J = 1.5 Hz, 1H), 6.62 (d, J = 1.5 Hz, 1H), 3.76 (m, 1H), 3.53 (m, 1H), 
2.54 (td, J = 11.3 Hz, 2.2 Hz, 1H), 2.15-2.10 (m, 1H), 1.91 (m, 1H), 1.50 (td, J = 11.5 Hz, 
2.2 Hz, 1H), 1.43-1.34 (m, 4H), 1.21 (m, 1H), 1.05 (s, 3H), 0.97 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 191.9, 157.7 (d, JCF = 233.1 Hz), 146.9 (d, JCF = 4.7 
Hz), 139.8 (d, JCF = 24.6 Hz), 136.3, 136.2, 136.1, 124.7, 121.0, 111.9, 108.4, 78.6, 71.2, 
49.8, 39.2, 36.5, 35.5, 28.0, 27.1, 19.1 
IR (thin film, cm-1): 3420 (br), 2979, 2935,2870, 1669, 1574, 1421, 1342, 1056 
HR EI+ Mass Spec. Calculated for C21H22FNO4: 371.1533, found: 371.1539 (1.6 ppm 
error) 
EI+(m/z): 371 (M+, 100), 353 (60), 284 (22), 270 (17), 199 (44), 124 (67) 





















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 3.80 min and 97.7% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 7.56-7.50 (m, 2H), 7.47-7.44 (m, 1H), 7.38-7.34 (m, 
1H), 6.74 (d, J = 1.8 Hz, 1H), 6.62 (d, J = 1.8 Hz, 1H), 3.77 (m, 1H), 3.56 (m, 1H), 2.55 
(td, J = 11.3 Hz, 2.2 Hz, 1H), 2.14 (m, 1H), 1.92 (m, 1H), 1.51 (td, J = 11.6 Hz, 2.2 Hz, 
1H), 1.44-1.36 (m, 4H), 1.22 (m, 1H), 1.06 (s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 196.6, 164.8, 162.9, 157.2 (d, JCF = 230.4 Hz), 141.3 
(d, JCF = 6.3 Hz), 131.3 (d, JCF = 7.8 Hz), 126.9 (d, JCF = 2.1 Hz), 120.2 (d, JCF = 21.5 
Hz), 117.1 (d, JCF = 22.4 Hz), 112.1, 109.1, 78.5, 71.3, 50.0, 39.4, 36.5, 35.4, 28.1, 27.1, 
19.1 
IR (thin film, cm-1): 3399 (br), 2979, 2936, 2870, 1708, 1653, 1573, 1419, 1340, 1265, 
1139, 1047 
HR EI+ Mass Spec. Calculated for C22H23FO4: 370.1580, found: 370.1594 (3.8 ppm 
error) 
EI+(m/z): 370 (M+, 42), 352 (50), 337 (17), 309 (55), 283 (32), 123 (100), 95 (26), 69 
(13) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 3.68 min and 97.0% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.02-7.97 (m, 2H), 7.92 (d, J = 7.8 Hz, 1H), 7.72 (t, J 
= 7.8 Hz, 1H), 6.74 (d, J = 1.8 Hz, 1H), 6.63 (d, J = 1.8 Hz, 1H), 3.81-3.74 (m, 1H), 3.56 
(m, 1H), 2.56 (td, J = 11.3 Hz, 2.2 Hz, 1H), 2.14 (m, 1H), 1.93 (m, 1H), 1.52 (td, J = 11.6 
Hz, 2.0 Hz, 1H), 1.45-1.36 (m, 4H), 1.23 (m, 1H), 1.07 (s, 3H), 1.00 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 196.4, 158.2, 156.4, 140.0, 137.0, 134.4, 131.8 (q, 
JCF = 32.7 Hz), 130.4, 129.8 (q, JCF = 3.0 Hz), 127.1 (q, JCF = 3.5 Hz), 125.3 (q, JCF = 
271.7 Hz), 119.3, 112.0, 109.1, 78.5, 71.3, 50.0, 39.4, 36.6, 35.4, 28.1, 27.2, 19.1 
IR (thin film, cm-1): 3399 (br), 2979, 2938, 2871, 1652, 1573, 1420, 1345, 1328, 1234, 
1170, 1131, 1056 
HR EI+ Mass Spec. Calculated for C23H23F3O4: 420.1548, found: 420.1551 (0.7 ppm 
error) 
EI+(m/z): 420 (M+, 78), 402 (16), 387 (21), 359 (63), 333 (28), 173 (100), 145 (33), 69 
(16) 




















Chiral HPLC (0.46 cm x 25 cm Chiralcel OD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 254 nm) 3.75 min and 98.1% chemical purity. 
mp: 158-161°C (dec.) 
1H NMR (MeOH-d4, 500 MHz):  δ 8.26 (dd, J = 6.8 Hz, 1.3 Hz, 1H), 7.86 (s, 1H), 7.48 
(dd, J = 6.8 Hz, 1.3 Hz, 1H), 7.29-7.22 (m, 2H), 6.75 (d, J = 2.0 Hz, 1H), 6.68 (d, J = 2.0 
Hz, 1H), 3.79 (m, 1H), 3.58 (m, 1H), 2.56 (td, J = 11.3 Hz, 2.5 Hz, 1H), 2.15 (m, 1H), 
1.93 (m, 1H), 1.52 (td, J = 11.8 Hz, 2.3 Hz, 1H), 1.45-1.36 (m, 4H), 1.23 (m, 1H), 1.09 
(s, 3H), 1.01 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 193.6, 158.0, 156.2, 141.2, 138.5, 137.2, 127.8, 
124.6, 123.3, 122.9, 117.1, 117.0, 112.9, 110.6, 108.3, 78.3, 71.3, 50.1, 39.6, 36.6, 35.3, 
28.1, 27.2, 19.2 
IR (thin film, cm-1): 3250(br), 2930, 2867, 1625, 1599, 1371, 1056 
HR EI+ Mass Spec. Calculated for C24H25NO4: 391.1784, found: 391.1779 (1.3 ppm 
error) 
EI+(m/z): 391 (M+, 5), 373 (29), 352 (53), 334 (50), 291 (61), 265 (38), 149 (90), 105 
(100) 


















Chiral HPLC (0.46 cm x 25 cm Chiralcel AD-H, 50% 2-propanol in hexanes, 1 mL/min, 
UV detection at 212 nm) 10.20 min and 96.9% chemical purity. 
1H NMR (MeOH-d4, 500 MHz):  δ 8.26 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 7.45 (d, J = 8.0 
Hz, 1H), 7.30 (t, J = 7.4 Hz, 1H), 7.26 (t, J = 7.4 Hz, 1H), 6.73 (d, J = 1.8 Hz, 1H), 6.65 
(d, J = 1.8 Hz, 1H), 3.84 (s, 3H), 3.76 (m, 1H), 3.57 (m, 1H), 2.53 (td, J = 11.3 Hz, 2.5 
Hz, 1H), 2.12 (m, 1H), 1.90 (m, 1H), 1.48 (td, J = 11.6 Hz, 2.2 Hz, 1H), 1.42-1.34 (m, 
4H), 1.19 (m, 1H), 1.06 (s, 3H), 0.98 (m, 1H) 
13C NMR (MeOH-d4, 126 MHz):  δ 193.1, 158.3, 156.2, 141.1, 140.9, 139.2, 128.4, 
124.6, 123.6, 123.2, 117.1, 115.9, 111.2, 110.4, 108.4, 78.3, 71.3, 50.1, 39.6, 36.6, 35.3, 
33.7, 28.1, 27.2, 19.2 
IR (thin film, cm-1): 3358(br), 2978, 2935, 2870, 1732, 1605, 1567, 1523, 1464, 1369, 
1055 
HR EI+ Mass Spec. Calculated for C25H27NO4: 405.1940, found: 405.1950 (2.5 ppm 
error) 
EI+(m/z): 405 (M+, 23), 354 (42), 291 (35), 207 (38), 158 (76), 129 (78), 115 (45), 105 
(64), 91 (66), 73 (100) 
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